

Long-range Transcriptome Sequencing Reveals Cancer Cell Growth Regulatory Chimeric mRNA^{1,2}

Roberto Plebani*,³ Gavin R. Oliver^{†,3},
Marco Trerotola*,⁴ Emanuela Guerra*,
Pamela Cantanelli*, Luana Apicella*,
Andrew Emerson[‡], Alessandro Albiero[§],
Paul D. Harkin^{†,¶}, Richard D. Kennedy^{†,¶},
and Saverio Alberti*,#

*Unit of Cancer Pathology, Centre of Excellence for Research on Aging, "G. D'Annunzio" University Foundation, Chieti, Italy;

[†]Almac Diagnostics, Craigavon, United Kingdom; [‡]CINECA, Bologna, Italy; [§]BMR Genomics, Padova, Italy; [¶]Centre for Cancer Research & Cell Biology, Queen's University, Belfast, United Kingdom; [#]Department of Neuroscience and Imaging, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy

Abstract

mRNA chimeras from chromosomal translocations often play a role as transforming oncogenes. However, cancer transcriptomes also contain mRNA chimeras that may play a role in tumor development, which arise as transcriptional or post-transcriptional events. To identify such chimeras, we developed a deterministic screening strategy for long-range sequence analysis. High-throughput, long-read sequencing was then performed on cDNA libraries from major tumor histotypes and corresponding normal tissues. These analyses led to the identification of 378 chimeras, with an unexpectedly high frequency of expression ($\approx 2 \times 10^{-5}$ of all mRNA). Functional assays in breast and ovarian cancer cell lines showed that a large fraction of mRNA chimeras regulates cell replication. Strikingly, chimeras were shown to include both positive and negative regulators of cell growth, which functioned as such in a cell-type-specific manner. Replication-controlling chimeras were found to be expressed by most cancers from breast, ovary, colon, uterus, kidney, lung, and stomach, suggesting a widespread role in tumor development.

Neoplasia (2012) 14, 1087–1096

Introduction

Several chimeric transcripts have been discovered in human solid tumors, which derive from chromosomal translocations. These often encode structurally and functionally altered signaling molecules or transcription factors [1] or may also function as non-coding RNA [2]. More than half of prostate cancers harbor fusion sequences, mostly *TMPRSS-ERG* [3]. The *SLC45A3-ELK4* (ETS family) fusion transcript can be generated both by chromosomal rearrangement and by trans-splicing, and it was found to be expressed in both normal prostate tissue and in prostate cancer. High levels of *SLC45A3-ELK4* mRNA are restricted to a subset of prostate cancer samples [4]. A small inversion within chromosome 2p leads to the formation of a fusion gene comprising *EML4* and *ALK* in non-small cell lung cancer [5]. The fusion of *MAML2* with *CRTC1* or *CRTC3* has a role in the development of mucoepidermoid carcinomas [6]. Rearrangements of *RAF* pathway members occur in prostate and gastric cancers [7], and a paracentric inversion of chromosome 7q results in an in-frame fusion

Abbreviations: FP, fusion point; NGS, next-generation sequencing; SD, standard deviation
Address all correspondence to: Prof. Saverio Alberti, MD, PhD, Unit of Cancer Pathology, Ce.S.I., University "G. d'Annunzio", Via Colle dell'Ara, 66100 Chieti Scalo (Chieti), Italy. E-mail: s.alberti@unich.it

¹This work was supported by Fondazione Cassa di Risparmio della Provincia di Chieti, Italian Ministry of Health (RicOncol grant RF-EMR-2006-361866), Fondazione Compagnia di San Paolo (grant 2489IT), Ministero dello Sviluppo-Made in Italy (contract N° MI01_00424), and the Italian Foundation for Cancer Research (fellowship to M.T.).

²This article refers to supplementary materials, which are designated by Tables S1 to S11 and Figures S1 to S4 and are available online at www.neoplasia.com. The Fusion-Miner software is freely available at FusionMiner.sourceforge.net.

³These authors contributed equally to this work.

⁴Current address: Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107.

Received 16 August 2012; Revised 16 August 2012; Accepted 30 September 2012

Copyright © 2012 Neoplasia Press, Inc. All rights reserved 1522-8002/12/\$25.00
DOI 10.1593/neo.121342

between exons 1 and 8 of the *AKAP9* gene and between exons 9 and 18 of *BRAF* in radiation-induced papillary carcinomas [8]. Other thyroid carcinoma-specific events include fusion of the *RET* oncogene to various partners [9]. Further oncogenic fusions have been detected in other solid tumors [10,11].

Cancer transcriptomes also contain mRNA chimeras that arise as transcriptional (long intergenic transcription) or post-transcriptional (trans-splicing [12]) events that may play a role in tumor development. Previous findings showed that oncogenic transcripts can indeed be generated post-transcriptionally [13–15]. The fusion of *CYCLIN D1* mRNA to *TROP2* transcripts generates oncogenic *CYCLIN D1-TROP2* chimeras, whose tumor-promoting function is induced with a dramatically increased mRNA stability [13]. The oncogenic *JAZF1-JAZ1* chimeric mRNA can be originated by trans-splicing as well as by a chromosomal translocation [14]. Similarly, the *SLC45A3-ELK4* chimeric transcript can be generated in the absence of chromosomal rearrangements [4,16]. Intergenic splicing generates a ubiquitous chimeric mRNA between the *P2Y11* and *SSFI* transcripts [17]. The generation of these chimeras appears as a regulated event [13,14] and was shown to also occur in normal tissues [4,13,14,17–20]. Several of these chimeric transcripts have been used as diagnostic or prognostic [21] markers and as targets for anti-neoplastic therapy [10,13,22,23].

Screening strategies were previously developed for *in silico* identification of mRNA chimeras in cancer cells [24]. Next-generation sequencing (NGS) approaches now provide much larger sequence information for chimera discovery [7,19,20,25–27]. However, most second-generation NGS approaches generate highly multiplexed, short-tag sequence reads, which are then condensed in strings of base-call probabilities, through a probabilistic fitting of massively parallel data sets. This makes contig assemblies and target alignments correspondingly more difficult [19,25,27,28]. Alignments to complex genomes are even more hampered, because of higher sequence complexity [29] and homology within closely related gene families and pseudogenes.

These problems have led to significant efforts for achieving longer sequence reads and higher sequencing accuracy. In 2005, 454 launched the first NGS apparatus, which was able to generate 100-bp reads. Sequence reads extended to 200 bp in 2007 [30] and are close to 900 bp at present [31]. SOLID sequencing generated 35-bp reads in 2007 [30], and this extended to 75 bp in 2011 [32]. Illumina generated 36-bp sequence reads in 2006 to 2008 [30]. These extended to 100 bp in 2010 [31] and to 300 bp in 2012 (www.illumina.com). Ion Torrent introduced its first sequencer at the end of 2010, and this was capable of 100-bp-long reads. As of 2012, reads of 525-bp average length have been obtained (www.iontorrent.com/lib/images/PDFs/pe_appnote_v12b.pdf). Pacific Biosciences (www.pacificbiosciences.com) succeeded in obtaining even longer reads, which currently are up to 1500 bp.

To take advantage of these technical advances, we have developed an analytical strategy for high-accuracy identification of mRNA chimeras in long-read DNA sequence data sets (Figure 1). This strategy was shown to work efficiently for chimera recognition (Tables S1–S7 and Figure S1). High-throughput, long-read sequencing was then performed on cDNA libraries from major tumor histotypes and corresponding normal tissues. This led to the identification of 378 chimeras, from both normal and transformed cells, indicating an unexpectedly high frequency of expression ($\approx 2 \times 10^{-5}$ of all mRNA). Functional assays in breast and ovarian cancer cell lines showed that a large fraction of mRNA chimeras regulate cell replication. Strikingly, chimeras were shown to include both positive and negative regulators

of cell growth, which functioned as such in a cell-type-specific manner. Replication-controlling chimeras were found to be expressed by most cancers from breast, ovary, colon, uterus, kidney, lung, and stomach, suggesting selective pressure for a role in tumor development.

Materials and Methods

Cells

Human MCF-7, MCF-7/Almac, HBL-100, SK-BR-3, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, MDA-MB-468, HS578, and ZR751 breast cell lines and SKOV-3, IGROV-1, OVCAR-3, and OVCA-432 ovarian cancer cell lines were grown in RPMI 1640 medium supplemented with 10% FBS, 100 IU/ml penicillin, and 100 µg/ml streptomycin (Euroclone, Milan, Italy). All cell lines were obtained from ATCC (LGC Standards, Teddington Middlesex, United Kingdom) where they were authenticated by standardized procedures (www.atcc.org).

Cell Growth Assays

MCF-7, HBL-100, SK-OV-3, IGROV-1, and OVCAR-3 cells were seeded at 1×10^3 to 10×10^3 cells/well in 96-well plates (five replicates per data point). Cell numbers were quantified by staining with crystal violet [33]. Standard growth curves for each cell line were generated by seeding two-fold serial dilutions of defined cell numbers. Crystal violet standard curves showed good linear responses ($R^2 > 0.998$, in all cases) (Figure S2). To support the crystal violet readings, quantification was also performed by image analysis (ImageJ). Digital pictures were taken from 96-well plates after fixation. Picture noise was removed with GIMP software, after random sampling of cell-free pixels. ImageJ analysis was then performed by quantifying black areas in each culture well after image conversion to a gray scale (manuscript in preparation).

DNA Transfection

Cells were transfected with DNA in Lipofectamine 2000 (HBL-100, SKOV-3, IGROV-1, and OVCAR-3 cells) or LTX (Invitrogen, San Diego, CA), which was found to be optimal for MCF-7 cells (Figure 5C) [34], following the manufacturer's instructions. pEYFP transfection was used to quantify transfection efficiency [35] (EYFP expression, as measured by flow cytometry).

Flow Cytometry Immunofluorescence

Flow cytometry analysis was performed as described previously [36,37], on fluorescence-activated cell sorters (FACSCalibur, Becton-Dickinson, Sunnyvale, CA). To improve the detection of EYFP transfecteds, we performed subtraction of cell autofluorescence and displacement of true transfecteds in the red channel as described [35,38].

Human Samples for Tumor Transcriptome Sequencing

Non-small cell lung cancer. Non-small cell lung cancer libraries were generated from a set of frozen tissue samples, comprising 65 tumor samples (30 adenocarcinomas, 20 squamous cell carcinomas, and 15 other morphologies) from the Roy Castle Lung Cancer Research Institute (University of Liverpool) and Queens University Belfast. To maximize chances of mRNA chimera discovery, we proceeded to generate libraries from both tumor and normal tissues. Normal lung RNA was obtained from multiple commercial suppliers (Clontech, Palo Alto, CA; Ambion, Austin, TX; BioCat, Heidelberg, Germany; Stratagene, La Jolla, CA; Cybrid, Rockville, MD; and OriGene, Rockville, MD), overall from 16 donors of different ethnicity.




Figure 1. Flow diagram of chimera identification and validation steps.

Ovarian cancer. Ovarian library A comprised 64 ovarian tumors (31 serous, 14 endometroid, 6 mucinous, 5 clear cell, and 8 undifferentiated cancers; 52 were stage III/IV and 12 were stage I/II). For ovarian library B, RNA from normal ovarian tissue was obtained from commercial suppliers (Ambion and AMS Biotechnology [Bioggio, Switzerland]). The library was generated with equal quantities of RNA from different ethnicities (Asian, Caucasian, and African-American), with 23 donors overall. For ovarian library C, ovarian tumor total RNA was obtained from various commercial suppliers (Ambion, Clontech, Cytomyx [Lexington, MA], Biocat, and Asterand [Detroit, MI]). The library was composed of equal quantities of RNA of different ethnicity (Asian, African-American, and Caucasian), with 37 donors overall.

Prostate cancer. The prostate cancer library was constructed from 30 tumors (74% Caucasian and 26% African-American), 8 normal prostate RNA supplied by Clontech, AMS Biotechnology, and Cybrid.

and 56 normal tissues adjacent to tumors obtained from St. Vincents Hospital (Dublin, Ireland).

Breast cancer. The breast cancer library was composed of 90 tumors and 18 normal samples [39–41].

Colorectal cancer. The colorectal library comprised 40 tumor samples and 40 normal tissues.

Tumor Validation Sample Set

cDNA was synthesized from 25 human primary tumors (10 breast, 6 colon, 3 stomach, 2 ovary, 2 kidney, and 2 uterus), which were independent from those used to construct the cDNA libraries. These 25 samples were used as a test set to validate chimera expression by both conventional polymerase chain reaction (PCR)/sequencing and real-time reverse transcription (RT)–PCR.

Normal Tissues

Normal breast, colon, uterus, prostate, placenta, lung, kidney, pancreas, and stomach RNA were obtained from Clontech.

cDNA Library Construction

All of the frozen tumor tissues were homogenized in RNA STAT-60 (Tel-Test, Friendswood, TX), and the RNA was extracted according to the manufacturer's instructions. Equal amounts of good quality total RNA were pooled, and the mRNA was isolated using μ MACS mRNA isolation kits (Miltenyi Biotec, Bergisch Gladbach, Germany), as described by the manufacturer. Lung cDNA libraries were constructed from 3 μ g of mRNA using the CloneMiner cDNA library construction kit (Invitrogen), according to the manufacturer's instructions. cDNA were inserted in the pDONR 222 vector from Invitrogen. Titer and average insert size in each cDNA library were determined according to the manufacturer's instructions. Plasmid preparations of individual clones were carried out using a modified Montáge alkaline lysis method (Millipore, Billerica, MA) that incorporates MultiScreen Plasmid 384 Miniprep clearing plates for centrifugal lysate clearing.

Sequencing of cDNA Libraries

Colony sequencing automation was implemented (QPix colony picker Biomek liquid handlers). Cycle sequencing reactions were performed in 10- μ l volumes using a 1/16 dilution of Big Dye Terminator v3.1 ready reaction mix in Big Dye sequencing buffer (Applied Biosystems, Foster City, CA), 5 μ M M13 primer, and 100 ng of template DNA. Cycle sequencing was performed for 40 cycles at 95°C for 10 seconds, 50°C for 5 seconds, and 60°C for 2.5 minutes. Excess dye terminators were removed using CleanSEQ (Agencourt Biosciences Corporation, Beverly, MA). Sequencing plates were analyzed on Applied Biosystems 3730/3730 \times 1 DNA Analyzers using Applied Biosystems Sequence Analysis software. M13 forward primers were used for 5' end sequencing of the colorectal and breast libraries; M13 reverse primers were used for 3' end sequencing of the normal lung and prostate libraries; both M13 forward and reverse primers were used for 5' and 3' end sequencing of the lung tumor and ovarian cancer libraries.

Plasmids

The pEYFP expression vector (Clontech) was used to express YFP. The pSUPER vector [42] was used for RNA interference.

Small Inhibitory RNA (siRNA)

siRNA design followed four complementary strategies, i.e., Tuschl criteria (position in the mRNA, guanine-cytosine [GC] content, base composition, and flanking sequences) [43], Invitrogen algorithms (rnaidesigner.invitrogen.com/rnaiexpress/; sequence composition, nucleotide content, thermodynamic properties, and experimental validation), Whitehead Institute screening procedures (jura.wi.mit.edu/bioc/siRNAext/; Tuschl criteria, predictions of binding energies and BLAST filtering of cross-hybridizing sequences) [44], and Sonnhammer searches (www.sirnawizard.com/design_advanced.php; data mining on validated siRNA databanks, using motif rules and energy parameters) [45].

Annealed siRNA oligos were subcloned into the pSUPER vector. siRNA expression constructs were transiently transfected in MCF-7 and HBL-100 breast cancer cells and in SK-OV-3, IGROV-1, and OVCAR-3 ovarian cancer cells. siRNA-targeted transcript levels were quantified by real-time PCR. Negative-control siRNA directed toward irrelevant targets were used; these were chosen after extensive testing for lack of off-target influence on cell growth.

Quantitative RT-PCR

Hybrid sequences in cancer cell lines and tumor samples were amplified by quantitative RT-PCR. One microgram of total RNA was reverse transcribed with the M-MLV Reverse Transcriptase (Promega, Madison, WI) according to standard protocols. cDNA was quantified by ethidium bromide fluorescence in solution [46]. Quantitative RT-PCR was performed with an ABI-PRISM 7900HT Sequence Detection System (PE Applied Biosystems, Foster City, CA), using Sybr Green as the probe (Applied Biosystems). Samples were assayed as replicates (two or three independent samples), and the $1.83^{-\Delta\Delta CT}$ method was used to calculate the relative changes in gene expression [13]. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping gene was used as an internal control. For setup curves, ΔCT (C_T , target gene – $C_{T_{\text{GAPDH}}}$) was calculated for each cDNA dilution. The data were fit using least-squares linear regression analysis. As amplification efficiency was linear over the range of RNA amounts used, amplification curves were used to calculate crossover point values for siRNA-treated samples. To check for the correctness of amplified bands, amplification products were run on 3% agarose gels. Amplified products were purified and extensively sequenced (BMR Genomics, Padova, Italy). Quantitative RT-PCR was also performed with PrimeTime IDT (Integrated DNA Technologies, Bologna, Italy; www.idtdna.com) to reliably detect with higher sensitivity the interchromosomal CHD2-CHMP1A fusion in normal tissues.

Diagnostic PCR

Interchromosomal *CHD2-CHMP1A* and *ADK-DHX8* and intrachromosomal *PRKAA1-TTC33*, *SAMM50-PARVB* and *P2RX5-TAX1BP3*, *URB1-C21orf45*, *CTBS-GNG5*, *THC2538403 ZNF498-CUX1*, *THC2523555 C9orf47-S1PR3*, and *THC2668182 KLH22-SCARF* were amplified in 10 breast and 4 ovarian cancer cell lines and in 25 tumor samples by nested PCR. Chimeric mRNA were amplified by 35 amplification cycles (30 seconds at 94°C for denaturation, 30 seconds at 60°C for annealing, and 30 seconds at 72°C for extension). Hot Master Taq-polymerase 0.7 units (Eppendorf) and 12.8 pmol of forward and reverse primers were used for the amplification reaction. All of the amplified products were purified and sequenced (BMR Genomics).

Statistical Analysis

Two-way analysis of variance and *post-hoc* Bonferroni *t* tests were used for growth curve comparisons. Data were analyzed using Sigma Stat (SPSS Science Software UK Ltd, Birmingham, United Kingdom) and GraphPad Prism (GraphPad Software Inc, La Jolla, CA).

Results

Chimeric mRNA Detection Procedure


A procedure (FusionMiner) was designed to process BLAST analyses of query sequences against genomic databanks, through sequential stages of analysis and exclusion and pass-or-fail tests, as described in the Supplemental Online Material (Figure 1 and Tables S1–S7). FusionMiner performance was assessed by screening the Dana Farber Cancer Institute Gene Index Project tentative human consensus (THC) collection (Figure S1) and long-sequence-read 454 Titanium data sets (Supplemental Online Material). Samples of the identified chimeras were then validated by diagnostic PCR and by real-time quantitative PCR analysis of cancer cell lines.

Transcriptome Sequencing for Growth Regulatory Chimera Discovery

To discover growth regulatory chimeras, we then performed a large-scale sequencing and analysis of tumor and normal tissue transcriptomes. To maximize chances of discovery of growth regulatory chimeras, both major tumor histotypes, i.e., non-small cell lung, breast, prostate, ovary, and colorectal cancers, and the corresponding normal tissues were analyzed. Long-sequence-read (900 bp on average) cDNA library data sets were obtained: 481,765 from ovary, 485,049 from prostate, 157,259 from breast, 46,445 from colon, and 603,935 from lung.

These sequences were run through FusionMiner. Twenty-five mRNA chimeras were identified (15 intrachromosomal and 10 interchromosomal; Table S8, Supplemental Sequence Data). All sequences were shown to possess the structural characteristics of *bona fide* chimeric mRNA [24] (Supplemental Sequence Data). Breast and ovarian chimeras were validated by RT-PCR and functional assays (see below).

These findings led to estimate absolute chimera frequencies as 1.4×10^{-5} of all mRNA. This was in remarkable agreement with NGS sequencing data ($\approx 2 \times 10^{-5}$) (Supplemental Online Material), indicating an unexpectedly high frequency of expression of chimeric mRNA.



Chimeric Transcript Expression in Cancer Cells

Expression of the nine chimeras from the breast library and of the four chimeras from the ovarian library was analyzed in breast (MCF-7, HBL-100, SK-BR-3, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, MDA-MB-468, HS578, and ZR751) and ovarian (SKOV-3, IGROV-1, OVCAR-3, and OVCA-432) cancer cell lines (Figure 2 and Table S8). Six of the nine chimeras were successfully amplified by RT-PCR (Figure 2A and Table S9). Amplification from breast cancer cells was obtained for *PRKAA1-TTC33* (10/10 lines), *SAMM50-PARVB* (5/10 lines), *P2RX5-TAX1BP3* (3/10 lines), and *CHD2-CHMP1A* (9/10 lines) (Figure 2A, left). All individual amplicons were sequence verified (Figure 2C). Three of these chimeras were also detected in ovarian cancer cells: *PRKAA1-TTC33* (4/4 lines); *SAMM50-PARVB* (3/4 lines), and *CHD2-CHMP1A* (4/4 lines) (Figure S3).

The *URB1-C21ORF45* and *CTBS-GNG5* chimeras from the ovarian library were identified in all four ovarian cancer cell lines (Figure 2A, right). They were also detected in all breast cancer lines. Notably, different cancer cells expressed different steady-state levels of the chimeric mRNA, e.g., *CTBS-GNG5* was approximately 20 times

Figure 2. Chimeric mRNA expression in cancer cell lines. (A) Expression of chimeras discovered from tumor and normal tissue library sequencing; agarose electrophoresis of nested or real-time PCR products. Breast and ovarian cancer cell lines are indicated; *SK-BR-3. (B) URB1-C21ORF45 (top) and CTBS-GNG5 (bottom) expression in breast cancer cell lines by quantitative RT-PCR; results are expressed as percent values (MCF-7 = 100); three replica samples were analyzed per data point. Bars, SD. (C) CHD2-CHMP1A. Sequence of the PCR amplicon versus that of the chimera isolated from the breast library. (D) Structure of validated chimeric mRNA; 5' partners (orange) and 3' partners (green) are shown; exon junctions are indicated.




Figure 3. Cell growth modulation by chimeras. (A) Control (Table S10) and chimera-targeting siRNA are color coded. (Top, left) MCF-7; PRKAA1-TTC33 (cyan), SAMM50-PARVB (green), control (black). (Top, right) HBL-100; CHD2-CHMP1A (orange), control (black). (Bottom, left) OVCAR-3; URB1-C21ORF45 (blue), CTBS-GNG5 (red). (Bottom, right) HBL-100 treated with siRNA for chimeras from ovarian libraries; URB1-C21ORF45 (blue), CTBS-GNG5 (red). Bars, SD. Brackets, P value of two-way analysis of variance; Bonferroni t test significance: *P ≤ .05; ***P ≤ .001. (B) Real-time PCR of siRNA-transfected cells. (Top) Chimeric RNA (left to right: PRKAA1-TTC33 and SAMM50-PARVB in MCF-7; URB1-C21ORF45 and CTBS-GNG5 in OVCAR-3). (Bottom) Single-partner RNA expression after the indicated siRNA treatment (left to right: PRKAA1-TTC33 and SAMM50-PARVB in MCF-7). (C) Flow cytometry analysis of transfected HBL-100 and MCF7 cells; YFP was used as a transfection efficiency benchmark. (Left) HBL-100; LTX (red) or Lipo-2000 (blue). (Right) MCF-7; LTX transfection. (D) MCF-7 cell growth blockade after PRKAA1-TTC33-targeted or SAMM50-PARVB-targeted siRNA treatment (day 6 after transfection).

less expressed in HBL-100 cells, as compared with MDA-MB-415 cells (Figure 2B).

Overall, 75% of the THC chimeras and 54% of the chimeras from breast and ovary libraries (Tumor Transcriptome Sequencing Project) were detected in breast and ovarian cancer cell lines/primary tumors.

Fusion Proteins Encoded by the Growth Regulatory Chimeras

CHD2-CHMP1A. CHD2 encodes the chromodomain helicase DNA-binding protein 2; CHMP1A encodes the chromatin-modifying protein 1A. Of interest, both of these chimera partners encode proteins with regulatory roles on chromatin/DNA structure. However, only the first 20 amino acids of helicase DNA-binding protein 2 are retained in the fusion-protein product (Table S11). This contains a casein kinase II phosphorylation site (prosite.expasy.org/). One out-of-frame C-terminal amino acid is provided by the chromatin-modifying protein 1A sequence (Table S11) and generates a hybrid N-glycosylation site, although it is not clear if this is processed *in vivo*.

CTBS-GNG5. CTBS encodes chitobiase; GNG5 encodes the di-N-acetyl-binding and guanine-nucleotide-binding proteins. Chitobiase is a lysosomal glycosidase that is involved in degradation of asparagine-linked oligosaccharides on glycoproteins. It is also involved in the hydrolysis of N-acetyl-β-D-glucosamine. GNG5 encodes the γ chain of trimeric G proteins. A fusion mRNA between chitobiase and guanine-nucleotide-binding protein was also identified by Akiva et al. [47] and by Nacu et al. [26]. The CTBS-GNG5 is an “in-frame” fusion that preserves the first 319 amino acids from the N-terminal partner and the last 41 amino acids from the C-terminal partner (Table S11). CTBS provides an apparently functional chitinase catalytic domain, with a formal glycosylation site at S300. Most of Gγ5 is retained in the fusion (Supplemental Figure S4), which raises the possibility that the fusion protein can bind its Gβ partner, whether at the cell membrane or in the cytoplasm.

PRKAA1-TTC33. PRKAA1 encodes a 5'-AMP-activated protein kinase catalytic subunit α-1; TTC33 encodes tetratricopeptide repeat domain 33. PRKAA1 is a Ser/Thr protein kinase that protects cells from

stress-dependent ATP depletion by switching off ATP-consuming biosynthetic pathways; *PRKAA1* also regulates fatty acid and cholesterol synthesis. The N-terminal segment retained in the chimera contains most of the protein kinase A1 protein (478/559 amino acids; Table S11). This retains the full catalytic domain (46–279). However, it loses 12 phosphorylation sites (T488, T490, T522, S496, S502, S506, S508, S516, S520, S523, S524, and S527), which suggests the loss of at least some of its physiological regulation. The fusion protein contains 32 C-terminal amino acids from the 3' partner mRNA (*TTC33*), which do not correspond to its canonical reading frame (out-of-frame fusion; Table S11).

SAMM50-PARVB. *SAMM50* encodes the sorting and assembly machinery (SAM) component 50 homolog; *PARVB* encodes β-parvin. SAM-50 is part of the SAM complex, which has a role in integrating β-barrel proteins into the outer mitochondrial membrane. β-Parvin is an actin-binding protein that associates with focal contacts. Parvin is a key regulator of integrin-linked kinase (ILK) and of its downstream pathways. The encoded fusion protein contains an almost entire SAM-50, which only misses its last 15 C-terminal amino acids (Table S11). However, this may lead to disruption of the second major functionally relevant domain of SAM-50. Only two amino acids are contributed by the β-parvin mRNA, as an out-of-frame sequence (Table S11).

URB1-C21orf45. *URB1* encodes the pre-ribosomal-associated protein 1 (Npa1p); *C21orf45* encodes the kinetochore protein homolog

A. Npa1p is a component of pre-60S ribosomal particles and associates with small nucleolar ribonucleoprotein particles (RNPs) that are required for peptidyl transferase center modification. The kinetochore protein homolog A is involved in mitosis and associates with chromatin. It also associates with centromeres in interphase cells, from late anaphase to G₁. The fusion protein keeps essentially all the exons of the N-terminal partner (38/39), including its S1385 phosphorylation site (Table S11), suggesting a largely unaltered function. Albeit the C-terminal sequence is not in its native frame, it is unusually long (121 amino acids; Table S11) and may carry novel associated functions.

Chimeras Contain Positive and Negative Regulators of Cell Growth

The six chimeras that were found to be expressed by target cell lines in culture were assayed for a role in cell growth. siRNA targeting the chimeric joint (Table S11) were used to inhibit the expression of the corresponding chimeras in breast cancer cells (Figure 3). Transfection efficiency was optimized by using a co-transfected pEYFP reporter plasmid (Figure 3C, left); the vast majority of target cells appeared successfully transfected (Figure 3C). Transfected siRNA downregulated mRNA chimera levels by ≈75% (Figures 3B and S3). To ensure absence of off-target effects, due to artificial reduction of chimera partner transcript levels, 5' and 3' chimeric partners were analyzed in parallel. Levels of partner transcripts of growth regulatory chimeras remained unaffected by siRNA targeting the chimera junction regions (Figure 3B).

Remarkably, five of six tested chimeras appeared to regulate cell growth. The strongest growth inhibition in HBL-100 cancer cells




Figure 4. Expression of mRNA chimeras in normal tissues. (A) (Left) Agarose electrophoresis analysis of real-time PCR products (Sybr Green real-time PCR). (Right) Real-time PCR analysis of the *CHD2-CHMP1A* chimeric mRNA in normal tissues (PrimeTime real-time PCR). HBL-100 cell cDNA was used as a positive control. (Bottom) Amplification plots of *CHD2-CHMP1A* mRNA in the HBL-100 breast cancer cell line (blue) and normal breast tissue (red). *CHD2-CHMP1A* (top lanes) and GAPDH (bottom lanes) were amplified in duplicate. Green triangles, successful amplification; red triangles, no amplification. (B) Agarose electrophoresis of nested PCR products of *PRKAA1-TTC33*, *SAMM50-PARVB*, *CTBS-GNG5*, and *URB1-C21orf45* in normal tissues.




Figure 5. Expression of mRNA chimeras in primary tumors. (A, B) Agarose electrophoresis analysis of amplification products. Tumor origin and sample numbers are indicated. (A) Intrachromosomal chimeras as analyzed by real-time PCR. *PRKAA1-TTC33* and *CTBS-GNG5* were diagnosed in all 25 tumors; *SAMM50-PARVB* chimera was found in 15 tumors, *P2RX5-TAX1BP3* in 8 tumors, and *URB1-C21orf45* in 21 tumors. (B) PCR amplicons of the interchromosomal *CHD2-CHMP1A* chimera. (C) Interchromosomal *ADK-DHX8* chimeric. Melting temperature and real-time amplification curves.

was caused by down-regulation of *CHD2-CHMP1A* (Figure 3A). Parallel growth blockade in MCF-7 cells was observed on shutdown of *PRKAA1-TTC33* and *SAMM50-PARVB* (Figures 3A and S3B). Monitoring of cell growth inhibition by *PRKAA1-TTC33* and *SAMM50-PARVB* siRNA through optical microscopy (Figure 3D) and image analysis (Figure S3, B and C) confirmed a dramatic reduction of MCF-7 cell growth. Growth inhibition by *PRKAA1-TTC33* and *SAMM50-PARVB* down-regulation was also demonstrated for HBL-100 cells.

We then went on to test *URB1-C21orf45*-targeting siRNA in ovarian cell lines. Unexpectedly, an increase in cell growth was reproducibly observed in OVCAR-3 (Figure 3A) and IGROV-1 cells, which indicates a growth inhibitory role of the *URB1-C21orf45* chimera. Albeit *URB1-C21orf45* is expressed by SKOV-3 and HBL-100 cells, the corresponding siRNA had no effects on these cells, suggesting a cell-

specific function of these growth inhibitory chimeras (Figure 3A). These tests were repeated using *CTBS-GNG5*-targeted siRNA. These assays showed that the *CTBS-GNG5* chimera also has a growth inhibitory function in OVCAR-3 and IGROV-1 cells (Figures 3 and S3B). Again, SKOV-3 and HBL-100 cancer cells were insensitive to the inhibitory function of *CTBS-GNG5*, consistent with a differential tuning of chimera-dependent growth-control circuitries in specific cell lines.

Protein-encoding reading frames of the growth regulatory chimeras were analyzed (Table S11). In all cases but one, the downstream partners did not provide in-frame sequences, generating out-of-frame, mostly short chimeric tails. This suggested altered regulation and/or dominant-negative function of a truncated molecule as a mechanism of action of these chimeric products. However, the *CTBS-GNG5* is an in-frame chimera that retains the first 319 amino acids from the

Table 1. Expression of Chimeric mRNA by Tumor Type.

Chimera	Breast* [n/10 (%)]	Ovary [n/2 (%)]	Stomach [n/2 (%)]	Colon [n/7 (%)]	Kidney [n/2 (%)]	Uterus [n/2 (%)]
<i>PRKAA1-TTC33</i>	8 (80)	2 (100)	2 (100)	7 (100)	2 (100)	2 (100)
<i>SAMM50-PARVB</i>	5 (50)	—	1 (50)	5 (71)	2 (100)	1 (50)
<i>P2RX5-TAX1BP3</i>	2 (20)	—	—	5 (71)	1 (50)	1 (50)
<i>URB1-C21orf45</i>	8 (80)	—	1 (100)	7 (100)	2 (100)	2 (100)
<i>CTBS-GNG5</i>	8 (80)	1 (50)	2 (100)	7 (100)	2 (100)	2 (100)
<i>CHD2-CHMP1A</i>	3 (30)	—	2 (100)	2 (28)	1 (50)	2 (100)
<i>ADK-DHX8</i>	—	—	—	1 (14)	1 (50)	—

—, Not detected.

*Tumors; total numbers are below each histotype.

N-terminal chitobiase and most of the C-terminal G γ 5 (41 amino acids), including its G β -binding interface (Figure S2). This suggested that the chimeric protein can bind its G β partner in trimeric G proteins (Supplemental Sequence Data).

Chimera Expression in Normal Tissues

We assessed the presence and expression levels of the five growth-controlling chimeras in mRNA from normal tissues (breast, lung, placenta, uterus, prostate, stomach, colon, pancreas, and kidney) by nested and real-time PCR. The four intrachromosomal chimeras (*PRKAA-TTC33*, *SAMM50-PARVB*, *URB1-C21ORF45*, and *CTBS-GNG5*) were detected in all screened normal tissues (Figure 4). This was consistent with previous findings on the expression of oncogenic mRNA chimeras in normal tissues [4,13,14,17–20]. However, we found essentially no trace of the *CHD2-CHMP1A* interchromosomal chimera in normal tissues. *CHD2-CHMP1A* was expressed by almost all cancer cell lines (13/14), thus appearing as a cancer-related event.

Expression of Growth Regulatory Chimeras in Primary Tumors

In vitro cell growth regulatory chimeras are expressed by different cancer histotypes. Total RNA was extracted from breast, ovarian, gastric, colon, kidney, and uterine tumors [13,48], was reverse transcribed, and amplified. We took advantage of chimeric-band melting-temperature specificity peaks (Figure S3E) to select for *bona fide* amplification candidates. Amplified candidates were then systematically sequenced. *PRKAA-TTC33* was detected in all 25 of these tumors, *SAMM50-PARVB* in 15 tumors, *P2RX5-TAX1BP3* in 8 tumors, and *URB1-C21ORF45* in 21 tumors; *CTBS-GNG5* was detected in almost all tumors (Figure 5A and Table 1); *CHD2-CHMP1A* was identified in 11 tumors (Figure 5B). *ADK-DHX8* was diagnosed in two tumors (Figure 5C). Hence, growth regulatory chimeras are broadly expressed in human tumors but in heterogeneous manners. This suggests a positive selective pressure [49] for a fusion mRNA-based growth regulatory mechanism during tumor development, which appears to operate in a chimera and tumor-type-specific manner.

Discussion

We have opened the field of the *in silico* identification of mRNA chimeras in cancer cells, through analysis of cDNA sequence databases [24]. NGS approaches have enormously increased the amount of sequencing data of potential use for chimera discovery. However, short-read second-generation NGS analyses identify mRNA chimeras through a probabilistic fitting of highly multiplexed short-tag data sets [7,19,20,25–28,50–53], which severely affects both specificity and sensitivity of detection of mRNA chimeras. However, rapid progress is being made toward achieving longer sequence reads and higher sequencing accuracy, which allows to reduce sequence errors while improving contig assembly procedures. To permit high-throughput, high-specificity chimera discovery in long-read sequence data sets, we have developed the FusionMiner search strategy. This was shown to reach a 95.9% chimera identification specificity, with a low 4.1% false-negative classification rate. This search strategy was extensively validated by RT-PCR and cDNA sequencing (Table S1b).

Global chimera frequencies were computed for separate sequencing projects. Analysis of a human transcriptomic 454 data set of 19,527 contigs and 173,005 singlettons led to the identification of four sequences as *bona fide* chimeras, for a chimera frequency of 4/192,532, i.e., 2×10^{-5} of all mRNA. High-throughput sequencing

of cDNA libraries from tumors and corresponding normal tissues generated 1,774,453 long-read sequences. Twenty-five were identified by FusionMiner as *bona fide* chimeras, for a chimera frequency of 25/1,774,453, i.e., 1.4×10^{-5} , in remarkable agreement with the NGS data. Taken together, these findings suggest a chimera frequency of $\approx 2 \times 10^{-5}$ in cellular transcriptomes. Issues of data set size and of transcriptome tissue specificity suggest these to be minimal estimates. A proof of principle of this scenario was obtained, as one of the interchromosomal chimeras, which could not be detected in cell lines, and was identified in 2 of 10 primary breast cancers.

Most of the chimeras analyzed were shown to have a regulatory role in transformed cell growth [54,55]. Notably, tumor growth inhibitory mRNA chimeras, e.g., *URB1-C21ORF45* and *CTBS-GNG5*, were also discovered. Of interest, these were shown to have inhibitory capacity on the growth of a subset of ovarian cancer cells, whereas other ovarian and breast cancer cells were not affected, suggesting different regulatory contexts for chimera-driven growth control in different cell lines. Most tumors were shown to express these growth regulatory chimeras, consistent with a positive selective pressure for exploiting this growth regulatory mechanism during tumor development.

Acknowledgments

We thank M. Iacono for providing the Roche NGS data sets and C. Berrie for critical reading and editing of the manuscript.

References

- [1] Mitelman F, Johansson B, and Mertens F (2007). The impact of translocations and gene fusions on cancer causation. *Nat Rev Cancer* **7**, 233–245.
- [2] Mercer TR, Dinger ME, and Mattick JS (2009). Long non-coding RNAs: insights into functions. *Nat Rev Genet* **10**, 155–159.
- [3] Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* **310**, 644–648.
- [4] Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F, et al. (2009). SLC45A3-ELK4 is a novel and frequent erythroblast transformation–specific fusion transcript in prostate cancer. *Cancer Res* **69**, 2734–2738.
- [5] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. (2007). Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer. *Nature* **448**, 561–566.
- [6] Fehr A, Roser K, Heidorn K, Hallas C, Loning T, and Bullerdiek J (2008). A new type of MAML2 fusion in mucoepidermoid carcinoma. *Genes Chromosomes Cancer* **47**, 203–206.
- [7] Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleiman K, et al. (2010). Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nat Med* **16**, 793–798.
- [8] Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, and Nikiforov YE (2005). Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. *J Clin Invest* **115**, 94–101.
- [9] Santoro M, Melillo RM, and Fusco A (2006). RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. *Eur J Endocrinol* **155**, 645–653.
- [10] Edwards PA (2010). Fusion genes and chromosome translocations in the common epithelial cancers. *J Pathol* **220**, 244–254.
- [11] Skotheim RI, Thomassen GO, Eken M, Lind GE, Micci F, Ribeiro FR, Cerveira N, Teixeira MR, Heim S, Rognes T, et al. (2009). A universal assay for detection of oncogenic fusion transcripts by oligo microarray analysis. *Mol Cancer* **8**, 5.
- [12] Bruzik JP and Maniatis T (1992). Spliced leader RNAs from lower eukaryotes are trans-spliced in mammalian cells. *Nature* **360**, 692–695.
- [13] Guerra E, Trerotola M, Dell'Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccarella T, Crescenzi C, Lorenzini F, Rossi C, et al. (2008). A bicistronic

- CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. *Cancer Res* **68**, 8113–8121.
- [14] Li H, Wang J, Mor G, and Sklar J (2008). A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. *Science* **321**, 1357–1361.
- [15] Terrinoni A, Dell'Arciprete R, Fornaro M, Stella M, and Alberti S (2001). Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cells. *Genes Chromosomes Cancer* **31**, 209–220.
- [16] Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, and Chinnaiyan AM (2009). Transcriptome sequencing to detect gene fusions in cancer. *Nature* **458**, 97–101.
- [17] Communi D, Suarez-Huerta N, Dussossoy D, Savi P, and Boeynaems J-M (2001). Cotranscription and intergenic splicing of human *P2Y₁₁* and *SSF₁* genes. *J Biol Chem* **276**, 16561–16566.
- [18] Li H, Wang J, Ma X, and Sklar J (2009). Gene fusions and RNA trans-splicing in normal and neoplastic human cells. *Cell Cycle* **8**, 218–222.
- [19] Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin PC, Svensson MA, Kitabayashi N, Moss BJ, Macdonald TY, et al. (2010). Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. *Genome Res* **21**, 56–67.
- [20] Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, et al. (2011). Identification of fusion genes in breast cancer by paired-end RNA-sequencing. *Genome Biol* **12**, R6.
- [21] Ambrogi F, Biganzoli E, Querzoli P, Ferretti S, Boracchi P, Alberti S, Marubini E, and Nencini I (2006). Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods. *Clin Cancer Res* **12**, 781–790.
- [22] Rabbits TH and Stocks MR (2003). Chromosomal translocation products engender new intracellular therapeutic technologies. *Nat Med* **9**, 383–386.
- [23] Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, and Parodi S (2004). Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. *Biochim Biophys Acta* **1705**, 103–120.
- [24] Romani A, Guerra M, Trerotola M, and Alberti S (2003). Detection and analysis of spliced chimeric mRNAs in sequence databanks. *Nucleic Acids Res* **31**, 1–8.
- [25] Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS, et al. (2010). FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. *Genome Biol* **11**, R104.
- [26] Nacu S, Yuan W, Kan Z, Bhatt D, Rivers CS, Stinson J, Peters BA, Modrusan Z, Jung K, Seshagiri S, et al. (2011). Deep RNA sequencing analysis of read-through gene fusions in human prostate adenocarcinoma and reference samples. *BMC Med Genomics* **4**, 11.
- [27] Asmann YW, Hossain A, Necela BM, Middha S, Kalari KR, Sun Z, Chai HS, Williamson DW, Radisky D, Schrot JP, et al. (2011). A novel bioinformatics pipeline for identification and characterization of fusion transcripts in breast cancer and normal cell lines. *Nucleic Acids Res* **39**, e100.
- [28] Iyer MK, Chinnaiyan AM, and Maher CA (2011). ChimeraScan: a tool for identifying chimeric transcription in sequencing data. *Bioinformatics* **27**, 2903–2904.
- [29] Carletti E, Guerra E, and Alberti S (2006). The forgotten variables of DNA array hybridization. *Trends Biotechnol* **24**, 443–448.
- [30] Shendure J and Ji H (2008). Next-generation DNA sequencing. *Nat Biotechnol* **26**, 1135–1145.
- [31] Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, and Pallen MJ (2012). Performance comparison of benchtop high-throughput sequencing platforms. *Nat Biotechnol* **30**, 434–439.
- [32] Mardis ER (2011). A decade's perspective on DNA sequencing technology. *Nature* **470**, 198–203.
- [33] Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, and Varmus HE (2002). Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. *Cancer Cell* **1**, 53–62.
- [34] Alberti S and Fornaro M (1990). Higher transfection efficiency of genomic DNA purified with a guanidinium thiocyanate-based procedure. *Nucleic Acids Res* **18**, 351–353.
- [35] Dell'Arciprete R, Stella M, Fornaro M, Ciccocioppo R, Capri MG, Naglieri AM, and Alberti S (1996). High-efficiency expression gene cloning by flow cytometry. *J Histochem Cytochem* **44**, 629–640.
- [36] Alberti S, Nutini M, and Herzenberg LA (1994). DNA methylation prevents the amplification of TROP1, a tumor-associated cell surface antigen gene. *Proc Natl Acad Sci USA* **91**, 5833–5837.
- [37] Alberti S and Herzenberg LA (1988). DNA methylation prevents transfection of genes for specific surface antigens. *Proc Natl Acad Sci USA* **85**, 8391–8394.
- [38] Alberti S, Parks DR, and Herzenberg LA (1987). A single laser method for subtraction of cell autofluorescence in flow cytometry. *Cytometry* **8**, 114–119.
- [39] Biganzoli E, Coradini D, Ambrogi F, Garibaldi JM, Lisboa P, Soria D, Green AR, Pedriali M, Piantelli M, Querzoli P, et al. (2011). p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. *Jpn J Clin Oncol* **41**, 172–179.
- [40] Querzoli P, Coradini D, Pedriali M, Boracchi P, Ambrogi F, Raimondi E, La Sorda R, Lattanzio R, Rinaldi R, Lunardi M, et al. (2010). An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. *Br J Cancer* **103**, 1835–1839.
- [41] Tinari N, Lattanzio R, Natoli C, Cianchetti E, Angelucci D, Ricevuto E, Ficarella C, Marchetti P, Alberti S, Piantelli M, et al. (2006). Changes of topoisomerase IIα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. *Clin Cancer Res* **12**, 1501–1506.
- [42] Brummelkamp TR, Bernards R, and Agami R (2002). A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**, 550–553.
- [43] Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**, 494–498.
- [44] Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, and Fesik SW (2003). Specificity of short interfering RNA determined through gene expression signatures. *Proc Natl Acad Sci USA* **100**, 6347–6352.
- [45] Chalk AM, Wahlestedt C, and Sonnhammer EL (2004). Improved and automated prediction of effective siRNA. *Biochem Biophys Res Commun* **319**, 264–274.
- [46] Bonasera V, Alberti S, and Sacchetti A (2007). Protocol for high-sensitivity/long linear-range spectrofluorimetric DNA quantification using ethidium bromide. *Biotechniques* **43**, 173–176.
- [47] Akiva P, Toporik A, Edelheit S, Peretz Y, Diber A, Shemesh R, Novik A, and Sorek R (2006). Transcription-mediated gene fusion in the human genome. *Genome Res* **16**, 30–36.
- [48] Querzoli P, Pedriali M, Rinaldi R, Lombardi AR, Biganzoli E, Boracchi P, Ferretti S, Frasson C, Zanella C, Ghisellini S, et al. (2006). Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. *Clin Cancer Res* **12**, 6696–6701.
- [49] Alberti S (1997). The origin of the genetic code and protein synthesis. *J Mol Evol* **45**, 352–358.
- [50] Ge H, Liu K, Juan T, Fang F, Newman M, and Hoeck W (2011). FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. *Bioinformatics* **27**, 1922–1928.
- [51] Hu Y, Wang K, He X, Chiang DY, Prins JF, and Liu J (2010). A probabilistic framework for aligning paired-end RNA-seq data. *Bioinformatics* **26**, 1950–1957.
- [52] McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, Griffith M, Heravi Moussavi A, Senz J, Melnyk N, et al. (2011). deFuse: an algorithm for gene fusion discovery in tumor RNA-seq data. *PLoS Comput Biol* **7**, e1001138.
- [53] Kinsella M, Harismendy O, Nakano M, Frazer KA, and Bafna V (2011). Sensitive gene fusion detection using ambiguously mapping RNA-Seq read pairs. *Bioinformatics* **27**, 1068–1075.
- [54] Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, Lattanzio R, Piantelli M, and Alberti S (2012). The Trop-2 signalling network in cancer growth. *Oncogene*. DOI: 10.1038/onc.2012.151 [E-pub ahead of print].
- [55] Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, Lattanzio R, de Lange R, Weidle UH, Piantelli M, et al. (2012). Upregulation of Trop-2 quantitatively stimulates human cancer growth. *Oncogene*. DOI: 10.1038/onc.2012.36 [E-pub ahead of print].

SUPPLEMENTAL MATERIAL**Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNAs**

Roberto Plebani, Gavin R. Oliver, Marco Trerotola, Emanuela Guerra, Pamela Cantanelli, Luana Apicella, Andrew Emerson, Alessandro Albiero, Paul D. Harkin, Richard D. Kennedy and Saverio Alberti

Supplemental material includes:

Supplemental Material and Methods

Supplemental Sequence Data

Supplemental Figures 1-4

Supplemental Tables 1-11

Supplemental References

Supplemental Material and Methods

Chimeric mRNA detection procedure. We designed the FusionMiner software workflow (Figure 1) to process BLAST analyses of query sequences against genomic databanks via sequential stages of analysis and exclusion, pass-or-fail tests. Candidate chimera were cross-validated versus experimentally verified sequences and by RT-PCR.

Alignments versus genomic assemblies were first parsed to remove spurious data on the basis of length and percent identity (=98%, over =95% of a candidate length). Individual filtered alignments were then clustered and concatenated across alignment breaks and intronic regions, based on a permissible gap criterion, to identify their genomic context. Sequences aligning to one or two chromosomes were segregated and processed separately, as intra-chromosomal (which most frequently derive from inter-genic transcription) and inter-chromosomal (which most frequently derive from chromosomal translocations and trans-splicing) chimeric candidates, respectively.

The fusion point (FP) for inter-chromosomal candidates was expected to correspond to the point in a clustered alignment where a sequence ceased to align with one chromosome and started to align with the second. Alignments on either side of a FP were assessed on the basis of length and percent identity (defaults =100 bp length, =98% identity), following clustering of the original alignments and weighted averaging of percent identities. This was to ensure that only high-quality alignment data were used in chimeras detection, while low quality or spurious alignments were dropped out. FPs were then examined and filtered, based on the degree of overlap at this position (default =10 bp). Allowing this degree of error ensured retention of true chimeras with small areas of fortuitous sequence homology across the other side of the FP. A parallel filtration procedure was applied for gaps at FP (default =10 bp), which allowed to compensate for possible sequencing errors at this position. Successful candidates were then checked for agreement of their FP with known exon boundaries, using genomic coordinate data from Ensembl, although non-canonical FP (i.e. recombinations within exons) were also identified and separately stored. Ensembl was chosen as genomic coordinate reference site as it contains confirmed gene predictions, which are integrated with external data sources, including the Sanger Institute HAVANA [1], RefSeq at NCBI [2], and the UCSC Genome Browser [3]. When candidate-chimera FPs were found to correspond to an exon-exon boundary, candidates were accepted. Intra-chromosomal candidates were treated in a corresponding manner. A permissible error threshold (default 3 bp) was applied at this stage, to compensate for sequencing errors or alignment blurring due to small areas of local homology on either side of a boundary.

Both chimera partner mRNAs were selected for occurrence in the same reading orientation versus known mRNAs (i.e. plus orientation). Joining to a ‘minus’ strand is, indeed, most likely generated by cDNA recombination during library construction [4]. A special case is that of a gene that transcribes both the minus and the plus strands. Of note, both mRNA classes would be available for matching in transcript datasets. FusionMiner would then operationally qualify both mRNAs as ‘plus’.

Accepted candidates then entered a clustering step, whereby they were assessed and grouped if they shared the same FP. A disagreement of up to 10 bp was allowed during clustering, consistent with the errors permitted at the stage of FP definition. Chimeras were then sorted and presented in order of multiplicity of occurrence.

FusionMiner also allowed to identify and cluster candidates which were rejected during the exon-boundary checking stage. This was to permit the discovery of recurrent, non-canonical chimeras, which are expected to derive from DNA joining at recombination hot spots [5].

Prediction of reading-frame preservation at the FP was then performed.

FusionMiner search performance. The performance of the FusionMiner detection strategy (Figure S1) was assessed by screening the Dana Farber Cancer Institute (DFCI) Gene Index Project tentative human consensus (THC) collection (Figure S1). This led to the identification of 228 chimeras (105 inter-chromosomal and 123 intra-chromosomal), involving 414 genes (Tables S1-S3). Chimeras discovered by FusionMiner in the DFCI Gene Index Project encoded enzymes (16%), transcription factors/ chromatin modulators (11.5%), G proteins (5.8%), protein binding partners (5.8%), transporters (4.5%), cytoskeletal proteins (2.6%), receptors and proteases (1.9%). Curated sequence analysis [4] indicated that 221 of the 228 chimeric mRNAs candidates (96.9%) did fit all *bona fide* chimera criteria. Sixty-one of these chimeras were uniquely identified by FusionMiner (Table S3).

FusionMiner default settings were optimized to obtain maximum specificity in chimera detection. To provide differential estimates of performance (sensitivity versus specificity), FusionMiner analysis parameters were then systematically altered, and their impact on analysis outcomes was assessed.

Splicing at exon/exon borders: exon-exon boundary settings were relaxed, by extending the tolerance up to 8 bp, i.e. exon boundaries were allowed to be identified within 8 bp of BLAST alignments borders. This can be useful for specific requirements, e.g. for short-sequence-length datasets, or for alignments to poor-quality genome sequence regions. Thirty-nine additional sequences were obtained as compared with the default 3 bp tolerance (Tables S1b, S4-S6). Thirty-seven of these appeared to be

bona fide chimeras (96.6% specificity, versus 96.9% with optimal/ default parameters, -0.3% specificity; $228 + 39 = 267$; +17.1% sensitivity).

Bp gap: Extending the allowed gaps in FusionMiner to 30 bp, instead of the 10 bp default, resulted in identification of only 4 additional chimeras (Tables S1b, S4-S6). Three of these (75%) were *bona fide* fusion sequences.

Percent query identity (%ID): A low %ID might be due to gaps, bad sequencing, or real mismatch regions. The default requirement for 98% ID was thus relaxed to 94%, to allow detection of these problematic sequences. Thirty-four additional chimeras were detected versus default values (Tables S1b, S4-S6). Thirty two of these (91.4%) were confirmed to be true positive *bona fide* fusion sequences (-0.4% specificity; +14.9% sensitivity).

Query length: The FusionMiner strategy/ sequential validation/ parameter combination was optimized for the recognition of small, *bona fide* chimeric sequences from NGS analysis. We validated this by analyzing chimeras with 50-base matches around a fusion joint. By shortening the minimum allowed length for matches from 100 bp to 50 bp, we identified 59 additional THC sequences versus the default searches (Tables S1b, S4-S6). Strikingly, 56 out of these 59 (94.9%) were true positives (-0.4% specificity; +25.9% sensitivity). Remarkably, 349 of 364 (95.9%) chimeric mRNAs detected by FusionMiner from THC were shown to fit chimera identification criteria.

Validation of discovered THC chimeras. THC chimeras from breast cancer (4 sequences) were searched for in breast cancer cell lines (Figure S1). cDNAs were obtained from MCF-7, MCF-7/Almac, HBL-100, SK-BR-3, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, and MDA-MB-468 cells, and each chimera was amplified by direct or nested PCR. All PCR amplified bands were verified by sequencing. Successful amplification was achieved for 3 out of 4 chimeras (75%), i.e. *THC2538403 ZNF498-CUX1* (4/9 lines), *THC2523555* (an additional long intergenic transcript was identified as ENST00000358157) *C9orf47-S1PR3* (8/9 lines) and *THC2668182 KLH22-SCARF2* (7/9 lines) (Figure S1). We then extended this analysis to SKOV-3, IGROV-1, OVCAR-3 and OVCA-432 ovarian cancer cells. Two of the chimeras from breast cancer, i.e. *THC2523555 C9orf47-S1PR3* and *THC2668182 KLH22-SCARF2*, were identified in all four ovarian cancer cell lines (Figure S1), suggesting broad expression across different tumor histotypes. Chimeric sequence abundance was measured by real-time quantitative PCR (Figure S1B). Chimeras were detected at considerably different levels in the tested cell lines, consistent with a regulated expression [6-11].

FusionMiner performance on long-reads NGS datasets. FusionMiner was further validated on long-sequence read from 454-generated output files. A 454 Titanium dataset of 1,241,098 reads, 355.5 bp in average length (www.bmr-genomics.it/~alex/ALBERTI/) was compiled by Newbler into 19,527 contigs and 173,005 singletons; 28,561 sequences were identified as outliers. FusionMiner identified one inter-chromosomal and three intra-chromosomal *bona fide* chimeras (Tables S1, S7, Supplemental Sequence Data). These findings reveal absolute chimeras frequencies of 2×10^{-5} (4 out of 192,532) in whole cell transcriptomes.

Supplemental Sequence Data

Sequences, BLAST alignments, and exons involved in fusions are indicated for the individual novel chimeras identified from specific sequencing datasets. The interaction networks of the proteins encoded by growth-regulatory chimera partners are shown.

Legend:

Borders of exons involved at junction points are indicated before each BLAST alignment.

Arrows indicate beginning/ end of BLAST alignments.

Chromosome location of each partner gene is indicated.

Gene descriptions are provided (Entrez gene, UniProtKB/Swiss-Prot databases).

Chimeras sequences


PRKAA1-TTC33

```
TTGGATCAAAGATATCAGGAACATGAATGGTTAACAGGACCTCCAAAATATCTCTTCTGAGGATCCATCATAGTTCAACCAGATTGATGATGA
GCCTTAAAGAAGTATGTGAAAGTGTGCTCAGAAGAGGAAGTCTCAGCTGCTTTACAACAGAAATCACCAGGATCCTTGGCAGTTGCCTACCATC
TCATAATAGATAACAGGAAATAATGAATGAAGCCTACGGGACGGCATACCCGACTGATTCTTGATGATCATCACCTGACTCGGCCCC
TCCTGAAAGAGTACCCATTCTGGTTGCTGAAACACCAAGGGCACGCCATACCCGACTGATTAAATCCACAGAAATCACCAGGTTGAAGGAAAGC
AAATGGCATTAGGAATTAGAAGTCAAAGTCGACCAAATGATATTATGGCAGAAGTATGAGAGCAATCAAACAAATTGGATTATGAATGGAAGGTTGTAACAC
CATATTATTCGCTGTACGAAGGAAGAACCTGTGACAAGCACTTACTCCAAAATGAGTCTACAGTTACCAAGTGGATAGTAGAAACTTATCTACTGGATT
CCGTAGTATTGATGAATGGCTCCTTGGTGGAAAGAGGAAATTGGTGAGAAGGCTCAAGGTCACCTCCAGCAGCTGAAAGCTGCTGAGATGAG
AGGATGAGTTGACAACGATGAAAGAACTGGCTCATGCCATTAAACGTAGAAAGAAATTCTCTTGAAACGCTGTGCTGAGAAAAGTAAACAGCTGAAAGATG
AGAGCAGTTGGCTGAAAATAAAAGATTCGGGAGGAATTCAAGTGGGATGAAAGCACTACAGTTAACTCTAAATGATGCTACCTATACGAGATGAAA
CACAGTGCTAATGTCCTTCATGAAATGTTCCCGACGACTACATGCGACGAGAAATGCCGTACGCAAATCCACATTGAGTGGAGTCTGCAGACTTGGGACGTG
TCACCTGTTAGGAGAAATCTTGCAATTGAGGTTCACTAGCCCTCAATCTATCCATGACTGAATGGAAGGAGACCTCCTGGCAGACGCCCTCAGGA
GCCGAAAAGT
```

Sanger sequencing (forward and reverse)

EMBOSS_001	1	TTTGCCTGTACGAAGGAAGAACCTGTGACAAGCACTTACTCCAAAATGA	50
Pcr band	1	TTTGCCTGTACGAAGGAAGAACCTGTGACAAGCACTTACTCCAAAATGA	50
EMBOSS_001	51	GTCTACAGTTATACCAAGTGGATAGTAGAAACTTATCTACTGGATTCCGT	100
Pcr band	51	GTCTACAGTTATACCAAGTGGATAGTAGAAACTTATCTACTGGATTCCGT	100
EMBOSS_001	101	AGTATTGATGAATGGCTCCTTGGTGGAAAGAGGAAATTGGTGAGAAG	150
Pcr band	101	AGTATTGATGAATGGCTCCTTGGTGGAAAGAGGAAATTGGTGAGAAG	150
EMBOSS_001	151	GTCTCAAAGGTCACTTCCCAGC	172
Pcr band	151	GTCTCAAAGGTCACTTCCCAGC	172

5' partner: PRKAA1



Junction point
exon=9 1315..1441
/gene="PRKAA1"

/gene_synonym="AMPK; AMPK α 1; MGC33776; MGC57364"

BLAST vs mRNA

>ref|NM_006251.5| UniGene info linked to NM_006251.5GEO profiles info linked to NM_006251.5Gene info linked to NM_006251.5Genome view with mapviewer linked to NM_006251.5 Homo sapiens protein kinase, AMP-activated, alpha 1 catalytic subunit (PRKAA1), transcript variant 1, mRNA
Length=5085

Length=3083
GENE ID: 5562 PRKAA1 | protein kinase, AMP-activated, alpha 1 catalytic subunit [Homo sapiens]
Score = 1162 bits (629), Expect = 0.0
Identities = 629/629 (100%), Gaps = 0/629 (0%)


Strand=Plus/Plus

Query	5	ATCAAAGATATCAGGGAACATGAATGGTTAACAGGACCTTCCAAAATATCTCTTCCT	64
Sbjct	814	ATCAAAGATATCAGGGAACATGAATGGTTAACAGGACCTTCCAAAATATCTCTTCCT	873
Query	65	GAGGATCCATCATATACTTCAACCATGATTGATGATGAAGCCTTAAAGAAGTATGTGAA	124
Sbjct	874	GAGGATCCATCATATACTTCAACCATGATTGATGATGAAGCCTTAAAGAAGTATGTGAA	933
Query	125	AAGTTTGAGTGCTCAGAAGAGGAAGTCTCAGCTGTTACAAACAGAAATCACCAGGAT	184
Sbjct	934	AAGTTTGAGTGCTCAGAAGAGGAAGTCTCAGCTGTTACAAACAGAAATCACCAGGAT	993
Query	185	CTTTGCGCATTCGCCTACCATCTCATATAAGATAACAGGAGAATAATGAATGAAGCCAA	244
Sbjct	994	CTTTGCGCATTCGCCTACCATCTCATATAAGATAACAGGAGAATAATGAATGAAGCCAA	1053
Query	245	GATTCTATTTGGCGACAAGCCCACCTGATTCTTCTTGATGATCATCACCTGACTCGG	304
Sbjct	1054	GATTCTATTTGGCGACAAGCCCACCTGATTCTTCTTGATGATCATCACCTGACTCGG	1113
Query	305	CCCCATCCTGAAAGAGTACCATCTTGGTTGCTGAAACACCAAGGGCACGCCATACCCCTT	364
Sbjct	1114	CCCCATCCTGAAAGAGTACCATCTTGGTTGCTGAAACACCAAGGGCACGCCATACCCCTT	1173
Query	365	GATGAATTAAATCCACAGAAATCCAAACACCAAGGTGTAAGGAAAGCAAATGGCATTTA	424
Sbjct	1174	GATGAATTAAATCCACAGAAATCCAAACACCAAGGTGTAAGGAAAGCAAATGGCATTTA	1233
Query	425	GGAATTAGAAGTCAAAGTCGACCAAATGATATTATGGCAGAAGTATGTAGAGCAATCAA	484
Sbjct	1234	GGAATTAGAAGTCAAAGTCGACCAAATGATATTATGGCAGAAGTATGTAGAGCAATCAA	1293
Query	485	CAATTGGATTATGAATGGAGGTGTAACCCATATTATTCGCTGTACGAAGGAAGAAT	544
Sbjct	1294	CAATTGGATTATGAATGGAGGTGTAACCCATATTATTCGCTGTACGAAGGAAGAAT	1353
Query	545	CCTGTGACAAAGCACTTACTCCAAATGAGTCTACAGTTACCCAAGTGGATACTGAACT	604
Sbjct	1354	CCTGTGACAAAGCACTTACTCCAAATGAGTCTACAGTTACCCAAGTGGATACTGAACT	1413
Query	605	TATCTACTGGATTCCTGAGTATTGATGA	633
Sbjct	1414	TATCTACTGGATTCCTGAGTATTGATGA	1442

↑

PRKAA1 interaction network.


Protein kinase, AMP-activated, alpha 1 catalytic sub-unit (AMPK1). Major interactions are with AMP, p53, AKT, mTOR, TGFB1 and cell cycle regulatory proteins.



Summary for PRKAA1

PKA belongs to Ser/Thr protein kinases. It is the catalytic subunit of the cAMP-activated protein kinase (AMPK). AMPK is a cellular energy sensor conserved in all eukaryotic cells. The kinase activity of AMPK is activated by the stimuli that increase cell AMP/ATP ratio. AMPK regulates key metabolic enzymes through phosphorylation. It protects cells from stress that causes ATP depletion by switching-off ATP-consuming biosynthetic pathways. PKA regulates fatty acid synthesis by phosphorylation of acetyl-CoA carboxylase. It also regulates cholesterol synthesis via phosphorylation and inactivation of hormone-sensitive lipase and hydroxymethylglutaryl-CoA reductase.


3' partner: TTC33


Junction point
exon=2 148..369
/gene="TTC33"
/gene_synonym="OSRF"
BLAST vs mRNA

```
>ref|NM_012382.2| UniGene info linked to NM_012382.2GEO profiles info linked to NM_012382.2Gene info
linked to NM_012382.2Genome view with mapviewer linked to NM_012382.2 Homo sapiens tetratricopeptide
repeat domain 33 (TTC33), mRNA
Length=5519
GENE ID: 23548 TTC33 | tetratricopeptide repeat domain 33 [Homo sapiens]
Score = 741 bits (401), Expect = 0.0
Identities = 492/530 (93%), Gaps = 30/530 (5%)
```

Strand=Plus/Plus


Query 632	GAATGGCTTCCCTTGGGTGGAAGAGGAAAATTGGTGAGAAGGTCTCAAAGGTCACTTCCC	691
Sbjct 147	GAATGGCTTCCCTTGGGTGGAAGAGGAAAATTGGTGAGAAGGTCTCAAAGGTCACTTCCC	206
Query 692	AGCAGTTGAAGCTGAAGCTGCTGATGAGAAGGATGTAGTTGACAACGATGAA-AGAACT	750
Sbjct 207	AGCAGTTGAAGCTGAAGCTGCTGATGAGAAGGATGTAGTTGACAACGATGAAGGGAACT	266
Query 751	GGCTTCATGCCATTAACGTA-GAAAGAAAATTCTTCTTGAACGCTGTGCTGAGAAAAGTA	809
Sbjct 267	GGCTTCATGCCATTAACGTTAGGAAAGAAAATTCTTCTTGAAGGCTGTGCTGAGAAAAGTA	326
Query 810	AACAGCTGAA-GATGAA-GAGCCAGTTGGCTGAAAATAAAAGATATCGGAGGCAATT	867
Sbjct 327	AACAGCTGAAAGGTGAAGGAGGCCAGTTGGCTGAAAATAAAAGATATCGGAGGCAATT	386
Query 868	AGAACGGGATGAAGCACTACAGTTAACCTCTAAATGATGCTACCCCTATACGGAGATGAAAT	927
Sbjct 387	AGAACGGGATGAAGCACTACAGTTAACCTCCAAATGATGCTACCCCTATACGGAGATGAAAT	446
Query 928	CACAG-TGCTAATGTCTTCTCATGAAATGTTCCCAGCAGTACATGCAGCAGAAATG-CCG	985
Sbjct 447	CACAGGTGCTAATGTCTTCTCATGAAATGTTCCCAGCAGTACATGCAGCAGAAATGGCCG	506

TTC33 interaction network.


Summary for TTC33
Tetratricopeptide repeat protein 33. Size: 262
amino acids; 29411 Da Secondary accessions:
B2R6G0 O95105.


SAMM50-PARVB

TTGGGAAAGCGGACATTCACTGAAATCATCTCTTCGCACGCCATGGTCATCGATTCTCGGAATTCTTCCATCTTACCAAGGAGAGGTGCTTGCTGAAAGT
AACCAGGAACTGGCAGGCTACACTGGCGGGATGTGAGCTTCATCAAAGAAGATTGAACTTCAGTTGAAACAAGCAACTCATATTGATTCAAGCTTTCAG
CGTCTTCTGGGGCGGAATGGTACCCATTGGTATAAGCGTCAGCATTGCTGATAGGTTTACCTCGGGGACCCACAAGCGTCCCGGATTCA
GCACAGCATGGGGCACAGAGGCAAGGAGACTACAGGAGAGCTGACTGGGAGGAGCTGACCTGCAACCTCAACTATGGGAGGGCCCCAAAGCTCATATTGTAAGCTG
GGTGGCTTGAGAACACTTTCGAACACACTTCTTCTCAACCGCAGGAAACCTCTGCAACCTCAACTATGGGAGGGCCCCAAAGCTCATATTGTAAGCTG
CTGAGTCATCGCTGGTCACTGGGGGGATTGTCCTCAGGCTGGCAACATCGCTGGTGAACCTAATTACTGCGTCCCCATGGAGTACAGACAG
TGACAGTGAGTGACCTGCAGGAAGAAGGAAGAACATGCATCAACTCACCGATGTCCCCCGCCCTGGCGGATGTTCACCTGAAGACACCCAGCTGAGGAGA
CGAGGAGCGCACGATGATTGACCCCACCTCCACGAAGACCCCAAGTCAAGGAACGGTCAAGGTAAGTGGATTAATGACGTGCTGGTGGAGGAG
GGATCATTGTGAAGCAGCTGGAGGAAGACCTGTATGACGGCCAGGTGCTGAGAATCTCTGGAAAAACTGGCAAGGTGAAAGCTGAATGTGGCTGAGTGAC
CAGTCGAAATAGGCAGAAACAAAGCTGTCGACCGGTGCTGGAGCAGTACATGACCTGTCGCCCTAAGCTGGGCTCGTGGAGCGTGAATCAATTCCG
GAAGACTGTGCATCCTCACTGCTGTTCTCTGCATGACTCAGACCCATCCGCTCTGAACATGTACGGCAGGTGGGCGGAACCGAACGCTTGTATA
GCACTCCGGAGAAGTGACCTACATCGAGTATAGC

Sanger sequencing (forward and reverse)

RDBC0852_G11.	2	TCGCTCGTTGAACTTAATTACTGCGTCCCCATGGGAGTACAGACAGGT	51
FUSintra3-4R2	2	TCGCTCGTTGAACTTAATTACTGCGTCCCCATGGGAGTACAGACAGGC	51
RDBC0852_G11.	620	GACAGTGAGTGACCTGCAGGAAGAAGGCAAGAACATGCCATCAACTCACCG	101
FUSintra3-4R2	52	GACAGTGAGTGACCTGCAGGAAGAAGGCAAGAACATGCCATCAACTCACCG	101

5' partner: SAMM50



Junction point

exon=14 1420..1561
 /gene="SAMM50"
 /gene_synonym="CGI-51; FLJ35825; FLJ42905; FLJ99036;
 OMP85; SAM50; TOB55; TRG-3; YNL026W"

BLAST vs mRNA

```
>ref|NM_015380.4| UniGene info linked to NM_015380.4GEO profiles info linked to NM_015380.4Gene info
linked to NM_015380.4Genome view with mapviewer linked to NM_015380.4 Homo sapiens sorting and assembly
machinery component 50 homolog (S. cerevisiae) (SAMM50), mRNA
Length=1773
GENE ID: 25813 SAMM50 | sorting and assembly machinery component 50 homolog (S. cerevisiae) [Homo
sapiens]
Score = 1129 bits (611), Expect = 0.0
Identities = 617/620 (99%), Gaps = 0/620 (0%)
```


Strand=Plus/Plus

Query 5	GAAAGCGGACATTCACTGAAATCATCTCTTCGCACGCCATGGTCATCGATTCTCGGAAT	64
Sbjct 942	GAAAGCGGACATTCACTGAAATCATCTCTTCGCACGCCATGGTCATCGATTCTCGGAAT	1001
Query 65	TCTTCATCTTACCAAGGAGAGGTGCTTGTGAAAGTTAACCGGAACTGGCAGGCTAC	124
Sbjct 1002	TCTTCATCTTACCAAGGAGAGGTGCTTGTGAAAGTTAACCGGAACTGGCAGGCTAC	1061
Query 125	ACTGGGGGGATGTGAGCTTCATCAAAGAAGATTGAACTTCAGTTGAAACAAGCAACTC	184
Sbjct 1062	ACTGGGGGGATGTGAGCTTCATCAAAGAAGATTGAACTTCAGTTGAAACAAGCAACTC	1121
Query 185	ATATTGATTCACTGTTTCAGCGTCTTCTGGGGCGGAATGTTGGTACCCATTGGTAT	244
Sbjct 1122	ATATTGATTCACTGTTTCAGCGTCTTCTGGGGCGGAATGTTGGTACCCATTGGTAT	1181
Query 245	AAGCCGTCAGCATTGCTGATAGGTTTACCTCGGGGACCCACAAGCGTCCCGGATTC	304
Sbjct 1182	AAGCCGTCAGCATTGCTGATAGGTTTACCTCGGGGACCCACAAGCGTCCCGGATTC	1241

Query	305	AGCATGCACAGCATGGGCCACAGAGCGAAGGAGACTACCTAGGTGGAGAACCGTACTGG 	364
Sbjct	1242	AGCATGCACAGCATGGGCCACAGAGCGAAGGAGACTACCTAGGTGGAGAACCGTACTGG	1301
Query	365	GCCGGCGGCCCTGCACCTCACACCCCATTACCTTTCCGGCAGGCCAGGGTGCTTTGGA	424
Sbjct	1302	GCCGGCGGCCCTGCACCTCACACCCCATTACCTTTCCGGCAGGCCAGGGTGCTTTGGA	1361
Query	425	GAACCTTTCCGAACACACTTCTCAACCGAGAAACCTCTGCAACCTCAACTATGGG 	484
Sbjct	1362	GAACCTTTCCGAACACACTTCTCAACCGAGAAACCTCTGCAACCTCAACTATGGG	1421
Query	485	GAGGGCCCCAAAGCTCATATTCTGAAGCTGGCTGAGTCATCCGCTGGCTGAGGGGCC	544
Sbjct	1422	GAGGGCCCCAAAGCTCATATTCTGAAGCTGGCTGAGTCATCCGCTGGCTGAGGGGCC	1481
Query	545	GGGATTGTCTCAGGCTTGGCAACATCGCTCGGTTGGAACTTAATTACTGCGTCCCCATG 	604
Sbjct	1482	GGGATTGTCTCAGGCTTGGCAACATCGCTCGGTTGGAACTTAATTACTGCGTCCCCATG	1541
Query	605	GGAGTACAGACAGGTGACAGC 	624
Sbjct	1542	GGAGTACAGACAGGTGACAGC	1561

↑


SAMM50 interaction network.



Summary for SAMM50

SAMM50 is a component of the sorting and assembly machinery (SAM) complex of the outer mitochondrial membrane. The SAM complex has a role in integrating beta-barrel proteins into the outer mitochondrial membrane.

3' partner: PARVB



Junction point

exon=4 260..349

/gene="PARVB"

/gene_synonym= "CGI-56 "

BLAST vs mRNA

```
>ref|NM_001003828.1| UniGene info linked to NM_001003828.1GEO profiles info linked to  
NM_001003828.1Gene info linked to NM_001003828.1Genome view with mapviewer linked to NM_001003828.1  
Homo sapiens parvin, beta (PARVB), transcript variant 1, mRNA  
Length=1808  
GENE ID: 29780 PARVB | parvin, beta [Homo sapiens]  
Score = 684 bits (370), Expect = 0.0  
Identities = 471/514 (92%), Gaps = 30/514 (5%)
```

Strand=Plus/Plus


↓

Query	623	AGTGAGTGACCTGCAGGAAGAAGGCAAGAACATGCCAACTCACCGATGTCCCCGGCCCT	682
Sbjct	258	AGTGAGTGACCTGCAGGAAGAAGGCAAGAACATGCCAACTCACCGATGTCCCCGGCCCT	317
Query	683	GCGGGATGTTCACCTCTGAAGAACACCCAGCTCGAGGAGAACCGAGGAGCGCACGATGATTGA	742
Sbjct	318	GGTGGATGTTCACCTCTGAAGAACACCCAGCTTGAGGAGAACCGAGGAGCGCACGATGATTGA	377

Query 743	CCCCACTTCC-ACGAAGACCCCAGTTCAAGGAACCTGGTCAGGTCTCGACTGGAT	801
Sbjct 378	CCCCACTTCCAGGAAGACCCCAGTTCAAGGAACCTGGTCAGGTCTCGACTGGAT	437
Query 802	TAATGACGTGCTGGTGAGGAGAGGATCATTGTGAAGCAGCTGGAGGAAGACCTGTATGA	861
Sbjct 438	TAATGACGTGCTGGAGGAGAGGATCATTGTGAAGCAGCTGGAGGAAGACCTGTATGA	497
Query 862	CGGCCAGGTGCTCCAGAATCTCTGGAAAAACTGGCAAGGTGCAAGCTGAATGTGGCTGA	921
Sbjct 498	CGGCCAGGTGCTCCAGAAGCTCTGGAAAAACTGGCAGGGTGCAAGCTGAATGTGGCTGA	557

PARVB interaction network.

Beta parvin is involved in integrin linked kinase signaling. It directly interacts with ILK, ACTIN, ALPHA ACTININ and other proteins.



Summary for PARVB

Members of the parvin family, including PARVB, are actin-binding proteins associated with focal contacts. It probably has a role in the regulation of cell adhesion and cytoskeleton organization.

URB1-C21orf45


```

ATAGCCGGCTCTGTGGGGCTGAGGGGCTGGCAGGGCCTGTGCAGGAGGTGGCCTGCCTGTTCAATACGGTCATGCTGCAGCTGGCTGCCAGGGCCGGGAGGGAGCCCTTTCCACCCGGCATGGAAGCCCTCTCCCTGTCTCTGAGTGAAGAAGGATGAAGCCACACAAGGTGTTCTGTAATGTTCTGTGGATAAACGAACAGAAGCTATCCAACAGTGAAGAGAAAATGGTTGCGTCCTTGAGACTTTGTGCTGCGCGGGGTGCTCACTCAATCTGGCTACGTGTACAGATGCACGCCAAGAATCTTGTATTACAAGAGAGACTTGTGCTCAGTGTGAAGCCATTGAAAGTTATGTTTAGGGTCCCTGAAAGCAAATTGTGTAGAAGATAAGAGCTTTTAATCTTGAAAGCAGAGTTGAAATAGAAAAGTCTAACACAGATGGAAGATGCTTGTGAAGCATTACAATGAAGCTGTGGGAGGCCGAATCCTGAAATTGTGCTTTCCCACTTGTAAGGCTGAACCTAGTCTGTGTCCTCCATTCTGCCCTCCCTCCCTTATTGTTAAATGAAGCAACATAGTGAGCGTCGTCTCTAC
  
```

Sanger sequencing (forward and reverse)

EMBOSS_001	1 GCCCTCTCCCTGTCTTCTCTGAGTGAAGAAGGATGAAGCCACACAAGGTGT	50
PCR band	1 GCCCTCTCCCTGTCTTCTCTGAGTGAAGAAGGATGAAGCCACACAAGGTGT	50
EMBOSS_001	51 TTCCTGTAATGTTCTGTGGATAAGGAACAGAACAGTATCCAAACGTGAAA	100
PCR band	21 TTCCTGT-ATGTTCTGTGGATAAGGAACAGAACAGTATCCAAACGTGAAA	100
EMBOSS_001	101 AGGAAAATGGTTGCGTCCTTGAG-	123
PCR band	101 AGGAAAATGGTTGCGTCCTTGAGA	123

5' partner: URB1



Junction point
exon=38 6128..6727
/gene="URB1"
/gene_synonym="C21orf108; KIAA0539; NPA1"

BLAST vs mRNA


>ref|NM_014825.2| UniGene info linked to NM_014825.2GEO profiles info linked to NM_014825.2Gene info linked to NM_014825.2Genome view with mapviewer linked to NM_014825.2Download subject sequence NM_014825 spanning the HSP Homo sapiens URB1 ribosome biogenesis 1 homolog (S. cerevisiae) (URB1), mRNA
Length=10808
GENE ID: 9875 URB1 | URB1 ribosome biogenesis 1 homolog (S. cerevisiae) [Homo sapiens]
Score = 322 bits (174), Expect = 7e-87
Identities = 176/177 (99%), Gaps = 0/177 (0%)

Strand=Plus/Plus

Query 1	ATAGCCGGCTCTGTGGGCTGAGGGCTGGCAGGCCCTGTGCAGGAGGTGGCCTGCCGTG	60
Sbjct 6551	ATAGCCGGCTCTGTGGGCTGAGGGCTGGCAGGCCCTGTGCAGGAGGTGGCCTGCCGTG	6610
Query 61	TCAATACGGTCATGCTGCAGCTGGTGGCTGCCAGGGCCGGCAGGGAGCCCTTCCACC	120
Sbjct 6611	TCAATACGGTCATGCTGCAGCTGGTGGCTGCCAGGGCCGGCAGGGAGCCCTTCCACC	6670
Query 121	CGGCCATGGAAGCCCTCCCTGTCTCTGAGTGAGAAGGATGAAGCCACACAAG	177
Sbjct 6671	CGGCCATGGAAGCCCTCCCTGTCTCTGAGTGAGAAGGATGAAGCCACACAAG	6727




URB1 interaction network.



Summary for URB1

Nucleolar pre-ribosomal-associated protein 1.
Subcellular location: Nucleus, nucleolus. Secondary
accessions: Q96NX1 Q9NYQ1.

3' partner: C21orf45



Junction point
exon=2 386..452
/gene="MIS18A"
/gene_synonym="B28; C21orf45; C21orf46; FASP1; hMis18alpha; MIS18alpha"

BLAST vs mRNA


>ref|NM_018944.2| UniGene info linked to NM_018944.2GEO profiles info linked to NM_018944.2Gene info linked to NM_018944.2Genome view with mapviewer linked to NM_018944.2 Homo sapiens MIS18 kinetochore protein homolog A (S. pombe) (MIS18A), mRNA
Length=1587
GENE ID: 54069 MIS18A | MIS18 kinetochore protein homolog A (S. pombe) [Homo sapiens]
Score = 826 bits (447), Expect = 0.0
Identities = 451/453 (99%), Gaps = 0/453 (0%)

Strand=Plus/Plus

	↓	
Query 178	GTGTTCCCTGTAATGTTCTGGATAAGGAACAGAACGCTATCCAACACGTGAAAAGGAAA	237
Sbjct 386	GTGTTCCCTGTAATGTTCTGGATAAGGAACAGAACGCTATCCAACACGTGAAAAGGAAA	445
Query 238	ATGGTTCCGTCCTGAGACTTGTGCTCGCGGGGTGGTCACTCAATCTTGCTACGTGT	297
Sbjct 446	ATGGTTCCGTCCTGAGACTTGTGCTCGCGGGGTGGTCACTCAATCTTGCTACGTGT	505
Query 298	ACAGATGCACGCCAAGAATCTTGATTACAAGAGAGACTGTTGCCTCAGTGTGAAG	357
Sbjct 506	ACAGATGCACGCCAAGAATCTTGATTACAAGAGAGACTGTTGCCTCAGTGTGAAG	565
Query 358	CCATTGAAAGTTATGTTAGGGCCTCTGAAAAGCAAATTGTGTCAGAAGATAAGAGC	417
Sbjct 566	CCATTGAAAGTTATGTTAGGGCCTCTGAAAAGCAAATTGTGTCAGAAGATAAGAGC	625
Query 418	TTTTAATCTTGAAGCAGAGTTGAAATAGAAAAGTTCTAACACAGATGGAAGATGTCT	477
Sbjct 626	TTTTAATCTTGAAGCAGAGTTGAAATAGAAAAGTCTAACACAGATGGAAGATGTCT	685
Query 478	TGAAAGCATTACAATGAAGCTGTGGGAGGCCAATCCAAATTGTCCTTCCACTTGTAA	537
Sbjct 686	TGAAAGCATTACAATGAAGCTGTGGGAGGCCAATCCAAATTGTCCTTCCACTTGTAA	745
Query 538	AAAGCTGAACCTCTAGTCGTGTCCTCCATTCTGCCCGCCCTCCTCCCTTATTGTT	597
Sbjct 746	AAAGCTGAACCTCTAGTCGTGTCCTCCATTCTGCCCGCCCTCCTCCCTTATTGTT	805
Query 598	AAATGAAGCAACATAGTGAGACGTCGTCTCTAC	630
Sbjct 806	AAATGAAGCAACATAGTGAGACGTCGTCTCTAC	838

C21ORF45 interaction network.

It indirectly interacts with p53.

**Summary for C21ORF45**


MS18A_HUMAN, Q9NYP9. Protein Mis18-alpha. Subunit: Homodimer, and heterodimer with MIS18B. Identified in a complex containing MIS18A, MIS18B, MIS18BP1, RBBP7 and RBBP4. Subcellular location: nucleus. It associates with centromeres in interphase cells, from late anaphase to G1 phase. It is not detected on centromeres during earlier phases of mitosis and is associated with chromatin.

CTBS-GNG5

TGAATCTGCTGAGGATCATGTTGTACCATTGCAAAAGTCCTTCCGGGGGGCTCTGTAGTGACGCTGCAGGACGTCAGGTGCCCTACAAAAGATCA
GAAGCAAATAAATAGTTCTATTCTGGAACCTATGGGATAAGATCAGCGGGCTCTTATTATAACTATAAAAGTTCCCAGGCAGCTGCAGACTTGAAACAA
TTCTGCTGCAGAATGCTCAACATGACCCCTCTGCTGACTGGAGTATCTTCAAGTACAATCCCTCAGACCCCCAGAAAGTCTGTTCTTTGTAGAAAAAT
AATCTTCAAAGGTTCCAAACCACTCCTTATGATCAGTGAATATTCAAGAGAGCTACATTGAGCCTGTACAAAGCTTATCCTGTAACACATGTGCA
ATAATATACAAACTTTACTTCGTCAGTCCTAACATCTACCTCTGAATTTCATGAATTCTATTCACAAGGTAATTGTTATACACTGGCAGG
AGCATAACAATAAACTTAGTATGAAACTTT

Sanger sequencing (forward and reverse)

EMBOSS_001	1 -CCTACAAAACGATCATGAAGCAAATAAATAGTTCTATTCTGGAAACCT	49
PCR band	1 TCCTACAAAACGATCATGAAGCAAATAAATAGTTCTATTCTGGAAACCT	50
EMBOSS_001	50 ATGGGATAAAAGATCAGCGGGCTCTTATTATAACTATAAAAGTTCCCAGG	99
PCR band	51 ATGGGATAAAAGATCAGCGGGCTCTTATTATAACTATAAAAGTTCCCAGG	100
EMBOSS_001	100 CAGCTGCAGACTTGAAACAGTTCTGCTGCAGAATGCTAACATGACC	147
PCR band	101 CAGCTGCAGACTTGAAACAGTTCTGCTGCAGAATGCTAACATGACC	148

5' partner: CTBS**Junction point**

```

exon=6 861..1022
/gene="CTBS"
/gene_synonym="CTB"

```

BLAST vs mRNA

>ref|NM_004388.2| UniGene info linked to NM_004388.2GEO profiles info linked to NM_004388.2Gene info linked to NM_004388.2Genome view with mapviewer linked to NM_004388.2 Homo sapiens chitobiase, di-N-acetyl- (CTBS), mRNA Length=3152


GENE ID: 1486 CTBS | chitobiase, di-N-acetyl- [Homo sapiens]

Score = 327 bits (177), Expect = 1e-88


Identities = 177/177 (100%), Gaps = 0/177 (0%)

Strand=Plus/Plus

Query 1	TGAATCTGTCTGAGGATCATGTTGTACATTGCAAAAGTCCCTTCGGGGGCTCCTT	60
Sbjct 847	TGAATCTGTCTGAGGATCATGTTGTACATTGCAAAAGTCCCTTCGGGGGCTCCTT	906
Query 61	GTAGTGACGCTGCAGGACGTCAAGGTGCCCTACAAAACGATCATGAAGCAAATAATAGTT	120
Sbjct 907	GTAGTGACGCTGCAGGACGTCAAGGTGCCCTACAAAACGATCATGAAGCAAATAATAGTT	966
Query 121	CTATTTCTGGAAACCTATGGGATAAAGATCAGCGGGCTCCTTATTATAACTATAAG	177
Sbjct 967	CTATTTCTGGAAACCTATGGGATAAAGATCAGCGGGCTCCTTATTATAACTATAAG	1023

**CTBS interaction network.****Summary for CTBS**

Chitobiase is a lysosomal glycosidase involved in degradation of asparagine-linked oligosaccharides on glycoproteins. It is also involved on hydrolyzation of N acetyl-beta-D-glucosamine (1-4)N-acetylglucosamine chitobiose from the reducing end of the bond. This requires prior cleavage by glycosyl-asparaginase.

3' partner: GNG5**Junction point**

```

exon=3 436..580
/gene="GNG5"
/gene_synonym="FLJ92393"

```

BLAST vs mRNA


>ref|NM_005274.2| UniGene info linked to NM_005274.2GEO profiles info linked to NM_005274.2Gene info linked to NM_005274.2Genome view with mapviewer linked to NM_005274.2 Homo sapiens guanine nucleotide binding protein (G protein), gamma 5 (GNG5), mRNA Length=823

GENE ID: 2787 GNG5 | guanine nucleotide binding protein (G protein), gamma 5 [Homo sapiens]
Score = 682 bits (369), Expect = 0.0
Identities = 371/372 (99%), Gaps = 0/372 (0%)

Strand=Plus/Plus

	↓	
Query 174	AAAGTTTCCCAGGCAGCTCAGACTTGAAACAGTTCTGTCAGAACATGAC	233
Sbjct 433	AAAGTTTCCCAGGCAGCTCAGACTTGAAACAGTTCTGTCAGAACATGAC	492
Query 234	CCTCTGCTGACTGGAGTATCTCAAGTACAATCCCTCAGACCCCCAGAAAGTCTGTTCC	293
Sbjct 493	CCTCTGCTGACTGGAGTATCTCAAGTACAATCCCTCAGACCCCCAGAAAGTCTGTTCC	552
Query 294	TTTTGTAGTAAAATGAATCTTCAAAGGTTCCAAACCACCTCCTATGATCCAGTGAA	353
Sbjct 553	TTTTGTAGTAAAATGAATCTTCAAAGGTTCCAAACCACCTCCTATGATCCAGTGAA	612
Query 354	TATTCAAGAGAGCTACATTGAAGCCTGACAAAAGCTTATCCCTGTAACACATGTGCCA	413
Sbjct 613	TATTCAAGAGAGCTACATTGAAGCCTGACAAAAGCTTATCCCTGTAACACATGTGCCA	672
Query 414	TAATATACAAACTTTACTTCGTCAGTCCTAACATCTACCTCTCTGAATTTCATGAA	473
Sbjct 673	TAATATACAAACTCTACTTCGTCAGTCCTAACATCTACCTCTCTGAATTTCATGAA	732
Query 474	TTCTATTTACAAGGTAATTGTTTATATACACTGGCAGCAGCATACAATAAAACTTA	533
Sbjct 733	TTCTATTTACAAGGTAATTGTTTATATACACTGGCAGCAGCATACAATAAAACTTA	792
Query 534	GTATGAAACTTT	545
Sbjct 793	GTATGAAACTTT	804

GNG5 interaction network.



Summary for GNG5


G proteins are trimeric proteins that regulate flow of information from cell surface receptors to internal metabolic effectors. Interactions of a G protein with its activated receptor promotes exchange of GTP for GDP (alpha subunit). The alpha-GTP complex dissociates from the beta-gamma heterodimer so as to interact with and regulate effector molecules. G proteins are involved as modulators or transducers in transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interactions.

CHD2- CHMP1A

CTACTAGTAGATAGGACTCTGGTTGGACATACTACATGGATCAGTAAATACCTGGCACAGGACTTCAAAGCAACACAGATTCCCCCTCCCCCTTAATA
TTAAGAATTAAAAGATGATGAGAAAATAAGGACAAAAGCCAAGAGGAGGACAGTCGCTACACAGCAATGCATCGAGGTGACCAAGAATATGGCCAGGTGAC
AAAGCCCTGGACAAGGCCCTGAGCACCATGGACCTCGAGAACAGGTCTCCTCAGTGTGGACAGGTTGAGCAGGGTGGACAGCCTCATCATGAGATCGCCGAGGAATGGCTGGAGG
TGATGGAGGACTCCATGAGCTGCCGACCAACCCCTGACCAACGCCAGGGCGAGAGCTCTGTGXXXXXXXXXXXXXXXXXXXXXXXXTGGCCGCTTGAGGAA
GGACCAAGCTGCCAGCTGCCGAGGGCGCCTCTGCCGTGGCGAGAGCTCTGTGXXXXXXXXXXXXXXXXXXXXXXXXTGGCCGCTTGAGGAA
TAGCCGTGCCCGCCGGTGTGACCGCCCTGCCGTGGCTAGGGTTGTTCTTGTGCTGAGGCTCTCTCCCCACCGCGCTTGTGCTGACCCCGCGGGG
GGCGCCGGCAGCCACTCTGCGTCTCTCACCTGCCAGGCCACAGCGGGAGGCAAGAAGGGCCCTGGACCTTACCCAGCACTGTGGGGCCTTCA
ACTCTGGGCAGCAGACATGCTGCTTCCATCAGCAGAGGGGTCAAGGCCCTGCCGTGGCTAGGGTTGTTCTTGTGCTGAGGCTCTCCGACCAACTCATCGGGC
GGAGGTCTACCCATGTTGGACGACATAGCCCTAGGAGGACACCACAGGTCTAGTGTGGCTTGGGGATGTCAGGTCACTAAGCGTTCTGGGTGATTCAAT
ACATCCTTCTTCAAATTACTTTCAAGAG

Sanger sequencing (forward and reverse)

EMBOSS_001	51	TACCTGGCACAGGACTTCAAAGCAAACACAGATTCCCCCTCCCCCTAA	100
PCR band	1	 ATTCCCCCTCCCCCTAA	18
EMBOSS_001	101	TATTTAAGAATTAAAAGATGATGAGAAAATAAGGACAAAAGCCAAGAGGAG	150
PCR band	19	 TATTTAAGAATTAAAAGATGATGAGAAAATAAGGACAAAAGCCAAGAGGAG	68
EMBOSS_001	151	GACAGTTCGCTACACAGCAATGCATCGAGGTGACCAAGAATATGGCCAG	200
PCR band	69	 GACAGTTCGCTACACAGCAATGCATCGAGGTGACCAAGAATATGGCCAG	118
EMBOSS_001	201	GTGACCAAAAGCCCTGGACAAGGCCCTGAGCACCATGGACCTGCAGAAGGT	250
PCR band	119	 GTGACCAAAAGCCCTGGACAAGGCCCTGAGCACCATGGACCTGCAGAAGGT	168
EMBOSS_001	251	CTCCTCAGTGATGGACAGGTTCGAGCAGCAGGTGCAGAACCTGGACGTCC	300
PCR band	169	 CTCCTCAGTGATGGACAGGTTCGAGCA	195

5' partner: CHD2**Junction point****exon=2 505..637****/gene="CHD2"****/gene_synonym="DKFZp547I1315; DKFZp686E01200; DKFZp781D1727; FLJ38614"****BLAST vs mRNA**


```
>ref|NM_001271.3| Homo sapiens chromodomain helicase DNA binding protein 2 (CHD2),
transcript variant 1, mRNA
Length=9374
GENE ID: 1106 CHD2| chromodomain helicase DNA binding protein 2 [Homo sapiens]
Score = 324 bits (358), Expect = 3e-91
Identities = 179/179 (100%), Gaps = 0/179 (0%)
```

Strand=Plus/Plus

Query 1	CTACTAGATAGGACTTTGGACATACTACATGGATCAGTAAATACCTGGCA	60
Sbjct 459	CTACTAGATAGGACTTTGGACATACTACATGGATCAGTAAATACCTGGCA	518
Query 61	CAGGACTTCAAAGCAAACACAGATTCCCCCTCCCCCTTAATTTAAGAATTAAAGATG	120
Sbjct 519	CAGGACTTCAAAGCAAACACAGATTCCCCCTCCCCCTTAATTTAAGAATTAAAGATG	578
Query 121	ATGAGAATAAGGACAAAGCCAAGAGGAGACAGTCGCTACACAGCAATCGAG	179
Sbjct 579	ATGAGAATAAGGACAAAGCCAAGAGGAGACAGTCGCTACACAGCAATCGAG	637



CHD2 interaction network.



Junction point

exon=5 366..494

/gene="CHMP1A"

/gene_synonym="CHMP1; KIAA0047; PCOLN3; PRSM1"

BLAST vs mRNA

```
>ref|NM_001083314.1| Homo sapiens chromatin modifying protein 1A (CHMP1A), transcript variant 1, mRNA
Length=2353
GENE ID: 5119 CHMP1A| chromatin modifying protein 1A [Homo sapiens]
Score = 1292 bits (1432), Expect = 0.0
Identities = 814/878 (92%), Gaps = 14/878 (1%)
```

Strand=Plus/Plus


Query	179	GGTGACCAAGAATATGGCCAGGTGACCAAAGCCCCTGGACAAGGCCCTGAGCACCATGGA	238
Sbjct	365	GGTGACCAAGAATATGGCCAGGTGACCAAAGCCCCTGGACAAGGCCCTGAGCACCATGGA	424
Query	239	CTCTGCAGAAGGTCCTCAGTGATGGACAGGTTCAGGCTCAGCACAGGTCAGAACCTGGACGT	298
Sbjct	425	CTCTGCAGAAGGTCCTCAGTGATGGACAGGTTCAGGCTCAGCACAGGTCAGAACCTGGACGT	484
Query	299	CCATACATCGGTGATGGAGGACTCATGAGCTCGGCCACCACCTGACCACGCCGAGGA	358
Sbjct	485	CCATACATCGGTGATGGAGGACTCATGAGCTGGCCACCACCTGACCACGCCGAGGA	544
Query	359	GCAGGGTGGACAGCCTCATCATGCAGATCGCCGAGGAGAAATGGCTGGAGGTGCTGGACCA	418
Sbjct	545	GCAGGGTGGACAGCCTCATCATGCAGATCGCCGAGGAGAAATGGCTGGAGGTGCTGGACCA	604
Query	419	GCTCAGCCAGCTGCCCGAGGGCCCTCTGCCCTGGGGCAGAGCTCTGTnnnnnnnnnnnn	478
Sbjct	605	GCTCAGCCAGCTGCCCGAGGGCCCTCTGCCCTGGGGCAGAGCTCTGTGCGCAGCCAGGA	664
Query	479	nn	538
Sbjct	665	GGACCAAGCTCACGGAGGTTGCCCGCCCTGGAGAACTAGCCCTGCCCGCCGGTGTGCA	724
Query	539	CCGCCTCTGCCCGTGTGCTGGAAAGGCTCTGTCCCTCTCCCCACCGCGTCTGGCT	598
Sbjct	725	CCGCCTCTGCCCGTGTGCTGGAAAGGCTCTGTCCCTCTCCCCACCGCGTCTGGCT	784
Query	599	TGTGCTGACCCCCGGGGCTGCCGGCGAGGAACTCTGGCTCTCACCTGCCAGGCC	658
Sbjct	785	TGTGCTGACCCCCGGGGCTGCCGGCGAGGAACTCTGGCTCTCACCTGCCAGGCC	844
Query	659	GGGTGGCCCTTAGGGTTGTTCTGTTCTTTAGGTTGGCGGTGGGTCTGTCTGGT	718
Sbjct	845	GGGTGGCCCTTAGGGTTGTTCTGTTCTTTAGGTTGGCGGTGGGTCTGTCTGGT	904
Query	719	TGAGTTCTGCAAATTCTGGGGTGATTTCTGTGACTCTGGGCCACAGCGGGGAGGCC	778
Sbjct	905	TGAGTTCTGCAAATTCTGGGGTGATTTCTGTGACTCTGGGCCACAGCGGGGAGGCC	964
Query	779	AAGAAGGGCCCTGTGGACTTCAACCAGCACTGTGGGGCCTTCAGACTCTGGGCAGCA	838
Sbjct	965	AAGAAGGGCCCTGTGGACTTCAACCAGCACTGTGGGGCCTTCAGACTCTGGGCAGCA	1024
Query	839	GACATGCTGCTTCCCATCAG-CAGAGGGGTCAGGCTGCCCTGTCGCAAACAACCTCT	897

```

Sbjct 1025 GACATGCTGCTTCCCACAGCCAGGGGGTCAGGGCTGCCCTGTTGCCAAACAACCTCCC 1084
Query 898 TGAGGCCTCTCGCACCAACTCATGGCAGGAGGTCTCACCATGTTGGAC-GACATAG 956
Sbjct 1085 TGAGGCCTCTCGCACCACTCATGGCAGGAGGTCCCA-CCATG-TGGACAGACATAG 1142
Query 957 CCCTAGGAGGACACCACAGGTCTAGTGTGGCTTGGGGATGTCAGGT--CACTAACGC--- 1011
Sbjct 1143 CCCAAGGAGG-CACCAAGGTCTA-TGTGTGCTGGGGATGTCAGGTGCCACCCAACGCT 1200
Query 1012 GTTCTGGGTGATT--CAATGACATCCTCCCTCTTCA 1047
Sbjct 1201 GTCCTGGTGGTATTACATGACATCC-TCCCTCTCCA 1237

```

CHMP1A interaction network.



Summary for CHMP1A

CHMP1A a member of the CHMP/Chmp family. CHMP1A is a component of endosomal sorting transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. The MVB pathway appears to require the sequential function of ESCRT-O, -I, -II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1). Involved in recruiting VPS4A and/or VPS4B to the midbody of dividing cells. May also be involved in chromosome condensation. Targets the Polycomb group (PcG) protein BMI1/PCGF4 to regions of condensed chromatin.

P2RX5-TAX1BP3

```


TTGGCTCACATCTGGCCAGGGCTGCTGGGATGCCGGAGCAGCAGGAGCTGCAGGAGGCCACCCGAGGGCAAGCGTGAAGCAGCAGTCAGAAGGGGAAACGGG
TCTGTGCCCCAACAGCTCCTGGAGGCCCCAACAGCAAAGAGTTGAAATTCAACAAGCTGCGTCAAGGTGAGAACTTAATCCTGGGTTTCAGCATTGGAGGTGGAA
CGACCAAGGATCCTCTCCAGAAATCCCTTCTCTGAAGACAAGACGGACAAGGGTATTATGTACACGGGTGCTGAAGGAGGGCCCTGCTGAAATCCTGGGCT
CAGATTGGAGACAAGATCATGCAGGTGAACGGCTGGGACATGACCATGGTCACACAGCAGCAGGCCCCAACAGCAGTCAGTCCATGCTGCTAGCAGCCACCAAGC
GTCTGCTGGTGACCGGGCAGTCGCTGCAGAAGGGCGTGCAGCAGTCCATGCTGCTAGCAGCCACCAAGCAGTCAGTGGCCCTGGGCTCTGTAC
GTAACGCCACTTCCACACTCTGCCCCATCTGGCTCTGCTGACGGCTGGGCCCCAGCTCAGAAGGGCTATAGCTGGTCCAGAGGGCTGGGCTGGGCTGGGCT
TCCCTCTCCCATCCCTGGCTGGGCTCTGGGACGGGTTCTCTCCTGGACACCGAGGATTGAAATAAGGCCCTGGAGCTGAGTAGTAGGCCAGTCT
CTGTGACCACAGGCTCACGTCCGACCCCTGCTGGGCCACAGCAGTGGCTGGGAACTACCTTGGGACCCAAAAGCCTGGGAA

```

Sanger sequencing (reverse)

EMBOSS_001	2	GTCAGAAGGGAAACGGATCTGTGTGCCACAGCTCCTGGAGCCCCACAGC	51
PCR band	2	GTCAGAAGGGAAACGGATCTGTGTGCCACAGCTCCTGGAGCCCCACAGC	51
EMBOSS_001	52	AAAGAGTTGAAATTCAACAAGCTGCGTCAAGGTGAGAACTTAATCCTGGG	101
PCR band	52	AAAGAGTTGAAATTCAACAAGCTGCGTCAAGGTGAGAACTTAATCCTGGG	101
EMBOSS_001	102	TTCAGCATTGGAGGTGGAAT	151
PCR band	102	TTCAGCATTGGAGGTGGAAT	151

5' partner: P2RX5



Junction point
exon=11 1390..1586
/gene="P2RX5"
/gene_synonym="LRH-1; MGC47755; P2X5; P2X5R"

BLAST vs mRNA


>ref|NM_001204520.1| Gene info linked to NM_001204520.1 Homo sapiens purinergic receptor P2X, ligand-gated ion channel, 5 (P2RX5), transcript variant 5, mRNA
Length=2269
GENE ID: 5026 P2RX5 | purinergic receptor P2X, ligand-gated ion channel, 5 [Homo sapiens]
Score = 244 bits (132), Expect = 2e-63
Identities = 132/132 (100%), Gaps = 0/132 (0%)

Strand=Plus/Plus

Query	4	GCTCACATCTGGGCCAGGGCTGCTGGGATGCCGGAGCAGCAGGAGCTGCAGGAGGCC	63
Sbjct	1455	GCTCACATCTGGGCCAGGGCTGCTGGGATGCCGGAGCAGCAGGAGCTGCAGGAGGCC	1514
Query	64	CGAGGCGAACCGTGGAACGACGAGTCAGAAAGGGAACGGATCTGTGCCCCACAGCTCCT	123
Sbjct	1515	CGAGGCGAACCGTGGAACGACGAGTCAGAAAGGGAACGGATCTGTGCCCCACAGCTCCT	1574
Query	124	GGAGCCCCACAG 135	
Sbjct	1575	GGAGCCCCACAG 1586	

↑

3' partner: TAX1BP3



Junction point

exon=2 193..31

/gene="TAX1BP3"

/gene synonym="TIP-1"

BLAST vs mRNA

>ref|NM_014604.3| Gene info linked to NM_014604.3 Homo sapiens Tax1 (human T-cell leukemia virus type I) binding protein 3 (TAX1BP3), transcript variant 1, mRNA

Length=1398

GENE ID: 30851 TAX1BP3 | Tax1 (human T-cell leukemia virus type I) binding protein 3 [Homo sapiens]
Score = 1218 bits (659), Expect = 0.0

Identities = 680/689 (99%), Gaps = 6/689 (0%)

Strand=Plus/Plus


↓

Query	135	GCAAAGAGTGTGAAATTCAACAAGCTGCGTCAGGTGAGAACCTTAATCCTGGGTTTCAGCAT 	194
Sbjct	192	GCAAAGAGTGTGAAATTCAACAAGCTGCGTCAGGTGAGAACCTTAATCCTGGGTTTCAGCAT 	251
Query	195	TGGAGGTGGAATCGACCAGGATCCTTCCCAGAATCCCTCTCTGAAGACAAAGACGGACAA 	254
Sbjct	252	TGGAGGTGGAATCGACCAGGATCCTTCCCAGAATCCCTCTCTGAAGACAAAGACGGACAA 	311
Query	255	GGGTATTATGTACACGGGTCTCTGAAGGAGGCCCTGCTGAATCGCTGGGCTGCAGAT 	314
Sbjct	312	GGGTATTATGTACACGGGTCTCTGAAGGAGGCCCTGCTGAATCGCTGGGCTGCAGAT 	371
Query	315	TGGAGACAAGATCATGCAGGTGAACGGCTGGACATGACCATTGGCACACGACCAAGGC 	374
Sbjct	372	TGGAGACAAGATCATGCAGGTGAACGGCTGGACATGACCATTGGCACACGACCAAGGC 	431
Query	375	CCGCAAGCGGCTCACCACCGCTCGGAGGAGGTGGTGCCTCTGTGACCGGGCAGTC 	434
Sbjct	432	CCGCAAGCGGCTCACCACCGCTCGGAGGAGGTGGTGCCTCTGTGACCGGGCAGTC 	491
Query	435	GCTGCAGAACGGCGTGCAGCAGTCCATGCTGTCTAGCAGCCACCCATCTGGGACTCC 	494
Sbjct	492	GCTGCAGAACGGCGTGCAGCAGTCCATGCTGTCTAGCAGCCACCCATCTGGGACTCC 	551
Query	495	TGCTTGCGCCCTCTGTACACTAACGCCACTTCCACACTCTGTCCCCATCTGGCTTCG 	554
Sbjct	552	TGCTTGCGCCCTCTGTACACTAACGCCACTTCCACACTCTGTCCCCATCTGGCTTCG 	611
Query	555	CTGACCGCTGGGCCCCAGCTCAGAAGGGCTATAAGCTGGTCCAGAGGCCCTGGCTGGCT 	614
Sbjct	612	CTGACCGCTGGGCCCCAGCTCAGAAGGGCTATAAGCTGGTCCAGAGGCCCTGGCTGGCT 	671

NXPH1-TXNL4A

TTGGCAACTGTGCAAGCCTTGGCTCCCGGAACCAATCCTGAGCGCGACCCGGGACTGGACGGCAGCTCGCCAAAGCTGGACGAGGCAGCCGGACCCG
CTGCGCTGAGCATGGAGACGGAGCGCTGGAGGGCACGTCCGGCGCTGGAGACGCCAGGCCAGTGCTCTGAGAGCGCTCCTGCTGTAAAGTGGATGT
AAAGAAGGCACCGCCAAGGAAGTTGAGACGCCAGGGAGATGCAGGCTGCGTCTGGTACGTGCTTTCTCCTGCAGCCCACCGTACTTGGTAAAAATT
TGCAGTTATTTATTTGTGGATATTACAGAAGTGCCTGACTTCACAAAATGTATGAGTTATACGATCATGTACTGTCATGTTTCTCAGGAACAAGCA
ATCATGATTGACTGGGACTGGCAACAACAAGATAACTGGCCATGGAGGACAAGCAGGAGATGGTGGACATCATCGAGACGGTGTACCCGGGCG
GCAAAGGCCGCGCCCTGGTGGTCCCGAAGGACTACTCCACCAAGTACCGCTACTGAGGCCCTCAGTGCAGGATAATGTCGTGGAGACCTTT
TATAGAAAACATATTAAGCTATTTAAAGCCTTGGAAATACAGGAAGCTCCGGCTGG

5' partner: NXPH1



Junction point

exon=2 802..965

/gene="NXPH1"

/gene_synonym="Nbla00697; NPH1"

BLAST vs mRNA


```
>ref|NM_152745.2| UniGene infoGeoGene info Homo sapiens neurexophilin 1 (NXPH1), mRNA
Length=2931
GENE ID: 30010 NXPH1 | neurexophilin 1 [Homo sapiens]
Score = 720 bits (798), Expect = 0.0
Identities = 399/399 (100%), Gaps = 0/399 (0%)
```

Strand=Plus/Plus

Query 5	CAACTGTGCAAGCCTTGGCTCCCGGAACCAATCCTGAGCGCGACCCGGGACTGGAC	64
Sbjct 569	CAACTGTGCAAGCCTTGGCTCCCGGAACCAATCCTGAGCGCGACCCGGGACTGGAC	628
Query 65	GGCGACTCCGCCAACGCTGGACGAGGCAGCCGGACCCGCTCGCGCTCGAGCATGGAGACG	124
Sbjct 629	GGCGACTCCGCCAACGCTGGACGAGGCAGCCGGACCCGCTCGCGCTCGAGCATGGAGACG	688
Query 125	GAGCGCTGGAGGGCACGTCCGGGGCGCTGGAGACGCCAGGCCAGTGCTTCTCCAT	184
Sbjct 689	GAGCGCTGGAGGGCACGTCCGGGGCGCTGGAGACGCCAGGCCAGTGCTTCTCCAT	748
Query 185	GGAGCCTGCCAGAGCGGTCCCTCTCGCAGGATTGCCCCAAGTCTGTGGCTGCTG	244
Sbjct 749	GGAGCCTGCCAGAGCGGTCCCTCTCGCAGGATTGCCCCAAGTCTGTGGCTGCTG	808
Query 245	AGAGCGCTCTTGCTCTGAAAGTGGATGTCAGGTGGATCTATGTTCTGAAGGAACAAA	304
Sbjct 809	AGAGCGCTCTTGCTCTGAAAGTGGATGTCAGGTGGATCTATGTTCTGAAGGAACAAA	868
Query 305	GACTCAAAGAAGGCACCGCCAAGGAAGTTGAGACGCCAGGAGATGCAGGCTGCGTGCTG	364
Sbjct 869	GACTCAAAGAAGGCACCGCCAAGGAAGTTGAGACGCCAGGAGATGCAGGCTGCGTGCTG	928
Query 365	GTACGTGCTTTCTCTGAGCCCCACCGTCTACTTGGT	403
Sbjct 929	GTACGTGCTTTCTCTGAGCCCCACCGTCTACTTGGT	967



3' partner: TXNL4A



Junction point

exon=2 294..397

```
/gene="TXNL4A"
/gene_synonym="DIB1; DIM1; HsT161; TXNL4; U5-15kD"
```

BLAST vs mRNA

```
>ref|NM_006701.2| Homo sapiens thioredoxin-like 4A (TXNL4A), mRNA
Length=1415
Score = 654 bits (724), Expect = 0.0
Identities = 375/381 (98%), Gaps = 2/381 (0%)
```

Strand=Plus/Plus


↓

Query 401	GGTTAAAAATTTCAGTTATCTGTGGATTACAGAACAGTCCTGACTCAACAA	460
Sbjct 293	GGTTAAAAATTTCAGTTATCTGTGGATTACAGAACAGTCCTGACTCAACAA	352
Query 461	AATGTATGAGTTACGATCCATGTACTGCATGTTTCTCAGGAACAAGCACATCAT	520
Sbjct 353	AATGTATGAGTTACGATCCATGTACTGCATGTTTCTCAGGAACAAGCACATCAT	412
Query 521	GATTGACTTGGGACTGGCAACAACAACAAGATACTGGGCCATGGAGGACAAGCAGGA	580
Sbjct 413	GATTGACTTGGGACTGGCAACAACAACAAGATACTGGGCCATGGAGGACAAGCAGGA	472
Query 581	GATGGTGACATCATCGAGACGGTGTACCGCGGGGCCGAAAGGCCGCGGCTGGTGGT	640
Sbjct 473	GATGGTGACATCATCGAGACGGTGTACCGCGGGGCCGAAAGGCCGCGGCTGGTGGT	532
Query 641	GTCCTCCAAGGACTACTCCACCAAGTACCGCTACTGAGGCCCTCAGTCTCGCGGATA	700
Sbjct 533	GTCCTCCAAGGACTACTCCACCAAGTACCGCTACTGAGGCCCTCAGTCTCGCGGATA	592
Query 701	AATGTCGGAGACCTTTGTATAGAACATATTAAGCTATTTAAAGCCTTGG-AAA	759
Sbjct 593	AATGTCGGAGACCTTTGTATAGAACATATTAAGCTATTTAAAGCCTTGG-AAA	651
Query 760	TACAGGAAGCTCCGGCTGG 780	
Sbjct 652	TACAGGAAGCTCCGGCTGG 672	

KIAA1704-ITGB3BP

TTGGCAGTAAGAAAGATGAAGAACATATATTACAGGAAGAGATAAGAGACTGGCTGAGCAGGTATCTTCATACAATGAATCAAAAGATCAGAATCTCTTA
 GGACATACATCATAAAAAGTTAAAGAGTAAGGCTGCTGAAGACAAAATAAGCTCAAGAGAAATACCAATTGACCGTGATAAAGATCTCAAGGTTAATCG
 TTTGATGAGCTCAGAAAAAGCCCTAATAAAAAAAATCTAGAGAAACTAAACACCCAGATTTCACACGGCAAGGCAATATGTTTATATAAATTCTATGATGTT
 CTATCAAAGTTGAGAAATTGTCAGAAGAAATCATGGAGATAATGCAAATTAAAGTAGTGTATACAGGCTTGGAGGGCAGTAGAGAGACTGTTGAAAAGAGTACAGGAC
 GAATCTCCTGTGCATXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXGTGAATAAACAAAAACTGTTGAAAAGAGTACAGGAC
 TCCTCACAAAGGTAAAGTAGTTGTTAGTTTATACATAAAGATGCTTCATCCCATTGCAATTAAACTAATCATGAATCCTTTAGTGGTT
 TCTTTTCTCAGAGATCCCTGTTCTGAAGTATGTTCTTTAGAAGATCACAAATCTCATTTGAAAGCTTTATATTGATTTAGCAGAAGATGATATCTG
 TGAGATCAACTCTCTGATGATTGAACTTTTAAATGTCCTTGAAATGCAATCTCAACATAAAGATTGAAATTGCTTTTATTAAAATTCTTTTGAA
 AATACAAATAGGAGCAACAATGCATTAATATACTGCAGTTTTAGTGTGCACTAGAAGCATTGAAAGTTACTTCTAAACTAGTATTCTGGAAACTTCAG
 TCATTAATATGCTTGTCTACTATGACTCTTATGTCAGCATTGAGCATTCACTAGAATGAAAACTAATAACAGTTTGTCTTCAAGAAGTACACATCACACC
 TCACACCTCATAGCAAGTATCATGACTGTAATACCAACCTTAAACTAATAAGGAGGATAAAAGTACTACGATTGCCATAGCATCTGCATGAATAGGCTTAA
 GGGTGGGCGGTTCAAGCCTAACACTTTAT

5' partner: KIAA1704


Junction point

```
CDS 104..1126
/gene="KIAA1704"
/gene_synonym="AD029; bA245H20.2; LSR7; RP11-245H20.2"
```

BLAST vs mRNA

```
>ref|NM_018559.2| Homo sapiens KIAA1704 (KIAA1704), mRNA
Length=1431
Score = 527 bits (584), Expect = 2e-153
Identities = 292/292 (100%), Gaps = 0/292 (0%)
```

Strand=Plus/Plus


```

Query  5      CAGTAAGAAAAGATGAAGAACATATATTACAGGAAGAGATAAGAGACTGGCTGAGCAGGT  64
Sbjct  835     CAGTAAGAAAAGATGAAGAACATATATTACAGGAAGAGATAAGAGACTGGCTGAGCAGGT  894
Query  65     ATCTTCATACAATGAATCAAAAAGATCAGAATCTCTTATGGACATACATCATAAAAAGTT  124
Sbjct  895     ATCTTCATACAATGAATCAAAAAGATCAGAATCTCTTATGGACATACATCATAAAAAGTT  954
Query 125     AAAGAGTAAGGCTGCTGAAGACAAAATAAGCCTCAAGAGAGAATACCATTGACCGTGA  184
Sbjct  955     AAAGAGTAAGGCTGCTGAAGACAAAATAAGCCTCAAGAGAGAATACCATTGACCGTGA  1014
Query 185     TAAAGATCTCAAGGTTAACGGTTGATGAAGGCTCAGAAAAAGCCCTAATaaaaaaaaaTC  244
Sbjct 1015     TAAAGATCTCAAGGTTAACGGTTGATGAAGGCTCAGAAAAAGCCCTAATaaaaaaaaaTC  1074
Query 245     TAGAGAACTAACACCCAGATTTCACACGGCAAAGGCATATGTTTTATAA  296
Sbjct 1075     TAGAGAACTAACACCCAGATTTCACACGGCAAAGGCATATGTTTTATAA  1126

```



3' partner: ITGB3BP



Junction point

```

exon=5 286..364
/gene="ITGB3BP"
/gene_synonym="CENP-R; CENPR; HSU37139; NRIF3; TAP20"

```

BLAST vs mRNA

```

>ref|NM_014288.3| Homo sapiens integrin beta 3 binding protein (beta3-endonexin) (ITGB3BP), mRNA
Length=892
Score = 241 bits (266), Expect = 3e-67
Identities = 135/136 (99%), Gaps = 0/136 (0%)

```

Strand=Plus/Plus



```

Query 293 ATAAATTATGATGTTGCTATCAAAGTTGAGAAATTGTCAGAAGAAATCATGGAGATAA 352
Sbjct 282 ATGAATTATGATGTTGCTATCAAAGTTGAGAAATTGTCAGAAGAAATCATGGAGATAA 341
Query 353 TGCAAAATTAAAGTAGTATACAGGCTTGGAGGGCAGTAGAGAGCCTTGAAATCTCATG 412
Sbjct 342 TGCAAAATTAAAGTAGTATACAGGCTTGGAGGGCAGTAGAGAGCCTTGAAATCTCATG 401
Query 413 GAATCTCTGTGCATC 428
Sbjct 402 GAATCTCTGTGCATC 417


```

DHX8 -ADK

```

TTGGCTGTAGCCATGGCGGGAGCCTTAATCGGTCGGAGCCAGGCCCGCGGAAGAACCTGCCAACTCGAGTACCTGCTTGGTCAAAGGTTGCACTCAGCTGGACAATCACTGGGGATCAACGACAAGGACCTGCTGAATTGATCAGTCTGCTGAGAAAAAACCCACCTTGATACTTTAAGGCTCTCTCGCAAAAATGGTGCAGAAATTACGGATTCTCTTATTAGTAACCTGCTCGTCTCATACAAACCATGCGGCCCTCAGCGAAGCCTCCACTAGCAAAGGTTCTCTCAACTGGTCTGTACAAGCCTCTGACTGAATGTATCCGTGCTGGCCACTATGCAGCAAGCATCATAAATTAGACGGACTGGCTGCACCTTCTGAGAACAGACTTCCACTGATGGAAGAGCTGAAAACACAAGCCAGGAGTGAGACACTGCCCTAATTGCTTCTGAGAATTCCCATATTAATAAGAAGAAAATTATGCTGCATTTCCTACTATAATAATGCTGAATCTTAATTAGAGGGTACAAGGGTATGGTAATGCTGTAGAATCTTATTATCTCAACAAATCTAAAAAATGTTGTTATTTCATAGTTGATAGTGCCTAAATGCCAATTAAACAAGAAATATAACATTCAATAGAAATTTTTATTTCATTTCAATTACTTGTATACATTCTGCTTGAATGCAGATGCAAATTAAATATAATAGATTTTTAATGAATTAAATCTTAACATAGTAATCTTAGCTTTATACAAATATATTAAATTAGAGTATATGTTGCTATACACACACATACAAATACCACTACACTGATAGTCAAATAGGGTACAGAAATTATCTTGTCAATATGCCAATTATCCTTAATGTGCACTCCAACATGTAATAACTTGGATATTAAACACCCATCACGCCAATAG

```

5' partner: DHX8**Junction point**

exon=3 308..380

/gene="DHX8"


/gene_synonym="DDX8; HRH1; PRP22; PRPF22"

BLAST vs mRNA

```
>ref|NM_004941.1| Homo sapiens DEAH (Asp-Glu-Ala-His) box polypeptide 8 (DHX8), mRNA
Length=4201
Gene id: 4826690 ATP-dependent RNA helicase DHX8
Score = 542 bits (600), Expect = 2e-157
Identities = 300/300 (100%), Gaps = 0/300 (0%)
```

Strand=Plus/Plus

Query 2	TGGCTGTAGCCATGGCGGGAGCCTTAATCGGTGGAGGCCAGGCCCCCGCGGAAGAACATTG	61
Sbjct 81	TGGCTGTAGCCATGGCGGGAGCCTTAATCGGTGGAGGCCAGGCCCCCGCGGAAGAACATTG	140
Query 62	CCAAACTCGAGTACCTGTTGGTGTCAAAGGTTGCACTGAGCTGGACATCACTTGG	121
Sbjct 141	CCAAACTCGAGTACCTGTTGGTGTCAAAGGTTGCACTGAGCTGGACATCACTTGG	200
Query 122	GGATCAACGACAAGGACCTTGCTGAATTGTGATCAGTCTTGCTGAGAAAAATACCACTT	181
Sbjct 201	GGATCAACGACAAGGACCTTGCTGAATTGTGATCAGTCTTGCTGAGAAAAATACCACTT	260
Query 182	TTGATACTTTAAGGCTCTCGTCAAAAATGGTCAGAATTACGGATTCTCTTATT	241
Sbjct 261	TTGATACTTTAAGGCTCTCGTCAAAAATGGTCAGAATTACGGATTCTCTTATT	320
Query 242	GTAATTGCTGCGTCTCATACAAACCAGCGGCCTCCAGCGAAGCCTTCACTAGCAAAG	301
Sbjct 321	GTAATTGCTGCGTCTCATACAAACCAGCGGCCTCCAGCGAAGCCTTCACTAGCAAAG	380

**3' partner: ADK****Junction point**

exon=12 1037..2018

/gene="ADK"

/gene_synonym="AK"

BLAST vs mRNA

```
>ref|NM_006721.2| Homo sapiens adenosine kinase (ADK), transcript variant ADK-long, mRNA
Length=2018
GENE ID: 132 ADK| adenosine kinase [Homo sapiens]
Score = 1088 bits (1206), Expect = 0.0
Identities = 667/713 (93%), Gaps = 41/713 (5%)
```

Strand=Plus/Plus




Query 300	AGGTTTCTGTCTCAACTGGTCTCTGACAAGCCTCTGACTGAATGTATCCGTGGCCA	359
Sbjct 1035	AGGTTTCTGTCTCAACTGGTCTCTGACAAGCCTCTGACTGAATGTATCCGTGGCCA	1094
Query 360	CTATGCAGCAAGCATCATAATTAGACGGACTGGCTGCACCTTCTGAGAACCCAGACTT	419
Sbjct 1095	CTATGCAGCAAGCATCATAATTAGACGGACTGGCTGCACCTTCTGAGAACCCAGACTT	1154

Query 420	CCACTGATGGAAGAGCTGAAAACACAAGGCCAGGAGTCAGACACTGCCCTAATTGCTTC	479
Sbjct 1155	CCACTGATGGAAGAGCTGAAAACACAAGGCCAGGAGTCAGACACTGCCCTAATTGCTTC	1214
Query 480	CTGAGAATTCCCATATAAAGAAGAAAATTATCTGCCATTTCCTACTATAATAAA	539
Sbjct 1215	CTGAGAATTCCCATATAAAGAAGAAAATTATCTGCCATTTCCTACTATAATAAA	1274
Query 540	TGCTGATCTTAATTAGAGGGTACAAGGGTATGGTAATGCTTGAGAATTATTATTC	599
Sbjct 1275	TGCTGATCTTAATTAGAGGGTACAAGGGTATGGTAATGCTTGAGAATTATTATTC	1334
Query 600	TCAACAACTAAAAATGATGTTATTCATAGTTGATAGTGCCTAAATGCCAAT	659
Sbjct 1335	TCAACAACTAAAAATGATGTTATTCATAGTTGATAGTGCCTAAATGCCAAT	1394
Query 660	TAAACAAGAATATAACATTCAATAGAAAATTTTATTTCATTTCAATTACTTTGTA---	716
Sbjct 1395	TAAACAAGAATATAACATTCAATAGAAAATTTTATTTCATTTCAATTACTTTGTAAT	1454
Query 717	-----TACATTCTGCTTGAAATGCAGATGCAA	744
Sbjct 1455	TCGTGTATTTAGTACACTGATTGTTTTACATTCTGCTTGAAATGCAGATGCAA	1514
Query 745	ATTTAATATAATAGATTTAATGAATTAACTTAAACATAGTAATCTTAGCTTTTA	804
Sbjct 1515	--TTAATATAATAGATTTAATGAATTAACTTAAACATAGTAATCTTAGCTTTTA	1572
Query 805	TACAAATATTTAATTAGGAGTATATGTTGCTATACACACACATACATAAATAC	864
Sbjct 1573	TACAAATATTTAATTAGGAGTATATGTTGCTATACACACACATACATAAATAC	1632
Query 865	CACATATACA-CTGATAGTCAAATAGGGTACAGAAAATTATCTGTCAA-TATGCC-AA	921
Sbjct 1633	CACATATACACCTGATAGTCAAATAAGGTACAGAAAATTATCTGTCAAATTATGCCAA	1692
Query 922	TTATCTTTAATGTGCACTCCAACATGTAAT-AACTTGGATATTTAAAAAA	973
Sbjct 1693	TAATCTTTAATGTGCACTCCAACATGTAATAAACATTGGATAATTAAATAA	1745

PPIL1-KIAA1614

TTGGCGCTTGCCTAGACAAGCATTCCGCCGGCTTCGCTATGGCGCAATTCCCCCAGATTCCCTGGCAGCCACCCACGTTACTTGGAGACCAGCATGG
 AAATCATTGTGCTGGAGCTGTAAGCATGCTCCAAAGACCTGTAAGAAACTTTGCTGAGTTGGCTCGAGGTTACTACAATGGCACAAAATTCCACAG
 ATTATCAAAGACTCATGATCCAAGGAGGTGACCCAACAGGAGACAGGAGGCCAGGGCTTCTGGCTCAGCAGATTTGCCACCATCAACTCCACGGG
 TCACCCCTCCCTGCTCCTCAGAGGAGTCAGAGTCCAGAGGAATCAGAGGGAAGCCTGCAAGGGACAGGGTCAGGATCTGGAGGACATGTGCTGTCAAGAG
 ATCAGCAGGAGCTGGCACAGGGCCGGCTCCCCCTCGCTGCCCCTTGGGACAGAACAGAAAAGGAGCAGCAGCATAGCCTCCACCCCTGGGGCTGAAAAAA
 CTCTCTCAGCCCTGGGCCAGAGTCCCGGCCAAGCTGGCAAGTCCCGCAGCTACAGTGTGGAGCAGTTGAGCCGGCCCGCTGGCCTGACGTCACAG
 CCAGGGCCCCATCGTTACAATCCCTGACCCGGTGTCAACCTCTCACAGCGTCGGAAGCTGCTCTTTCAAGAACCTCCATTCTCTGCTGAGCAGCAAGG
 GGACCGGTCCAGCCTCACCTGGTAGCAGGGCCAGGGGACACAGTGCAGCTGGCAGCCGAGAACACTTCACCACGGCGTCCCTCAGTGTGGAGGACGTG
 GTGCTCCCAGCCTGTCTCGCACCGTGGCCCTGGTGGAGGTGTCAGACAGCACCAGCCAGCTGAGCAGCTGAGCAGCGCTCCAAGGGCACTTCGGCTT
 TGCGTGCCTCTGGGAATGGGCCAGACTCAGGGACGCACTCTGAGATATTGCTGCTGGCTGATCCATGGGCTCCCTGATTATTTCAGTGG
 TATGTGACTCGCACCTATCACACATATGCACTCAGCGAGGATCACGCCATGAATGCGBAAACTCTGCTGATCCTGGAAAGTACCTCACCTGCA
 CCTGGCACCCAAAGTTTCCAAGTGA

5' partner: PPIL1



BLAST vs mRNA

```
>ref|NM_016059.4| Homo sapiens peptidylprolyl isomerase (cyclophilin)-like 1 (PPIL1), mRNA
Length=1750
GENE ID: 51645 PPIL1| peptidylprolyl isomerase (cyclophilin)-like 1 [Homo sapiens]
Score = 437 bits (484), Expect = 3e-126
Identities = 242/242 (100%), Gaps = 0/242 (0%)
```


Strand=Plus/Plus

Query 12	CTAGACAAGCATTCCGCCGGCTTCGCTATGGCGCAATTCCCCCAGATTCCCTGGCAG	71
Sbjct 223	CTAGACAAGCATTCCGCCGGCTTCGCTATGGCGCAATTCCCCCAGATTCCCTGGCAG	282

Query	72	CCACCCAACGTTACTTGGAGACCAGCATGGAACTATTGTGCTGGAGCTGTACTGGAAG	131
Sbjct	283	CCACCCAACGTTACTTGGAGACCAGCATGGAACTATTGTGCTGGAGCTGTACTGGAAG	342
Query	132	CATGCTCCAAAGACCTGTAAGAACCTTGTGAGTTGGCTCGTGAGGTTACTACAATGGC	191
Sbjct	343	CATGCTCCAAAGACCTGTAAGAACCTTGTGAGTTGGCTCGTGAGGTTACTACAATGGC	402
Query	192	ACAAAATTCCACAGAATTATAAAGACTTCATGATCCAAGGAGGTGACCCAAACAGGGACA	251
Sbjct	403	ACAAAATTCCACAGAATTATAAAGACTTCATGATCCAAGGAGGTGACCCAAACAGGGACA	462
Query	252	GG 253	
Sbjct	463	GG 464	

↑

3' partner: KIAA1614



Junction point

exon=6 2829..2985

exon-5 2829..298
/gene="KIAA1614"

/gene synonym="RP11-46A10.3"

BLAST vs mRNA

>ref|NM_020950.1| Homo sapiens KIAA1614 (KIAA1614), mRNA
Length=4155

Length=4135
GENE ID: 57710 KIAA1614| KIAA1614 [Homo sapiens]

Score = 1238 bits (1372). Expect = 0.0

Score = 1238 bits (1372), Expect = 0.0
Identities = 712/724 (98%) Gaps = 4/724 (0%)

Strand=Plus/Plus

↓

Query 252 GGAGGACCCCGGGCTTCTGGCTCAGCAGATGTTGCCACCATCAACTCCACGGGCATC 311

Query 312 ACCCTCTCCCTGTCCTCAGAGGAGTCAGAGTCCAGCAAGGAATCAGAGGGAAAGCCTGCAG 371

Subject	8086	AGGACAGGGTCAGGATCTGGAGGACATGTGCTGTCAAGAGCATCAGCAGGAGCTGGCACAA	431
Query	372	AGGACAGGGTCAGGATCTGGAGGACATGTGCTGTCAAGAGCATCAGCAGGAGCTGGCACAA	431

SDJCL	2948	AGGACACGGGTCAGGGATCTGGAGGACATGCGTGCAGAACAGAGCATCAGCAGGAGCTGGCACAA	300
Query	432	GGACCCGGGCTCCCCCTCGGGCTGCCCTTTGGACCAAGAACAGAAAAGGAGCAGCAGCATA	491

Sbjct	3008	GGACCCGGCTCCCCCTCGCTGGCCCTTGGACCAGAACAGAAAAGGAGCACACGATA	306
Query	492	GCTCTCCACCCCTGGGCTGAAAAAGCTTCTCAGGCCCTGGGCCAGAGTCCCGGCCAAG 	551

Query 552 CTGGGCAAGTCCCGCAGCTACAGTGTGGAGCAGTTGCAGCCCCGCCCTGGCCTGACG 611

Query 612 TCACAGTCCAGGGCCCCATCGTTACAATCCCTGCACCCGGTGTACCCCTCTCACCAAGCGT 671

Subject	5186	TCAACCTTACGGCCCGGCCCCATCTTACAACTTCACCCCTGCCACCCGGGCTGCAACCCCTTCACCCACCTG	521
Query	672	CGGAAAGCTGCCTTTTCAAGAACCTCCATTCTCTGAGCAGCAAGGGGGACCCGGTCC	731

Sbjct	3248	CGGAAAGCTGCCCTTTTCAAGACCTCCATTCTGTGCTGAGCAGCAAGGGGAACCGTCC	330
Query	732	AGCCTCTACCTGGTAGGGCCAGGGGACACAGTCAGCTGGCA-GCCGGCCAAGACT	790

Sbjct	3308	AGCCTCTACCTGGTAGCAGGCCAGGGGACCACTGCACTGGCAGGCCAACAGT	3361
Query	791	TCACCAACGGCGTGCCCTCAGTGTGGAGGACGTGGGTGCTCCAGCCTGTCTCGCACCGTG	850


Sbjct	3368	TCACCA CGGGT GCCC TCA GTG GAGG AGCT GGGT GCT CCCAGC CTGGCT CGCACCGTG	3427
Query	851	GGCC CGCT GTG GAGG TGTT CCA CAG CAG ACC CAG CAG GCT GCAG GTG CAC CGCT TCCA	910

Sbjct 3428 GGCGGCTGGTGGAGGTGTTCCCAGACGGCACCAAGCCAGCTGCAGCTGCAGCGCTCCCCA 348

WDR70- ANKLE2

TTGGGGTTCTGCGGCGTGCAGCCATGGAGCGCTCTGGGCCAGCGAAGTGCACAGGCTCAGACGCATCGGGACCGCAGCTTCGGTACCATGCGCTTCACTGGGTGAACTGGTCAAGGAAACTGGTCAAAACACTGGGTGAAATGACAATGGATGCTCTGGTCTGATTGAAACTCTTGTAATCCAGATGACCTTAGAGAAGAAAATCTGCAAAAGCCGATTGAAATGTTGACCCATTACATCCTACTAACAGGTTCATTTTGAGAAAAAAATTGGCTCAGGTTACTGGAGGAAGGGAGCTGTTCTTACACCACATGGCAGGTGTCACAGCTGCCAGGACCCACAAAGGATTTTGAGGCCAGCTGAAGGGAACCCAACTGATCAGGCTGTTTCTGAAGACAGAGATTTGGTTACAGTGTGGGCTGTAATCTCCAGAGGAGGAAGCTGTGACATCCAAGACCTGCTGGTGCCTCTAGTGCACACCGCACCTACAGAGCTGGAGCAGTGTCTAAGGAGCCCTGTTATGGGGTGTGTCAGTGTATGAGGACGCTCCAGCGAGAAAATGAAAGGATCTATGTTATGAAAATAAAAGGAAGCATGCAAGCTGTCAGATGATCAAAAGGTCCCAGTTAAAGCTTTCTACACAGAGAAGACGCTGAGAAATTGCTAGAGGAATTGTTGATTATTCCTCTCAAGCAGCTTACCAACTGTTCTCTGTCAGACAGCTCCACTCTTAGCAATGACAGGTTGAAAGATGTTGCTGTTCTGGATCAGAACACGTCACAAAGAGCGAGCGAACAGTACAAAAATCCCCGACCGACACTCAGGCCAGCTTGGAAAGCTGAGAGAGACGAGACACCATTCGACCTTATCTGACCTTATCTGAGCACCCGGTATCTGATAGCTCAGGAGCACCCACTATCGTGCAGAGATGCACTACAGTGTATGCTGCAAGAGAACAGCTTCATCTGCAGCTGACTCTGACGCTGAAACACTGACTCTGAGGCAGAGTACTGATGACACAAGCATCGTGCAGCGATTCCGTACTGGGGGGACCTGTTATTCTCACACCCCGACA

5' partner: WDR70



```
Junction point
exon=3 150..233
/gene="WDR70"
/gene synonym="FLJ10233
```

BLAST vs mRNA


>ref|NM_018034.2| Homo sapiens WD repeat domain 70 (WDR70), mRNA
Length=2247
Score = 334 bits (370), Expect = 4e-95
Identities = 193/198 (97%), Gaps = 0/198 (0%)

Strand=Plus/Plus

Query	5	GGTTCTGCGCGCTGCGGCCAGCCATGGAGCCTCTGGGCCACCGAAGTGACAGGCTAG 	64
Sbjct	36	GGTTCTGGGTGTGCGGCCAGCCATGGAGCCTCTGGGCCACCGAAGTGACAGGCTAG 	95
Query	65	ACGCATCGGGACCGGACCCCGCAGCTTGCCTCACCATGGCTTACCGGGTTCCGTTAAA 	124
Sbjct	96	ACGCGTCGGGACCGGACCCCGCAGCTTGCCTCACCATGGCTTACCGGGTTCCGTTAAA 	155
Query	125	AAGCTCGCACATTGACTTGAAGCAATTTGAACAAACTCGAACAGACAGCTGGAAA 	184
Sbjct	156	AAGCTCGCACATTGACTTGAAGCAATTTGAACAAACTCGAACAGACAGCTGGAAA 	215
Query	185	GAAGTTGCAAAACACTGG 202 	
Sbjct	216	GAAGTCGCAAAACACTGG 233 	



3' partner: ANKLE2



Junction point
exon=2 249..707
/gene="ANKLE2"

/gene_synonym="FLJ22280; FLJ36132; KIAA0692; LEMD7"

BLAST vs mRNA


```
>ref|NM_015114.1| Homo sapiens ankyrin repeat and LEM domain containing 2 (ANKLE2), mRNA
Length=4491
Gene ID: 23141 ANKLE2 | ankyrin repeat and LEM domain containing 2 [Homo sapiens]
Score = 1517 bits (1682), Expect = 0.0
Identities = 986/1049 (93%), Gaps = 45/1049 (4%)
```

Strand=Plus/Plus

↓		
Query 202	GGTGAATGACAATGGATGCTCTGGCTCGATTGAAACTCTGAATCCAGATGACCTT	261
Sbjct 248	GGTGAATGACAATGGATGCTCTGGCTCGATTGAAACTCTGAATCCAGATGACCTT	307
Query 262	AGAGAAGAAATCGTCAAAGCCGGATTGAAATGTGGACCCATTACATCAACTACAAGGTT	321
Sbjct 308	AGAGAAGAAATCGTCAAAGCCGGATTGAAATGTGGACCCATTACATCAACTACAAGGTT	367
Query 322	ATTTTGAGAAAAAATTGGTCAGGCTTACTGGAGCAAGGGAGGAAGGCTGCTTCTTTC	381
Sbjct 368	ATTTTGAGAAAAAATTGGTCAGGCTTACTGGAGCAAGGGAGGAAGGCTGCTTCTTTC	427
Query 382	TACCACCATGAGGCAGGTGTACAGCTCTAGCCAGGACCCACAAGGATTGAAAGCCA	441
Sbjct 428	TACCACCATGAGGCAGGTGTACAGCTCTAGCCAGGACCCACAAGGATTGAAAGCCA	487
Query 442	GCTGAAGGAAACCAACTGATCAGGCTGGTTTCTGAAGACAGAGATTGGTTACAGT	501
Sbjct 488	GCTGAAGGAAACCAACTGATCAGGCTGGTTTCTGAAGACAGAGATTGGTTACAGT	547
Query 502	GTGGCCCTGAATCCTCAGAGGAGGAAGCTGTGACATCCAAGACCTGCTCGGTGCCCT	561
Sbjct 548	GTGGCCCTGAATCCTCAGAGGAGGAAGCTGTGACATCCAAGACCTGCTCGGTGCCCT	607
Query 562	AGTGCACACCACCTACAGAGCTGGAGCGACTGCGTCAAGGAGCCGCCCTGTACTAT	621
Sbjct 608	AGTGCACACCACCTACAGAGCTGGAGCGACTGCGTCAAGGAGCCGCCCTGTACTAT	667
Query 622	GGGGTGTGTCAGTGTAGGGACGTCACAGCAGAAATGAAAGGATCTATGTTTATGAA	681
Sbjct 668	GGGGTGTGTCAGTGTAGGGACGTCACAGCAGAAATGAAAGGATCTATGTTTATGAA	727
Query 682	AATAAAAAGGAAGCATTGCAAGCTGTCAAGATGATCAAAGGGTCCCATTAAAGCTTT	741
Sbjct 728	AATAAAAAGGAAGCATTGCAAGCTGTCAAGATGATCAAAGGGTCCCATTAAAGCTTT	787
Query 742	TCTACAGAGAACGCGTGAGAAATTGCTAGAGGAATTGTGATTATTCCTCTCCA	801
Sbjct 788	TCTACAGAGAACGCGTGAGAAATTGCTAGAGGAATTGTGATTATTCCTCTCCA	847
Query 802	AGCAAAACGTCTTACCACTGTCTCTGTGAAAACAGCTCCACTCTTAGCAATGACAGG	861
Sbjct 848	AGCAAAACGTCTTACCACTGTCTCTGTGAAAACAGCTCCACTCTTAGCAATGACAGG	907
Query 862	TTGAAAGATGGTTGTGCTTGTGG-ATCAG-AACAGTCACAAAGAGCGAGCGAACAGT	919
Sbjct 908	TTGAAAGATGGTTGTGCTTGTGAAATCAGAAACAGTCACAAAGAGCGAGCGAACAGT	967

TAF11- FAM62B

```
TTGGCTTCTGCCTCAGGCATCTCGCGATCTCTCCCTCCAATCTATCCGTGATGGACGATGCCACAGAGTGGAGAGACAGC
GGAGTCGGATGAGACGCCGCTGTGCCCCGGGGACCCGGGGCTACCGACACCGATGGAATCCCGAGAGGAAACTGACGGAGACGAGATGTGGACTTGTGAAAGA
GCTGCAGCGGAGGAAGGCGAGATTGATACAACAAACCAATGAACCTGTGTTGGAGGAAAACCTCACTTCTCATTCAACATCCAAGCGCCAGGACCTTGAA
TTGAGGTAGAGACGAGCAGCACCGAGTGTCCCTGGGAACCTGAAGGTCCCCCTCAGCCAGCTGCTCAGAGTACTGTGAGGCCAGCGCTTCC
GCTCAGTAACCTGGTCAAACAGCACCATCAAGATGAAGATTGCCCTGCGGGTGTCCATCTGAAAAGCGAGAAAGGCCCTCCAGACCAACACTCAGC
CAAGTCAAACGTCCCTCTGTGCTTAAAGAGGGAGGAAAACATCCATCAAATCTCATATGTCGGGTCTCCAGGCCCTGGTGCAGCAACACAGCTCCATCC
CACCAGTCATTGGGGCAGTGATAAGCCTGGTATGGAAGAAAAGGCCAGGCCCTGAGGCCCTCAAGGGCTGCACGACCTGGCAGAAGCTCCCTCAGC
CTCCTGGCCTCCCCAGGCCACATCTCAGTCAGGAGCGACCCCGAGCATGCCCTGGACATCTCGCTGCCATGCCACCCAGGAGCTGCCAGGCAAACACTG
CAGCTGGAAAACGGGACGCCCTGGACAGTCTCACTGGGCAGATCCAGCTGACCCATCCGGACAGCTCGCAGAGAACAGCTTATCGTGGTGTGCA
CTGCGAGAAAACCTCATTGCTTCTCTGAGACGCTCTGACCCATGTCGATGTATTATTACGGACAGAGCGGTCAAGGAGAGAAACCCCGGTCAAGAAAATT
TCAATGTTGATCAGCTGATCAGTTGCTACAAATGCAAGAACCTGACGTGCTGAGACTGCGCTCGTCAGACAGGTCCCTGGCAGATTGTGCTGCAACCTGAA
CTTGCCA
```

5' partner: TAF11**Junction point**


```
exon=1 1..256
/gene="TAF11"
/gene_synonym="MGC:15243; PRO2134; TAF2I; TAFII28"
```

BLAST vs mRNA

```
>ref|NM_005643.2| Homo sapiens TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28kDa (TAF11), mRNA
Length=1599
GENE ID: 6882 TAF11 | TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28kDa [Homo sapiens]
Score = 405 bits (448), Expect = 2e-116
Identities = 224/224 (100%), Gaps = 0/224 (0%)
```

Strand=Plus/Plus

Query 4	GCTTCTGCCTCAGGCATTCGGCATCTCCCTCTCCCCTCAATCCTATCGTGATGGACG	63
Sbjct 33	GCTTCTGCCTCAGGCATTCGGCATCTCCCTCTCCCCTCAATCCTATCGTGATGGACG	92
Query 64	ATGCCACAGTCCCGACAAGGTGGAGAGACAGGGAGTCGGATGAGACGGCG	123
Sbjct 93	ATGCCACAGTCCCGACAAGGTGGAGAGACAGGGAGTCGGATGAGACGGCG	152
Query 124	CTGTGCCGGGGACCCGGGGTACCGACACCGATGGAATCCAGAGAAACTGACGGAG	183
Sbjct 153	CTGTGCCGGGGACCCGGGGTACCGACACCGATGGAATCCAGAGAAACTGACGGAG	212
Query 184	ACCGAGATGTGGACTTGAAAGAACGTCGAGCGGAGGAAGGGAG	227
Sbjct 213	ACCGAGATGTGGACTTGAAAGAACGTCGAGCGGAGGAAGGGAG	256

**3' partner: FAM62B****Junction point**

```
exon=15 1705..1791
/gene="FAM62B"
/gene_synonym="CHR2SYT; ESYT2; KIAA1228"
```

BLAST vs mRNA

```
>ref|NM_020728.2| Homo sapiens family with sequence similarity 62 (C2 domain containing) member B (FAM62B), mRNA
Length=5957
GENE ID: 57488 FAM62B | family with sequence similarity 62 (C2 domain containing) member B [Homo sapiens]
Score = 1321 bits (1464), Expect = 0.0
Identities = 802/828 (96%), Gaps = 18/828 (2%)
```

Strand=Plus/Plus




Query 217	AGGAAGGCGAGATTGATACAAACCAATGAACCTGTGGAGGAAACTTCACTTTCT	276
Sbjct 1694	AGGAGAGCAAGATTGATACAAACCAATGAACCTGTGGAGGAAACTTCACTTTCT	1753

Query 277	TCATTCAAAATCCAAGCGCCAGGACCTTGAAGTTGAGGTCAAGAGCAGCAGCACAGT	336
Sbjct 1754	TCATTCAAAATCCAAGCGCCAGGACCTTGAAGTTGAGGTCAAGAGCAGCAGCACAGT	1813
Query 337	GTTCCCTGGGGAACCTGAAAGTCCCCCTCAGCCAGCTGCTCACCAAGTGAGGACATGACTG	396
Sbjct 1814	GTTCCCTGGGGAACCTGAAAGTCCCCCTCAGCCAGCTGCTCACCAAGTGAGGACATGACTG	1873
Query 397	TGAGCCAGCGCTTCCAGTCAACTCGGGTCCAAACAGCACCATCAAGATGAAGATTG	456
Sbjct 1874	TGAGCCAGCGCTTCCAGTCAACTCGGGTCCAAACAGCACCATCAAGATGAAGATTG	1933
Query 457	CCCTGCGGGTGCTCCATCTCGAAAAGCGAGAAAGGCCCTCAGACCACCAACTCAGCTC	516
Sbjct 1934	CCCTGCGGGTGCTCCATCTCGAAAAGCGAGAAAGGCCCTCAGACCACCAACTCAGCTC	1993
Query 517	AACTCAACGTCCCTGTCAAAGAGGGGAGGAAAACATCCATCAAATCTCATATGT	576
Sbjct 1994	AACTCAACGTCCCTGTCAAAGAGGGGAGGAAAACATCCATCAAATCTCATATGT	2053
Query 577	CTGGGTCTCCAGGCCCTGGTGGCAGCACACAGCTCCATCCCACACCAGTCATTGGGGCA	636
Sbjct 2054	CTGGGTCTCCAGGCCCTGGTGGCAGCACACAGCTCCATCCCACACCAGTCATTGGGGCA	2113
Query 637	GTGATAAGCTGGTATGGAAGAAAGGCCAGGCCCCCTGAGGCCGGCCCTCAAGGGCTGC	696
Sbjct 2114	GTGATAAGCTGGTATGGAAGAAAGGCCAGGCCCCCTGAGGCCGGCCCTCAAGGGCTGC	2173
Query 697	ACGACCT-GGCAGAAGCTCCAGCCTCTGGCTCCCAGGCCACATCTCAGTCAGG	755
Sbjct 2174	ACGACCTGGCAGAAGCTCCAGCCTCTGGCTCCCAGGCCACATCTCAGTCAGG	2233
Query 756	AGCCGACCCCCAGCATGCCCTGGACATCTCGCTGCCCATGCCACCCAGGAGCTGCC	815
Sbjct 2234	AGCCGACCCCCAGCATGCCCTGGACATCTCGCTGCCCATGCCACCCAGGAGCTGCC	2293

NOL11- C7orf42

TCAAATTATAACAAGTCCAGCTGTGCAACTTCAAACCTGGAGAGTATGTTGTTGACACGTTAATAAGGTTTAAGAATATGAAATAATGAAGATGTAA
 CCTGGATAAAAGTATTTAAAGCTACATTGTCAGCAGAACTATAGGAACTTTCAGTCAAGGGACAGAACCCCTGGTCTTCAGGAAGGTGCTGTTG:
 GGTTTAGAGGCCTTGTTGCAAGCCCCCAGCAGAAAATTGAAACTGTTATCTCTGATGAAGAAGTGAATTAAAGCCACCGCACTGTGTTCTGACACGTAC:
 GCAACGCCACGTTCTGGTACAAGATCTTACAACACTGCCAGGGATGCCAACACAAAATACGCCAAGATTACAATCCTTCTGGTATAAGGGGCCATTG:
 AAAAGTTTATCATGCTTTAAATCCAAGCTTACAGTGATTGTTCAAGATGATGACCGTTATTAAATTGATCATATCAAGCACACAGTTACTTCCTAA:
 GTGATGGTGTAAACAATGTTGAAAGATGTAATCTGGCTGACGTAGCAAAAGAGTCAGAGCAATCAAGAAAAATCCCGAGAAGGTGGATTG

5' partner: NOL11



Junction point

```
exon=4 316..464
/gene="NOL11"
/gene_synonym="DKFZp586L0724"
```

BLAST vs mRNA

```
>ref|NM_015462.3| Homo sapiens nucleolar protein 11 (NOL11), mRNA
Length=2454
GENE ID: 25926 NOL11 | nucleolar protein 11 [Homo sapiens]
Score = 484 bits (536), Expect = 2e-140
Identities = 275/278 (98%), Gaps = 1/278 (0%)
```

Strand=Plus/Plus

Query 5	CTTGGGAGCTGGTCAGTCAAAGGTCAAATTAAACATGTCCAGCTGTGCAACTT	64
Sbjct 162	CTTGGGAGCTGGTCAGTCAAAGGTCAAATTAAACATGTCCAGCTGTGCAACTT	221
Query 65	TCAAACCTGGAGAGTATGTTGTCAGCAGATAAAAGGTTAAGAATATGAAATAATGA	124
Sbjct 222	TCAAACCTGGAGAGTATGTTGTCAGCAGATAAAAGGTTAAGAATATGAAATAATGA	281
Query 125	AGATGTAACCTGGATAAAAGTATTAAAGCTACATTGTCAGCAGAAGTATAGGAACT	184
Sbjct 282	AGATGTAACCTGGATAAAAGTATTAAAGCTACATTGTCAGCAGAAGTATAGGAACT	341
Query 185	TTCAAGTCAAGGGACAGAACCTTGGTCTCTCAAGGAAGGTGCTGTTGTTAGA	244
Sbjct 342	TTCAAGTCAAGGGACAGAACCTTGGTCTCTCAAGGAAGGTGCTGTTGTTAGA	401

Query	245	GGCCTTGCTTCAGACCCCCAGCAGAAAAATTGAAACTGTTATCTGTATGAAGAAGTGTAT	304
Sbjct	402	GGCCTTGCTTCAGACCCCCAGCAGAAAAATTGAAACTGTTATCTGTATGAAGAAGTGTAT	461
Query	305	TAAA 308	
Sbjct	462	TAAA 465	

↑

3' partner: C7orf42



Junction point

exon=5 861..1044

/gene="C7orf42"

/gene_synonym="FLJ10099; FLJ13090"

BLAST vs mRNA

>ref|NM_017994.4| Homo sapiens chromosome 7 open reading frame 42 (C7orf42), mRNA Length=4238
GENE ID: 55069 C7orf42| chromosome 7 open reading frame 42 [Homo sapiens]
Score = 475 bits (526), Expect = 2e-137
Identities = 309/338 (91%), Gaps = 1/338 (0%)


Strand=Plus/Plus

↓

Query	308	ACAGGCCACCGCACTGTGTTCTGACACGTACAGCACGCCACGCTCTGGTACAAGATCTT 	367
Sbjct	861	ACAGGCCACCGCACTGTGTTCTGACACGTACAGCACGCCACGCTCTGGTACAAGATCTT 	920
Query	368	CACAAC TGCCAGAGATGCCAACACAAAATACGCCAAGATTACAATCCTTCTGGTGT TA 	427
Sbjct	921	CACAAC TGCCAGAGATGCCAACACAAAATACGCCAAGATTACAATCCTTCTGGTGT TA 	980
Query	428	TAAGGGGGCATTGGAAAAGTCTATCATGTTAAATCCCAGCTTACAGT GATTGTTCC 	487
Sbjct	981	TAAGGGGGCATTGGAAAAGTCTATCATGTTAAATCCCAGCTTACAGT GATTGTTCC 	1040
Query	488	AGATGATGACC GTT CATTAA TAA ATTG CATCTCATGCACACCAGTTACCTCCTCTTG 	547
Sbjct	1041	AGATGATGACC GTT CATTAA TAA ATTG CATCTCATGCACACCAGTTACCTCCTCTTG 	1100
Query	548	GATGGT GATAACAA TGT TGT GCT ATGCT GTT ATCAAGGGCAGACCTAGCAAATTGCGTCA 	607
Sbjct	1101	GATGGT GATAACAA TGT TGT GCT ATGCT GTT ATCAAGGGCAGACCTAGCAAATTGCGTCA 	1160
Query	608	GAGCAAT CCTG AATT TGT CCC GAGAAGGTGGCTTGGCTGAAGCTTAATTCCACAGCTC 	667
Sbjct	1161	GAGCAAT CCTG AATT TGT CCC GAGAAGGTGGCTTGGCTGAAGCTTAATTCCACAGCTC 	1220
Query	668	CTTGT TTTT GAGAGAGACTGAGAGAACATAATCCTGCTGTGAACCCAGCTGGGC 	727
Sbjct	1221	CTTGT TTTT GAGAGAGACTGAGAGAACATAATCCTGCTGTGAACCCAGCTGGGC 	1280
Query	728	CTGGATGCTCTGTGAA TACAT TATCTGGATGTTGGTTATTCCAGCCAAAGACATTTC 	787
Sbjct	1281	CTGGATGCTCTGTGAA TACAT TATCTGGATGTTGGTTATTCCAGCCAAAGACATTTC 	1340
Query	788	AA GTGCCTGTA ACTGATTTGACATATTTAT-AAAATCTT CAGA 	832
Sbjct	1341	AA GTGCCTGTA ACTGATTTGACATATTTATAAAATCTT CAGA 	1386

NSUN5B- CPSF3

TTGGGCCGCCCCAGGGCTCTATCAAGGGGCTGGTACTCCAGCAACTTCCAGAACGTGAAGCAGCTGTACGCCGCTGGTGTGCAAACGCCAGCGCTACTCCGCC
TGCTGGATGCCGTGATCTCCAGGCCGCCCTCTCAGTGCAGAAGCTGCAGGCCACCTGCCAAGGGTGCAGTACAGAAGGTTTTAAAAAAATTAGAAA
GCACGTTTACAGCAAGAGGTTGGAGATCATGCCAGGACATTTGGAGAAGACTGTGTAAGTGTAAAGGATGACTCTATTGGTAGCGTCACAGTGGACGG
AAAAGTCCCACCTTAACTGGAGACACGGACTGTAGAAATGTGAGAGGGAAAGTGAAGACGATGAATCCTCCGAGAAATGGTGGAGCTGGCTGCACAGAGA
TGTAGGCCCCCTGACGCCAGTTCACTGAGACTGTGCCGTATATGAACCTTGAAAAAAACTTGTACTTTACTTTGTACCTAAAATAAATGCAATTGTT
TTTTG

5' partner: NSUN5B**Junction point**


```
exon=2 121..241
/gene="NSUN5P1"
/gene_synonym="FLJ99347; MGC129801; NSUN5B; WBSCR20B"
```

BLAST vs mRNA

```
>ref|NR_033322.2| Homo sapiens NOP2/Sun domain family, member 5 pseudogene 1 (NSUN5P1), non-coding RNA
Length=1751
GENE ID: 155400 NSUN5P1| NOP2/Sun domain family, member 5 pseudogene 1 [Homo sapiens]
Score = 311 bits (168), Expect = 3e-84
Identities = 168/168 (100%), Gaps = 0/168 (0%)
```

Strand=Plus/Plus

Query 5	GCCGCCAGGGCTCTATCAAGGGCTGGTGTACTCCAGCAACTTCCAGAACGTGAAGCAGC	64
Sbjct 74	GCCGCCAGGGCTCTATCAAGGGCTGGTGTACTCCAGCAACTTCCAGAACGTGAAGCAGC	133
Query 65	TGTACGGCTGGTGTGGAAACGCCAGGCCCTACTCCGGCGTGGATGCCGTGATCTCCA	124
Sbjct 134	TGTACGGCTGGTGTGGAAACGCCAGGCCCTACTCCGGCGTGGATGCCGTGATCTCCA	193
Query 125	GCGCCGGCTCCTCAGTGCGAAGAACGTCAGCCGACCTGGCCAAGG	172
Sbjct 194	GCGCCGGCTCCTCAGTGCGAAGAACGTCAGCCGACCTGGCCAAGG	241

**3' partner: CPSF3****Junction point**

```
exon=16 1822..1891
/gene="CPSF3"
/gene_synonym="CPSF; CPSF-73; CPSF73; YSH1"
```

BLAST vs mRNA

```
>ref|NM_016207.2| Homo sapiens cleavage and polyadenylation specific factor 3, 73kDa (CPSF3), mRNA
Length=2286
Score = 609 bits (674), Expect = 5e-178
Identities = 343/347 (98%), Gaps = 0/347 (0%)
```

Strand=Plus/Plus



Query 169	AAGGGTGCAGTACAGAAGGTTTTAAAAAATTAGAAATGCACGTTTACAGCAAGAGGTTG	228
Sbjct 1818	AAAGGTGCAGTACAGAAGGTTCTAAAAAATTAGAAATGCACGTTTACAGCAAGAGGTTG	1877
Query 229	GAGATCATGCTCCAGGACATATGGAGAAGACTGTGTAAGTGAAAGGATGACTCTATT	288
Sbjct 1878	GAGATCATGCTCCAGGACATATGGAGAAGACTGTGTAAGTGAAAGGATGACTCTATT	1937
Query 289	TTTAGCGTACAGTGGACGGAAAATGCCAACCTAACCTGGAGACACGGACTGTAGAA	348
Sbjct 1938	CTTAGCGTACAGTGGACGGAAAATGCCAACCTAACCTGGAGACACGGACTGTAGAA	1997

```


Query  349  TGTGAAGAGGAAAGTGAAGACGATGAATCCCTCGAGAAATGGTGGAGCTGGCTGCACAG  408
|||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||
Sbjct  1998  TGTGAAGAGGAAAGTGAAGACGATGAATCCCTCGAGAAATGGTGGAGCTGGCTGCACAG  2057
|||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||
Query  409  AGACTGTACGAGGCCCTGACGCCAGTTCACTGAGACTGTGCCGTATATGAACATTGAAA  468
|||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||
Sbjct  2058  AGACTGTACGAGGCCCTGACGCCAGTTCACTGAGACTGTGCCGTATATGAACATTGAAA  2117
|||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||
Query  469  AAATACTTGACTTTACTTTGTTACCTAAAAAATGCAATTGCTTT  515
|||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||
Sbjct  2118  AAATACTTGACTCTACTTTGTTACCTAAAAAATGCAATTGCTTT  2164
|||.....|||||.....|||||.....|||||.....|||||.....|||||.....|||

```

MSMB- POLE4

AATGCAACTTTGTACAAAAAAGTTGGAGGAGTCCTGCTTATCACAAATGAATGTTCTCCTGGCAGCGTTGTGATCTTGCCACCTCGTGACTTTATGCAA
 GCATCATGCTATTCATACCTAATGAGGGAGTTCCAGGAGATTCAACCAGGAATGATGGATCTCAAAGGAAACAAACACCCAATAACTCGGAGTGGCAGI
 CTGACAACGTGAGACATGCACTGCTACGAAACAGAAATTTCATGTTGCACCCCTATAATGCAATAGAAGCTGTGGATGAATTGCTTTCTGAAAGGACT
 TAGATTGATTGCCAGCAGGGGGAGTTTGAGCCTTCATCTGAAGCCTTCAGTTCACCCCTCTGCACAGGCTCAGCTTGAAGAACGGAGTCTTGCACI
 ACACACACTCTTCCTGTTCTGCCCTCACCTATGCCGGATAAGCAGAGATCTCATCAATTAGCTCTCTGCAAGGTCTTCACTGTTCTGCTGTCTTC
 ATATCAAGCCTGGATGCACTGCTGCTGCTTAGAGCAGAGATGAAGAAAGTGTCTGCATAAGTGGCTCCTGAATGATGAGGAGCAGAATAAGGTTTIGI
 TCAACCTC

5' partner: MSMB



Junction point

exon=3 142..247
 /gene="MSMB"
 /gene_synonym="HPC13; IGBF; MSP; MSPB; PN44; PRPS; PSP;
 PSP-94; PSP57; PSP94"

BLAST vs mRNA

```

>ref|NM_002443.2| Homo sapiens microseminoprotein, beta- (MSMB), transcript variant PSP94, mRNA
Length=572
GENE ID: 4477 MSMB microseminoprotein, beta- [Homo sapiens]
Score = 423 bits (468), Expect = 1e-122
Identities = 234/234 (100%), Gaps = 0/234 (0%)

```

Strand=Plus/Plus


```

Query  28  AGGAGTCTGCTTATCACAAATGAATGTTCTCCTGGCAGCGTTGTGATCTTGCCACCTT  87
Sbjct  14  AGGAGTCTGCTTATCACAAATGAATGTTCTCCTGGCAGCGTTGTGATCTTGCCACCTT  73
Query  88  CGTGACTTATGCAATGCATCATGCTATTCTACCTAACGAGGAGTTCCAGGAGATTC  147
Sbjct  74  CGTGACTTATGCAATGCATCATGCTATTCTACCTAACGAGGAGTTCCAGGAGATTC  133
Query  148  AACCAAGGAAATGCATGGATCTCAAAGGAAACAAACACCCAATAACTCGGAGTGGCAGAC  207
Sbjct  134  AACCAAGGAAATGCATGGATCTCAAAGGAAACAAACACCCAATAACTCGGAGTGGCAGAC  193
Query  208  TGACAACTGTGAGACATGCACTTGCACGAAACAGAAATTTCATGTTGCACCC  261
Sbjct  194  TGACAACTGTGAGACATGCACTTGCACGAAACAGAAATTTCATGTTGCACCC  247

```



3' partner: POLE4



Junction point

exon=3 331..372
 /gene="POLE4"
 /gene_synonym="p12"

BLAST vs mRNA

>ref|NM_019896.2| Homo sapiens polymerase (DNA-directed), epsilon 4 (p12 subunit) (POLE4), mRNA Length=710
 GENE ID: 56655 POLE4 | polymerase (DNA-directed), epsilon 4 (p12 subunit) [Homo sapiens]
 Score = 654 bits (724), Expect = 0.0
 Identities = 364/365 (99%), Gaps = 0/365 (0%)

Strand=Plus/Plus


↓

Query 262	ATAATGCAATAGAACGCTGTGGATGAATTGCTTTCTGGAAGGTACTTAGATTGATTGC	321
Sbjct 331	ATAATGCAATAGAACGCTGTGGATGAATTGCTTTCTGGAAGGTACTTAGATTGATTGC	390
Query 322	CGAGCGGGCAGTTGTGAGCCTTCATCTGAAGCCTTCAGGTCACCCCTCTGCACAGGC	381
Sbjct 391	CGAGCGGGCAGTTGTGAGCCTTCATCTGAAGCCTTCAGGTCACCCCTCTGCACAGGC	450
Query 382	CTCAGCTTGAGAACGGAGCTTGCACCTAACACACTCTCCTGTTGCCCTCACCC	441
Sbjct 451	CTCAGCTTGAGAACGGAGCTTGCACCTAACACACTCTCCTGTTGCCCTCACCC	510
Query 442	TATGCCGGATAAGCAGAGATCTCATCAATTAGCTCTCTGCAAGGTCTTCACTGTT	501
Sbjct 511	TATGCCGGATAAGCAGAGATCTCATCAATTAGCTCTCTGCAAGGTCTTCACTATT	570
Query 502	TCTGTCCTGCTTCCATATCAAGCCTGGATGCAGCTGCTGCTTAGAGCAGAGATGAAG	561
Sbjct 571	TCTGTCCTGCTTCCATATCAAGCCTGGATGCAGCTGCTGCTGCTTAGAGCAGAGATGAAG	630
Query 562	AAAGTGTCTGCATAAGTGGCTCCTGAATGATGAGGACCAGAATAAAGGTTTTGATCA	621
Sbjct 631	AAAGTGTCTGCATAAGTGGCTCCTGAATGATGAGGACCAGAATAAAGGTTTTGATCA	690
Query 622	ACCTC 626	
Sbjct 691	ACCTC 695	

AZGP1-GJC3

TTGGAGAATGGTGCCTGCTCTGCTCTGCTGCTCTGGGCTCTGCTGCCCCCAGGAGAACCAAGATGGTCGTTACTCTCTGACCTATATCTACAC
 GGGCTGTCCAAGCATGTTGAAGACGCTCCCGCGTTCAAGCCCTTGGCTCACTCAATGACCTCCAGTTCTTAGATACACAGTAAGAGACAGGAAGTCAGC
 CCATGGGACTCTGGAGACAGGGTGAAGGAATGGAGGATTGGAAGCAGGACAGCCAACCTTCAGAAGGCCAGGGAGACATCTTATGGAGACCCCTGAAAGACA
 CGTGGAGTATTACACAGCAAGCTAACGGAGTGTGTCAGGTTCTCGCAGGCTGGCTGGCTGGAGTCTATGGTATGAGCAGAGTAATTGTCGTCACACCCAGCAGCCGGCT
 CCGTGCCTGGATTCCGCTTGTGCTGCTGGCTGCAGTGGGCTGGAGTCTATGGTATGAGCAGAGTAATTGTCGTCACACCCAGCAGCCGGCT
 CAAGGCTGCTGCTCGATGCCCTCACCCCTCTCCCGCTGCCTTCTGGGCTTCCAGGTATCTGGGTGCTGTCACCCAGCAGCCCTCTATATGGGTT
 ACTCTGTATCACGTGATCTGCACTGGATTATCAGGAAAGGGGAAGGGAGGAGATCTGATCCAGGGACGGGAGGGCAACACAGATGTCCTAGGGGG
 TGGAAAGCTCTCACGCTGCTGGGCTTATGTGGCTCAGCTGGGGCTCGGCTTGCTGTAGGGGGCAGCCCTGGGGTGCAGTACCCCTGTATGGGTTCC
 GATGCCAGCTCTTGATGTCGCCAGAACCTTGCTGGTAGTATAACCTGCAATCTGCCGCTCTGAGAACGCCATTCTCAAAGACCATGTC
 TGGAGTCAGCGGTTCTGCTCTTGTCTTGTGAGCTGTGCTTCTGGGTTGGGGAGATGGTGGAGGACTGAGCACAATCTCCTCTTCTAAATA
 TCTAACTCGAAAGCACCGAAGACCAAGAACGACAGATAAGCCTCCCAGTGGGTATCAAGAGCATTCAAGAGCAGTTCAAGAGGAGCTAGCTAGGAAAACAAGAA
 AGTTGAAGTGTGAGAATGTCTGGAGAATAAAACTTTTGT

5' partner: AZGP1



Junction point

exon=2 169..429

/gene="AZGP1"

/gene_synonym="ZA2G; ZAG"

BLAST vs mRNA

>ref|NM_001185.3| UniGene info linked to NM_001185.3GEO profiles info linked to NM_001185.3Gene info linked to NM_001185.3Genome view with mapviewer linked to NM_001185.3 Homo sapiens alpha-2-glycoprotein 1, zinc-binding (AZGP1), mRNA Length=1278
 GENE ID: 563 AZGP1 | alpha-2-glycoprotein 1, zinc-binding [Homo sapiens]
 Score = 614 bits (332), Expect = 2e-174
 Identities = 332/332 (100%), Gaps = 0/332 (0%)

Strand=Plus/Plus


```

Query  5  AGAATGGTGCCTGCTCTGCTCTGCTGCTGCTCTGGTCCTGCTGTCCCCCAGGAG  64
Sbjct  99  AGAATGGTGCCTGCTCTGCTCTGCTGCTGCTCTGGTCCTGCTGTCCCCCAGGAG  158
Query  65  AACCAAGATGGTCGTTACTCTGACCTATATCTACACTGGGCTGTCCAAGCATGTTGAA  124
Sbjct  159  AACCAAGATGGTCGTTACTCTGACCTATATCTACACTGGGCTGTCCAAGCATGTTGAA  218
Query  125  GACGTCCCCCGCGTTTCAGGCCCTGGCTCACTCAATGACCTCCAGTTAGATAAAC  184
Sbjct  219  GACGTCCCCCGCGTTTCAGGCCCTGGCTCACTCAATGACCTCCAGTTAGATAAAC  278
Query  185  AGTAAAGACAGGAAGTCTCAGCCCATGGGACTCTGGAGACAGGTGGAAGGAATGGAGGAT  244
Sbjct  279  AGTAAAGACAGGAAGTCTCAGCCCATGGGACTCTGGAGACAGGTGGAAGGAATGGAGGAT  338
Query  245  TGGAAAGCAGGACAGCCAACTTCAGAAGGCCAGGGAGGACATCTTATGGAGACCCTGAAA  304
Sbjct  339  TGGAAAGCAGGACAGCCAACTTCAGAAGGCCAGGGAGGACATCTTATGGAGACCCTGAAA  398
Query  305  GACATCGTGGAGTATTACAACGACAGTAACCG  336
Sbjct  399  GACATCGTGGAGTATTACAACGACAGTAACCG  430

```



3' partner: GJC3


Junction point
exon=1 1..781
/gene="GJC3"
/gene_synonym="CX29; CX30.2; CX31.3; GJE1"
BLAST vs mRNA

```

>ref|NM_181538.2| UniGene info linked to NM_181538.2GEO profiles info linked to NM_181538.2Gene info
linked to NM_181538.2Genome view with mapviewer linked to NM_181538.2 Homo sapiens gap junction
protein, gamma 3, 30.2kDa (GJC3), mRNA
Length=1131
GENE ID: 349149 GJC3 | gap junction protein, gamma 3, 30.2kDa [Homo sapiens]
Score = 1266 bits (685), Expect = 0.0
Identities = 806/857 (95%), Gaps = 37/857 (4%)

```

Strand=Plus/Plus



```

Query  337  ATGTGTGGCAGGTTCTGGCGCGCTGCTGGCGAGGAGAGCCGGCGCTCACCCCCGTG  396
Sbjct  1     ATGTGTGGCAGGTTCTGGCGCGCTGCTGGCGAGGAGAGCCGGCGCTCACCCCCGTG  60
Query  397  GGGCGCCTCTGCTTCCCGTCTGGATTCGGCTTGCTGCTGGCTGCCAGTGG  456
Sbjct  61     GGGCGCCTCTGCTTCCCGTCTGGATTCGGCTTGCTGCTGGCTGCCAGTGG  120
Query  457  CCTGGAGTCTATGGTGTAGCAGAGTGAATTCTGTGTGTCACACCCAGCAGCCGGCTGC  516
Sbjct  121    CCTGGAGTCTATGGTGTAGCAGAGTGAATTCTGTGTGTCACACCCAGCAGCCGGCTGC  180
Query  517  AAGGCTGCCCTCGATGCCCTCCACCCCTCTCCCGCTGCGTTCTGGTCTTCCAG  576
Sbjct  181    AAGGCTGCCCTCGATGCCCTCCACCCCTCTCCCGCTGCGTTCTGGTCTTCCAG  240
Query  577  GTCATCTGGTGGCTGTACCCAGCGCCCTATATGGGTTCACTCTGTATCACGTGATC  636
Sbjct  241    GTCATCTGGTGGCTGTACCCAGCGCCCTATATGGGTTCACTCTGTATCACGTGATC  300
Query  637  TGGCACTGGATTATCAGGAAAGGGGAACGGAGGAGGAGATCTGTGATCCAGGGACGGGA  696
Sbjct  301    TGGCACTGGATTATCAGGAAAGGGGAACGGAGGAGGAGACCTGATCCAGGGACGGGA  359
Query  697  GGGCAACACAGATGTCTTAGGGCTGGAAGCTCTCACGTGCTCTGGCTTATGTGGCT  756
Sbjct  360    GGGCAACACAGATGTCCC-AGGGCTGGAAGC-CTCAGGGCTGCTCTGGCTTATGTGGCT  417
Query  757  CAGCTGGGGCTCGGCTGTGCTGTAGGGGGCAGCCCTGGGGTTGCAGTACCACTGTAT  816
Sbjct  418    CAGCTGGGGCTCGGCTGTGCTGTAGGGGGCAGCCCTGGGGTTGCAGTACCACTGTAT  477


```

Query 817	GGGTTCCAGATGCCAGCTCTTGATGTCGCCGAGAACCTTGCCTGGTAGTATAACC	876
Sbjct 478	GGGTTCCAGATGCCAGCTCTTGATGTCGCCGAGAACCTTGCCTGGTAGTATAACC	537
Query 877	TGCAATCTGTCCCGCTCCTGAGAAGACCATTTCTAAAGACCATGTTGGAGTCAG	936
Sbjct 538	TGCAATCTGTCCCGCCCCCTGAGAAGACCATTTCTAAAGACCATGTTGGAGTCAG	596
Query 937	CGGTTCTGTCTTGTACTTTGGAGCTGTGCTGGTTGGGAGATGGTG	996
Sbjct 597	CGGTTCTGTCTTGTACTTTGGAGCTGTGCTGGTTGGGAGATGGTG	656

SLC25A16-DNA2

TTGGTACCCCTTCTGGCAGACCTTCATCAGACAATCTTAATGCTTAGTTGAAAACCTATGTAACACTTACTTTGCGGTGTTGCTGGAGCAATAGCGC
 GACAATATCCTACCCATTGATGTGACTCGTCGCCGAATGCAATTAGAACCTGTCAGCTGGAAATTGAAAGAACTGCTTCTGCCGGATTGAAAAGTC
 TTTCCAAGAACAGTTCTGAGCACAGGAATGGATAACCGGTACCTGGTGTGGCAGTCATAACTGTACAGAACAAAGAGGGAAACTGTGAAAAGCGCCTGGTC
 TCACTGCTTCACAGTCACTAGAAAATAAGAACATATGCATCCTTAGGAATGACTGGTGTCTGTTCCAGTAGAGCCAGGAGATATCATTCAATTGGAGGGAG
 CTGCACATCTGACACTGGATAATAGATAAAGATTTGGATAATTGATTCTGATTCAGACATGCTGATTCTGGCACCCAGCATAGCCAGTAGTATTGATG
 ATGAGAAGAGCTGCTCTGAGTGGAAACTTTAGGAGCTCTGATCCAGCCACAGCCAAATGCTAATTGGTACGGTTCTCCATGAGGTTTCAAAAGCAATA
 ATAATAGCTTGCAGGAAAGCTACAAGAACATTGCTTTCAAACAAATTCAAGAATAAGACATTGAGGAAATGTCAGCTAAAGTCAAGATGAA
 ATAAAAACAAGAAGTAGAGGAACTATCTCCTTCGTTTGTAAATGGCAGGAGATTGATGCAATAAACACTTCGACTGACTCCCTCAGATGCAAGCTCT
 TGCCAAGTGATAATAGTAAGGATAATTCAACATGTAACATTGAAGTCGTGAAACCAATGGATATTGAAGAAGCATTTGGTCCCTAAGTTGGATGAAAGGC
 AAATAAATGTTACAGTTGGTGTGAAATACATGAGGTATAAACAAATACAGATATGCCGCTGGACTAGACTGCAAGATCAAATTCTATGAACTACGTAGTCAG
 GTTCTGTAACTCTACTAGTCAGAGAGAAAGCTGATCAAGCCTGACTGCTCCCTACTCAGAACTGTCAGTACCTGCCCTGCACATCTAAATAAGAATTAA
 CTGAAACCGAATGCATCCATTGTTACGATTAGCAAATGCCCTCTTCCGGGACACT

5' partner: SLC25A16



Junction point

exon=8 922..990
/gene="SLC25A16"
/gene_synonym="D10S105E; GDA; GDC; HGT.1; hML7; MGC39851; ML7"

BLAST vs mRNA


>ref|NM_152707.3| Homo sapiens solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16 (SLC25A16), nuclear gene encoding mitochondrial protein, mRNA
 Length=2264
 GENE ID: 8034 SLC25A16 solute carrier family 25 (mitochondrial carrier; Graves disease autoantigen), member 16 [Homo sapiens]
 Score = 327 bits (177), Expect = 3e-88
 Identities = 177/177 (100%), Gaps = 0/177 (0%)

Strand=Plus/Plus

Query 5	TACCCCTCTGGCAGACCTTCATCAGACAATCTTAATGCTTAGTTGAAAACCTATG	64
Sbjct 814	TACCCCTCTGGCAGACCTTCATCAGACAATCTTAATGCTTAGTTGAAAACCTATG	873
Query 65	AAACTTACTTTGTGGTGGTGTGGAGACATAGCGCAGACAATATCTACCCATTG	124
Sbjct 874	AAACTTACTTTGTGGTGGTGTGGAGACATAGCGCAGACAATATCTACCCATTG	933
Query 125	TGTGACTCGTCGGCGAATGCAATTAGAACCTGTCGCCGGATTGAAAAGTC	181
Sbjct 934	TGTGACTCGTCGGCGAATGCAATTAGAACCTGTCGCCGGATTGAAAAGTC	990



3' partner: DNA2L



```
exon=2 184..366
/gene="DNA2"
/gene_synonym="DNA2L; FLJ10063; KIAA0083; MGC133297"
```


BLAST vs mRNA

```
>ref|NM_001080449.2| Gene info linked to NM_001080449.2 Homo sapiens DNA replication helicase 2 homolog (yeast) (DNA2), mRNA  
Length=4287  
GENE ID: 1763 DNA2 | DNA replication helicase 2 homolog (yeast) [Homo sapiens]  
Score = 1496 bits (810). Expect = 0.0  
Identities = 933/984 (95%), Gaps = 41/984 (4%)
```

Strand=Plus/Plus

PACRGL-LIMCH1

5' partner: PACRGL



Junction point
exon=3 444..598
/gene="PACRGL"

/gene_synonym="C4orf28; MGC29898"

BLAST vs mRNA


>ref|NM_001130727.1| UniGene info linked to NM_001130727.1GEO profiles info linked to NM_001130727.1
 Gene info linked to NM_001130727.1Genome view with mapviewer linked to NM_001130727.1 Homo sapiens
 PARK2 co-regulated-like (PACRGL), transcript variant 2, mRNA
 Length=1796
 GENE ID: 133015 PACRGL | PARK2 co-regulated-like [Homo sapiens]
 Score = 394 bits (213), Expect = 1e-108
 Identities = 221/225 (99%), Gaps = 0/225 (0%)

Strand=Plus/Plus

Query 156	GGAGTGAAGGGAAAGCAATGCAAAATCAAAGGGCTCTGGAGGTACACAGTTGAAAAACA	215
Sbjct 375	GGAGTGAAGGGAAAGCAATGCAAAATCAAAGGGCTCTGGAGGTACACAGTTGAAAAACA	434
Query 216	GAGCAACAGGTAACTATGATCAAAGGACATCATCAAGCACACAGTTAAAACACAGGAATG	275
Sbjct 435	GAGCAACAGGTAACTATGATCAAAGGACATCATCAAGCACACAGTTAAAACACAGGAATG	494
Query 276	CAGTTAGGGAAAGCAAATCCCTATTGTCACCAGTTCTCCAAAGTCTGCAAGAAAACCTTC	335
Sbjct 495	CAGTTAGGGAAAGCAAATCCCTATTGTCACCAGTTCTCCAGAGTCTGCAAGAAAACCTTC	554
Query 336	ATCCTAACCAAGTGATAAAACTGAAACCTAAACAAATTAATCCGG	380
Sbjct 555	ATCCTAGACCAAGTGATAAAACTGAAACCTAAACAAATTAATCCGG	599



3' partner: LIMCH1



Junction point

exon=11 647..773

/gene="LIMCH1"

/gene_synonym="DKFZp434I0312; DKFZp686A01247;"

BLAST vs mRNA

>ref|NM_001112720.1| UniGene info linked to NM_001112720.1GEO profiles info linked to NM_001112720.1Gene info linked to NM_001112720.1Genome view with mapviewer linked to NM_001112720.1 Homo sapiens LIM and calponin homology domains 1 (LIMCH1), transcript variant 5, mRNA
 Length=5722
 GENE ID: 22998 LIMCH1 | LIM and calponin homology domains 1 [Homo sapiens]
 Score = 472 bits (255), Expect = 7e-132
 Identities = 258/259 (99%), Gaps = 1/259 (0%)

Strand=Plus/Plus




Query 379	GGAGCACCAGCATTTGACATGCGGTGTGAGGGAGGCCGCGGTGCAGCCGCACAGCA	438
Sbjct 646	GGAGCACCAGCATTTGACATGCGGTGTGAGGGAGGCCGCGGTGCAGCCGCACAGCA	705
Query 439	GGGCCCCCAGGAGCAGCTGCAGCTGATAAATAACCAAGCTGAGGGAAAGGGACGACAAT	498
Sbjct 706	GGGCCCCCAGGAGCAGCTGCAGCTGATAAATAACCAAGCTGAGGGAAAGGGACGACAAT	765
Query 499	GGCAAGATGACCTGGCTCGTGGAGAGACTCTAGAAGAAAGTCTTCAGGACTTAATCA	558
Sbjct 766	GGCAAGATGACCTGGCTCGTGGAGAGACTCTAGAAGAAAGTCTTCAGGACTTAATCA	825
Query 559	AGAAAGAGGAAGGaaaaaaaTGGAGAGTTACTGGCTGGAGAAAGATGGGACAAGT	618
Sbjct 826	AGAAAGAGGAAGGaaaaaaaTGGAGAGTTACTGGCTGGAGAA-GATGGGACAAGT	884
Query 619	GAACGAAGGAAAAGCATCA	637
Sbjct 885	GAACGAAGGAAAAGCATCA	903

TXNL1-CDH2

TTGGCTTAGAAAATGACCTCTGAGAAGCAATGAGGACACAGATATTCCAAAAGGCTATATGGATTTAATGCCCTTATTAACAAAGCTGGTTGTGAATGTCT
 AATGAAAGTGTGAGCATGGATTGACAACCTGTTACGAAAAGACACAACCTCTTGGAACTGACTGTGATGAACAGCTGTTATTACTGTGCCATTCAAT
 AACCTGTTAAGCTTATTCCATGAAATTCAAGGGCAGATAATGGTCAGGGCCCTAAATATGAAAAAATTTTATCACACCTACCCGATCTATGGATTTG
 AGAGGCAGAAAAGAAGTGAACCAACTCAAGCTCTGAACTGACAGAGGATGATATTAAAGAAGATGGCATTGTCACCTCGTTATGTTAAGTTTCAGAATG
 AACAGTGTAACTATATTGTTAGTCAGTCGAATCAAGGTGAAGAGGAAACAACAAGAATTTCATATTACTTTATTGGTACTCCAGTCAGGCAACAAATATG
 ATGACTTCAAACGAAAGTCAACAGTATACTGTTAATAATTCAAGCTACAGACATGGAAGGAACTCCCACATATGCCCTCAAACACAGCCACGGCGTCA
 CACAGTGACAGATGTCATGACAATCCTCAGAGTTACTGCCATGACGTTTATGGTGAAGTCCCTGAGAACACAGGGTAGACATCATAGTAGCTAATCTAAC
 GTGACCGATAAGATCAACCCCATACACCAGCCTGGAAACGCACTGTCAGACATGTCAGTGGCGGAGATCCTACTGGACGGGTTGCCATCAGACCGACCCAAAC
 CAACGACGGGTTAGTCACCGTGGTCAAACAAATCGACTTGTGAAACAAATAGGATTTGCTCCTACTGTTGCTGCCGAAAATCAAGTGCCTAGGAA
 AATTCAAGCACCCGCCCTCAGTCACGTCAACCGTGTGTTACAGTTATTGACGTAAATGAAAACCCATTTCGCCCCAATCTAAGATCATTGCCAGAA
 AAGGCTTCATGCCGTACCATGTTGAAAATTCACTGGCTCAGACCGAATTGATATGCAGGAAAATTAGAAACCACTTAATTATCTGGATCCTGGCC
 TGGCTAAATTGAGTTCTGTGAATGACAAAATTACCTATACATGTGCTGTTTGTGAGACA

5' partner: TXNL1



Junction point

exon=8 1090..1194

/gene="TXNL1"

/gene_synonym="TRP32; Txl; TXL-1; TXNL"


BLAST vs mRNA

>ref|NR_024546.1| Gene info linked to NR_024546.1 Genome view with mapviewer linked to NR_024546.1 Homo sapiens thioredoxin-like 1 (TXNL1), transcript variant 2, non-coding RNA
 Length=1434
 GENE ID: 9352 TXNL1 | thioredoxin-like 1 [Homo sapiens]
 Score = 957 bits (518), Expect = 0.0
 Identities = 523/525 (99%), Gaps = 2/525 (0%)

Strand=Plus/Plus

Query 5	CTTAGAAAATGACCTCTGAGAAGCAATGAGGACACAGATATTCCAAAAGGCTATATGGAT	64
Sbjct 672	CTTAGAAAATGACC-CTG-GAAGCAATGAGGACACAGATATTCCAAAAGGCTATATGGAT	729
Query 65	TTAATGCCCTTATTAAACAAAGCTGGTTGAATGCTTAATGAAAGTGTGAGCATGGAA	124
Sbjct 730	TTAATGCCCTTATTAAACAAAGCTGGTTGAATGCTTAATGAAAGTGTGAGCATGGAA	789
Query 125	TTTGACAACTGTTACGAAAAGACACACCTCTTGGAACTGACTGTGATGAACAGCTG	184
Sbjct 790	TTTGACAACTGTTACGAAAAGACACACCTCTTGGAACTGACTGTGATGAACAGCTG	849
Query 185	CTTATTACTGTGGCATTCAACCTGTTAACGCTTATTCCATGAAATTCAAGGGCCA	244
Sbjct 850	CTTATTACTGTGGCATTCAACCTGTTAACGCTTATTCCATGAAATTCAAGGGCCA	909
Query 245	GATAATGGTCAGGGCCCTAAATATGAAAAATTTCATCACCTACCCGATCTATGGAT	304
Sbjct 910	GATAATGGTCAGGGCCCTAAATATGAAAAATTTCATCACCTACCCGATCTATGGAT	969
Query 305	TTTGAAGAGGCAGAAAAGAAGTGAACCAACTCAAGCTCTGAACTGACAGAGGATGATATT	364
Sbjct 970	TTTGAAGAGGCAGAAAAGAAGTGAACCAACTCAAGCTCTGAACTGACAGAGGATGATATT	1029
Query 365	AAAGAAGATGGCATTGTCACCTCGTTAGTTAACGATGTTAACAGTGTAACT	424
Sbjct 1030	AAAGAAGATGGCATTGTCACCTCGTTAGTTAACGATGTTAACAGTGTAACT	1089
Query 425	ATATTGTTAGTCGAATCAAGGTGAAGAGGAAACAACAAGAATTTCATATTTCAGTT	484
Sbjct 1090	ATATTGTTAGTCGAATCAAGGTGAAGAGGAAACAACAAGAATTTCATATTTCAGTT	1149
Query 485	ATTGGTACTCCAGTCCAGGCAACAAATTGAAATGACTTCAAACGA	529
Sbjct 1150	ATTGGTACTCCAGTCCAGGCAACAAATTGAAATGACTTCAAACGA	1194



3' partner: CDH2**Junction point**

exon=8 1480..1617

/gene="CDH2"

/gene_synonym="CD325; CDHN; CDw325; NCAD"

BLAST vs mRNA

>ref|NM_001792.3| UniGene info linked to NM_001792.3GEO profiles info linked to NM_001792.3Gene info linked to NM_001792.3Genome view with mapviewer linked to NM_001792.3 Homo sapiens cadherin 2, type 1, N-cadherin (neuronal) (CDH2), mRNA
Length=4380
GENE ID: 1000 CDH2 | cadherin 2, type 1, N-cadherin (neuronal) [Homo sapiens]
Score = 1000 bits (541), Expect = 0.0
Identities = 634/673 (95%), Gaps = 29/673 (4%)


Strand=Plus/Plus



Query 529	AAAAGTCAACAGTATACTGTTAATAATTCAAGCTACAGACATGGAAGGCAATCCACATA	588
Sbjct 1479	AAAAGTCAACAGTATACTGTTAATAATTCAAGCTACAGACATGGAAGGCAATCCACATA	1538
Query 589	TGGCCTTCAAACACAGGCCACGGCCGTCATCACAGTGACAGATGTCATGACAATCCCTCC	648
Sbjct 1539	TGGCCTTCAAACACAGGCCACGGCCGTCATCACAGTGACAGATGTCATGACAATCCCTCC	1598
Query 649	AGAGTTTACTGCCATGACGTTTATGGTGAAGTTCTGAGAACAGGGTAGACATCATAGT	708
Sbjct 1599	AGAGTTTACTGCCATGACGTTTATGGTGAAGTTCTGAGAACAGGGTAGACATCATAGT	1658
Query 709	AGCTAATCTAACTGTGACCGATAA-GATCAACCCCATAACACCAGCCTGGAACGCAGTGT	767
Sbjct 1659	AGCTAATCTAACTGTGACCGATAAGGATCAACCCCATAACACCAGCCTGGAACGCAGTGT	1718
Query 768	CAGAACATGAGGGAGATCTACTGGACGGTTGCCATCCAGACCGACCCAAACAGCAA	827
Sbjct 1719	CAGAACATGAGGGAGATCTACTGGACGGTTGCCATCCAGACCGACCCAAACAGCAA	1778
Query 828	CGACGGGTTAGTCACCGTGGTCAAAC-AATCGACTTTGAAACAAATAGGATGTTGCT	886
Sbjct 1779	CGACGGGTTAGTCACCGTGGTCAAACCAATCGACTTTGAAACAAATAGGATGTTGCT	1838
Query 887	TACTGTTGCTGCCAAAAATCAAGTGCCTAGCCAAGGGAAATTCAAGCACCAGCCTCAG	946
Sbjct 1839	TACTGTTGCTGCCAAAAATCAAGTGCCTAGCCAAGGGAAATTCAAGCACCAGCCTCAG	1896
Query 947	TCAACTGCAACCGTGTGTTACAGTTATTGACGTAATGAAAACCTTATTTGCC	1006
Sbjct 1897	TCAACTGCAACCGTGTGTTACAGTTATTGACGTAATGAAAACCTTATTTGCC	1956

EEF1G-AHNAK

TTGGGGCCCAAGTTGATGCTAAAAAGTTGCGAGAGCCCAACCTAAAAAGGACACACCACGGAAAGAGAAGGGTTCACGGGAAGAGAACAGCAGAACGCCAGGC
GAGCGGAAGGGAGGAGAAAAGGGCGCTGCCCTGCTCCTGAGGGAGGAGATGGATGAATGTCAGGCGCTGGCTGAGGCCAAGGCCAGGCCCTTC
CTCACCTGCCCAAGAGGACTGTAGAAGCGCCAGGAAGAAAACCCCCCTTTAAGGTTGTTGACGCTGGAGCATGTTCTAGCTCCAGGCCAGGC
ATTACATATTGCTGTGCCAAGGGCAACAAACACCTGCAGTTAAAGGAATACCTCGCGAGGGCTGGAGCATGTTCTAGCTCCAGGCCAGGC
AGACCGAGGGCTGCTGCATAAGCCCTGCTGGTCAATTCTTACTTGAAGGGACAGAGTGTGGCTTAGGTTGGACTAGAGGGGCTTGGCAACTA
GGTCTCAGGTATTATCCTCGCTGTTATCCAATAAACATTATCAAGC

5' partner: EEF1G**Junction point**

exon=7 799..1003

/gene="EEF1G"
 /gene_synonym="EF1G; GIG35"

BLAST vs mRNA


>ref|NM_001404.4| UniGene info linked to NM_001404.4GEO profiles info linked to NM_001404.4Gene info linked to NM_001404.4Genome view with mapviewer linked to NM_001404.4 Homo sapiens eukaryotic translation elongation factor 1 gamma (EEF1G), mRNA
 Length=1552
 GENE ID: 1937 EEF1G | eukaryotic translation elongation factor 1 gamma [Homo sapiens]
 Score = 398 bits (215), Expect = 1e-109
 Identities = 218/219 (99%), Gaps = 1/219 (0%)

Strand=Plus/Plus

Query 5	GGCCCAGTTGATGCTAAAAG-TTGCAGAGACCCAAACCTAAAAAGGACACACCACGGAA	63
Sbjct 785	GGCCCAGTTGATGCTAAAAGTTGCAGAGACCCAAACCTAAAAAGGACACACCACGGAA	844
Query 64	AGAGAAGGGTTCACGGGAAGAGAACGAGAACGCCCCAGGCTGAGCGGAAGGAGGAGAAAAA	123
Sbjct 845	AGAGAAGGGTTCACGGGAAGAGAACGAGAACGCCCCAGGCTGAGCGGAAGGAGGAGAAAAA	904
Query 124	GGCGGCTGCCCTGCTCTGAGGAGGAGATGGATGAATGTGAGCAGGCCTGGCTGCTGA	183
Sbjct 905	GGCGGCTGCCCTGCTCTGAGGAGGAGATGGATGAATGTGAGCAGGCCTGGCTGCTGA	964
Query 184	GCCCAAGGCCAAGGACCCCTTCGCTCACCTGCCCAAGAG	222
Sbjct 965	GCCCAAGGCCAAGGACCCCTTCGCTCACCTGCCCAAGAG	1003



3' partner: AHNAK



Junction point

exon=7 743..1090
 /gene="AHNAK"
 /gene_synonym="AHNAKRS; MGC5395"

BLAST vs mRNA

>ref|NM_024060.2| UniGene info linked to NM_024060.2GEO profiles info linked to NM_024060.2Gene info linked to NM_024060.2Genome view with mapviewer linked to NM_024060.2 Homo sapiens AHNAK nucleoprotein (AHNAK), transcript variant 2, mRNA
 Length=1108
 GENE ID: 79026 AHNAK | AHNAK nucleoprotein [Homo sapiens]
 Score = 630 bits (341), Expect = 9e-180
 Identities = 345/347 (99%), Gaps = 0/347 (0%)

Strand=Plus/Plus




Query 221	AGGACTGTAGAAGCGGCAGGAAGAAAACCACCCCTTTAAGGTTGTTTGTGACCGT	280
Sbjct 741	AGGACTGTAGAAGCGGCAGGAAGAAAACCACCCCTTTAAGGTTGTTTGTGACCGT	800
Query 281	TTTTTGAGCATTGTTCAAAATGGAAATTACATATTGCTGTGCCAAGGGCAACAAAC	340
Sbjct 801	TCTTTGGAGCATTGTTCAAAATGGAAATTACATATTGCTGTGCCAAGGGCAACAAAC	860
Query 341	ACCTGCAGTAAAGGAATACCTTCCGCAGGGCTTTCGGAGCATGCATGTTATAGC	400
Sbjct 861	ACCTGCAGTAAAGGAATACCTTCCGCAGGGCTTTCGGAGCATGCATGTTATAGC	920
Query 401	TCCAGGCCAGGCCAGACCGAGGGCTGCTGCATAAGCCCTGCTGGTGCATTCTTACTTG	460
Sbjct 921	TCCAGGCCAGGCCAGACCGAGGGCTGCTGCATAAGCCCTGCTGGTGCATTCTTACTTG	980
Query 461	CAAGGGACAGAGTGTGGCCTTAGGTTGGACTAGAGGGGGCTTGGCAACTATGGTGC	520
Sbjct 981	CAAGGGACAGAGTGTGGCCTTAGGTTGGACTAGAGGGGGCTTGGCAACTATGGTGC	1040

Query	521	TCAGGTGATTATCCTCGCTCGTTATCCAATAACATTATCAAGC	567
Sbjct	1041	TCAGGTGATTATCCTCGCTCGTTATCCAATAACATTATCAAGC	1087

MBD1-CCDC11

TGGTGCCTGGCTGCCCTAGCAAGGCAGTAGACCCAGGCCCTGCCCTCTGTGAAGCAAGGCACTGACCCAGAGGAGGACAAGGGAGAACAGGATGATTCTCCTCCAAATTGGCCCCAGAGGAAGAGGCAGGAGGGCTGGCACACCCGTGATCACGGAGATTTTCAGCCTGGTGGAACCCGCTTCCAGATAACAGCAGTCTGTTGCCAAGAGATCCAAGGCCCTCTAAAGGCCAAGGAGCTGAGCACCATCTAGAAAGAATCGCAGCAGCCATCAGAAGCATAATGCTATTTGGCTTCCATTAGTCAGTGAGGGATGCGTGAAGACTGAGTGGGACAGCACAACTGACTGCAAGATTTGGACAGCCTTGTGCGAGCAAGAATCAAGGATGCTGTGCAAGGTTTATCTAAACATTGAAGAAAAGACGAAATAAGTAAGGCTCACAAACCTGGACATAAAACCATGAAATATTCTAAACACCACAATTGAGATTGACCAGTC; AAAATCAAATTAGCAAGGATCATGGCTGAGATATTATTAACATAGCTATTGCTGGTTAATATTTTAATATTTTTATTGTGATAGCCTGTATTGATGAAAAACAATATAATTGTTCATATTTCATT

5' partner: MBD1



Junction point

exon=16 2004..2065

```
/gene = "MBD1"
```

/gene_synonym="CXXC3; PCM1; RFT"

BLAST vs mRNA


```
>ref|NM_001204141.1| Gene info linked to NM_001204141.1 Homo sapiens methyl-CpG binding domain protein 1 (MBD1), transcript variant 10, mRNA  
Length=2860  
GENE ID: 4152 MBD1 | methyl-CpG binding domain protein 1 [Homo sapiens]  
Score = 388 bits (210), Expect = 7e-107  
Identities = 215/217 (99%), Gaps = 2/217 (0%)
```

Strand=Plus/Plus

Query	1	TGGTGCCCTGGCTGCCCTAGCAAGGCAGTAGACCCAGGCCCTGCCCTCTGTGAAGCAAGAG- 	59
Sbjct	1849	TGGTGCCCTGGCTGCCCTAGCAAGGCAGTAGACCCAGGCCCTGCCCTCTGTGAAGCAAGAGC	1908
Query	60	CA-CTGACCCAGAGGAGGACAAGGAGGAACAAGGATGATTCTGCCCTCAAATTGGCC 	118
Sbjct	1909	CACCTGACCCAGAGGAGGACAAGGAGGAACAAGGATGATTCTGCCCTCAAATTGGCC	1968
Query	119	CAGAGGAAGAGGCAGGGAGGGCTGGCACACCCGTGATCACGGAGATTTCAAGCTGGTG 	178
Sbjct	1969	CAGAGGAAGAGGCAGGGAGGGCTGGCACACCCGTGATCACGGAGATTTCAAGCTGGTG	2028
Query	179	GAACCCCGCTTCCGGAGATACAGCAGTCGGTTCGCCAAG- 	215
Sbjct	2029	GAACCCCGCTTCCGGAGATACAGCAGTCGGTTCGCCAAG	2065



3' partner: CCDC11



Junction point

exon=2 161..390

/gene="CCDC11

/gene synonym="FLJ32743"

BLAST vs mRNA

>ref|NM_145020.3| UniGene info linked to NM_145020.3GEO profiles info linked to NM_145020.3Gene info linked to NM_145020.3Genome view with mapviewer linked to NM_145020.3 Homo sapiens coiled-coil domain containing 11 (CCDC11), mRNA
Length=1837
GENE ID: 220136 CCDC11 | coiled-coil domain containing 11 [Homo sapiens]
Score = 429 bits (232), Expect = 4e-119
Identities = 232/232 (100%), Gaps = 0/232 (0%)

Strand=Plus/Plus


↓

Query 215	GAGATCCAAGCCTCCTAAAGGCCAAGGGAGCTGAGCACCATCTAGAAAGAATCCGACGCAG	274
Sbjct 160	GAGATCCAAGCCTCCTAAAGGCCAAGGGAGCTGAGCACCATCTAGAAAGAATCCGACGCAG	219
Query 275	CCATCAGAACATAATGCTATTTGGCTTCCATTAAAGTCAGTGAGCGGGATCGCTTGAA	334
Sbjct 220	CCATCAGAACATAATGCTATTTGGCTTCCATTAAAGTCAGTGAGCGGGATCGCTTGAA	279
Query 335	AGCTGAGTGGGACAGCACAAATGACTGCAAGATTTGGACAGCCTTGTGCGAGCAAGAAT	394
Sbjct 280	AGCTGAGTGGGACAGCACAAATGACTGCAAGATTTGGACAGCCTTGTGCGAGCAAGAAT	339
Query 395	CAAGGATGCTGTGCAAGGGTTTATCATTAAACATTGAAGAAAGACGAAATAAG	446
Sbjct 340	CAAGGATGCTGTGCAAGGGTTTATCATTAAACATTGAAGAAAGACGAAATAAG	391

CORO7-MAGMAS

TTGGGGCCTAATGGCAGCCCTGGCTTCAGCCTGCAGCCTCCTGACATGAGCCCAGTGAGCCAAGCCCCCGAGAGGGCCCTGCTCGTGGGGCCATC(TCAGCGCAGTACCTGGAAGAAAAGTCTGACCAGCAAAGAAGGAGGAGCTGCTGAATGCCATGGTGGAAACTGGGGACCCGGGAGGACCCACTCCCCCAGC ACTCCTTGAAGGGGTGGACGAGGACGAGTGGGCCAGTACCTGGGCCAGATCATTGTGATGGGCGTGCAGGGCTTGTGACGGGCTTGCAGGGCCTTGC(GCAGGAGTTGAGCCAGCCGGCCGCAGCTGATGCCGAGGACGCGCTGGACCCGGTCTGCAGCGCCTTCAACCTCTCCGGCTCAGCCTCCAGGAGGC(CAGCAGATTCTCAACGTGTCAAGCTGAGCTCTGAGGAGGTCCAGAAAGACTATGAACACTTATTAACGTGAATGATAAACTCGTGGGTGGCTCTTCTAC(GCAGTCAAAGGTGGTCCGCGCAAAGGAGCGCCTGGATGAGGAACCTCAAATCCAGGCCAGGAGACAGAGAAAAGGCAGATGCCCTACACGTGACTGCTG(TCCCCGCCACCCCGCCTCTAAATTAAAGTGTAAATTCTTTCTGCACGTAAAAAAAGCCACTTCTGTACAAGTGGCATAAAAAGAAGCATGCTTCA(TGTGACAGAACCTCTAACAGTCAATAATCGTATGCCATCCGCTGATCTAAAGACGATAATGCCACGTTCCGGACCTGCCGTCCATCTAAAGTCTTGCA(AAAATCTCTGAACATACGTCGAAACAGTGTATACGGTTAGCATACCGAAGTGGCGATATCCAGACGATATGGAAGTCA

5' partner: CORO7



Junction point

exon=27 2874..2960
/gene="CORO7"
/gene_synonym="0610011B16Rik; CRN7; FLJ22021; FLJ44188; POD1"

BLAST vs mRNA


>ref|NM_001201473.1| Gene info linked to NM_001201473.1 Homo sapiens coronin 7 (CORO7), transcript variant 3, mRNA
Length=3599
GENE ID: 79585 CORO7 | coronin 7 [Homo sapiens]
Score = 435 bits (235), Expect = 1e-120
Identities = 235/235 (100%), Gaps = 0/235 (0%)

Strand=Plus/Plus

Query 5	GGCGCTAATGGCAGCCCTGGCTTCAGCCTGCAGCCTCCTGACATGAGCCCAGTGAGC	64
Sbjct 2727	GGCGCTAATGGCAGCCCTGGCTTCAGCCTGCAGCCTCCTGACATGAGCCCAGTGAGC	2786
Query 65	CAAGCCCCCGAGAGGCCCTGCTCGGGCCCCATCCTCAGCGCAGTACCTGGAAAGAA	124
Sbjct 2787	CAAGCCCCCGAGAGGCCCTGCTCGGGCCCCATCCTCAGCGCAGTACCTGGAAAGAA	2846
Query 125	AAGTCTGACCAAGAAAGAAGGAGGAGCTGTAATGCCATGGTGGAAACTGGGAAC	184
Sbjct 2847	AAGTCTGACCAAGAAAGAAGGAGGAGCTGTAATGCCATGGTGGAAACTGGGAAC	2906
Query 185	CGGGAGGACCCACTCCCCCAGGACTCCTTGAAGGGCTGGACGAGGAGCAGTGGG	239
Sbjct 2907	CGGGAGGACCCACTCCCCCAGGACTCCTTGAAGGGCTGGACGAGGAGCAGTGGG	2961



3' partner: MAGMAS



Junction point

exon=2 142..226

/gene="PAM16"

/gene synonym="CGI-136; MAGMAS; TIM16; TIMM16"

BLAST vs mRNA


>ref|NM_016069.9| Gene info linked to NM_016069.9 Homo sapiens presequence translocase-associated motor 16 homolog (S. cerevisiae) (PAM16), nuclear gene encoding mitochondrial protein, mRNA
Length=600
GENE ID: 51025 PAM16 | presequence translocase-associated motor 16 homolog (S. cerevisiae) [Homo sapiens]
Score = 721 bits (390), Expect = 0.0
Identities = 428/444 (97%), Gaps = 12/444 (2%)

Strand=Plus/Plus

Query	Sbjct	Sequence	Length
Query 238	Sbjct 141	GGCCAAGTACCTGGCCCAGATCATTGTGATGGGCCTGCAGGTGGTGGGCAGGGCTTTGC GGCCAAGTACCTGGCCCAGATCATTGTGATGGGCCTGCAGGTGGTGGGCAGGGCTTTGC	297 200
Query 298	Sbjct 201	ACGGGCCCTTGCGGCAGGAGTTGCAGCCAGCGGGCCGCAGCTGATGCCGAGGACGCG ACGGGCCCTTGCGGCAGGAGTTGCAGCCAGCGGGCCGCAGCTGATGCCGAGGACGCG	357 260
Query 358	Sbjct 261	TGGACACCGGTCTGCAGCCGCTTCAACCTCTCCGGCTCAGCCTCCAGGAGGCACAGCA TGGACACCGGTCTGCAGCCGCTTCAACCTCTCCGGCTCAGCCTCCAGGAGGCACAGCA	417 320
Query 418	Sbjct 321	GATTCTCACCGTGTCCAAGCTGAGCTGAGGAGGTCAGAAGA-CTATGAACACTTATT GATTCTCACCGTGTCCAAGCTGAGCCCTGAGGAGGTCAGAAGAACTATGAACACTTATT	476 380
Query 477	Sbjct 381	TAACGTGAATGATAAATCCGTGGTGGCTCTCTACCTGCAAGTCAAAGGTGGTCCGGCG TAAGGTGAATGATAAATCCGTGGTGGCTCTCTACCTGCAAGTCAAAGGTGGTCCGGCG	536 440
Query 537	Sbjct 441	AAAGGAGCGCTGGATGAGGAACCTAAAATCCAGGCCAGGAG-ACAGAGAAAAAGG-CA AAAGGAGCGCTGGATGAGGAACCTAAAATCCAGGCCAGGAGACAGAGAAAAAGGCA	594 500
Query 595	Sbjct 501	GATGCCCTACACGTGACTGCTCG-CTCCCC-GCC-ACCC-GC-GCCTCTAATTATAGC GATGCCCTACACGTGACTGCTCGCTGGCTCCCCCGCCACCCGCCCTCTAATTATAGC	649 560
Query 650	Sbjct 561	T-G-TAATAA-TT-CTTTTCTGCA 669 TTGGTAATAAATTCTTTCTGCA 584	

TYMP-SCO2

TTGGCGCTCTGGTGGGACGTTAAGTCGGAGGGCCGCCGTCTCCCCAACCAGGAGCAGGCCGGAGCTGCAAAGACGCTGGTGGCGTGGGAGCCA
CCTAGGGCTTCGGTGCAGCCTGGACGCCATGGACAAGCCCTGGTCGCTGCGTGGGCCACGCCCTGGAGGTGGAGGAGGCCGCTGCTCTGCA
GGCGCAGGCCGCCAGACTTAAGGGACCTGGTACCCACGCTCGGGGCCCTGCTCTGGCTCAGCGAACACGCCGGGACTCAGGCCAGGGCGCTGCC
TGGCCGCGGCCTGGACGACGGCTCGGCCCTGGCGCTGGAGCGGATGCTGGCGCGCAGGGCGTGGATCCCGTCTGGCCGAGGCCCTGTC
TCCCAGAACGCCGCAGCTGCTGCCCTGCCGGGGAGCAGGAGGAGCTGCGCCCGCAGATGGACCATCAGATTCTGCTGCTGACTCGGAGC
CCACAGCTGGCACAGGCTCTCAGCTCAAGCCTCCGGCTCCCTGGACCCCTGGAGGCCAGGCCCTGCACTGAGGCTCTGGCTTTGTC
AAGGCAGGCCCTGGGCGAGCCCAGGGCTTCCGAACCCGGTCTGATCACAGGCCCTGTTCCGGCTGGACTCGGTGGGGCTGGCT
GCCCTGAGGGCTGAGAAGGGAGGGCTGCAGCAGCAAAAGCGAACAGAACGCCCTGCGCCGGCAGCTGGGCCAGGGCGACTTCA
ACCTGCTGGATCACAGATGCCCGGGCTGCTGCCAGGCTGACTTCCGGGCCAGTGGTGCTGATGTA
CTTGGCTTCCCTCACTGCCCAAAACAAACTGGAAAAGCTTGGTCAAGGTGGTGCAGCTGGGA
ATGCAAATGCGCTGGGAGGGCTGAGGCTGACTTCCGGGCCAGTGGTGCTGATGTA
CTTGGCTTCCCTCACTGCCCAAAACAAACTGGAAAAGCTTGGTCAAGGTGGTGCAGCTGGGA
TTGAAATCATGGCCCCGATACCTCAGGAAACTCCACCCAAAATGGTTGGGGTCTGATACC

5' partner: TYMP**Junction point**


exon=8 1049..1279
/gene="TYMP"
/gene_synonym="ECGF; ECGF1; hPD-ECGF; MEDPS1; MNGIE; MTDP51; PDEC5F; TP"

BLAST vs mRNA

>ref|NM_001113756.1| Homo sapiens thymidine phosphorylase (TYMP), transcript variant 3, mRNA
Length=1587
GENE ID: 1890 TYMP| thymidine phosphorylase [Homo sapiens]
Score = 881 bits (477), Expect = 0.0
Identities = 477/477 (100%), Gaps = 0/477 (0%)

Strand=Plus/Plus

Query 5	CGCTCTGGTGGACGTTAAGTCGGAGGGGCCGCTTCCCCAACCAAGGAGCAGGC	64
Sbjct 804	CGCTCTGGTGGACGTTAAGTCGGAGGGGCCGCTTCCCCAACCAAGGAGCAGGC	863
Query 65	CCGGGAGCTGGCAAAGACGCTGGTGCGTGGAGCCAGCCTAGGGCTCGGGTCGCG	124
Sbjct 864	CCGGGAGCTGGCAAAGACGCTGGTGCGTGGAGCCAGCCTAGGGCTCGGGTCGCG	923
Query 125	AGCGCTGACCGCCATGGACAAGCCCCTGGTCGCTGCGTGGGCCACGCCCTGGAGGTGGA	184
Sbjct 924	AGCGCTGACCGCCATGGACAAGCCCCTGGTCGCTGCGTGGGCCACGCCCTGGAGGTGGA	983
Query 185	GGAGGGCCTGCTCTGCATGGACGGCGCAGGCCGCCAGACTTAAGGGACCTGGTCACCAC	244
Sbjct 984	GGAGGGCCTGCTCTGCATGGACGGCGCAGGCCGCCAGACTTAAGGGACCTGGTCACCAC	1043
Query 245	GCTCGGGGGCGCCCTGCTCTGGCTCAGCGACACGCCGGGACTCAGGCCAGGGCGCTGC	304
Sbjct 1044	GCTCGGGGGCGCCCTGCTCTGGCTCAGCGACACGCCGGGACTCAGGCCAGGGCGCTGC	1103
Query 305	CCGGGTGGCCGGCGCTGGACGACGCCCTGGCCGCTTCAGGCCAGGGCGCTGC	364
Sbjct 1104	CCGGGTGGCCGGCGCTGGACGACGCCCTGGCCGCTTCAGGCCAGGGCGATGCTGGC	1163
Query 365	GGCGCAGGGCGTGGATCCGGCTGGCCCGAGGCCCTGTGCTCGGAAGTCCCGCAGAACG	424
Sbjct 1164	GGCGCAGGGCGTGGATCCGGCTGGCCCGAGGCCCTGTGCTCGGAAGTCCCGCAGAACG	1223
Query 425	CCGGCAGCTGCTGCCCTCGGCCGGAGCAGGAGGAGCTGCTGGCCGCCAGATGG	481
Sbjct 1224	CCGGCAGCTGCTGCCCTCGGCCGGAGCAGGAGGAGCTGCTGGCCGCCAGATGG	1280

**3' partner: SCO2****Junction point**

exon=2 146..1002
/gene="SCO2"
/gene_synonym="MGC125823; MGC125825; SCO1L"

BLAST vs mRNA


>ref|NM_001169110.1| Homo sapiens SCO cytochrome oxidase deficient homolog 2 (yeast) (SCO2), nuclear gene encoding mitochondrial protein, transcript variant 3, mRNA
Length=1002
GENE ID: 9997 SCO2| SCO cytochrome oxidase deficient homolog 2 (yeast) [Homo sapiens]
Score = 828 bits (448), Expect = 0.0
Identities = 560/609 (92%), Gaps = 28/609 (4%)

Strand=Plus/Plus

	↓	
Query 479	TGGAGCATCAGATCCATGCTGCTGCTGACTCGGAGCCCCACAGCTTGGCACAGGCTCTCT	538
Sbjct 144	TGGAGCATCAGATCCATGCTGCTGCTGACTCGGAGCCCCACAGCTTGGCACAGGCTCTCT	203
Query 539	CAGCTCAAGCCTCGGTCCCTCCCCTGGGACCCCTGGGAGGCCAGGCCCTGCATCTGAGGTCC	598
Sbjct 204	CAGCTCAAGCCTCGGTCCCTCCCCTGGGACCCCTGGGAGGCCAGGCCCTGCATCTGAGGTCC	263
Query 599	TGGCTTTGTCAGGAGGGCCCTGAGAGACAGGTGGGAGGGCCAGCCCCAGGGCCCT	658
Sbjct 264	TGGCTTTGTCAGGAGGGCCCTGAGAGACAGGTGGGAGGGCCAGCCCCAGGGCCCT	323
Query 659	GGGCTTCAACCCGGCTGCTGATCACAGGCCCTGTTGGGGCTGGACTCGGTGGGGCTGG	718
Sbjct 324	GGGCTTCAACCCGGCTGCTGATCACAGGCCCTGTTGGGGCTGGACTCGGTGGGGCTGG	383
Query 719	CTGGCCCTGAGGGCTGAGAAGGGAGGGCTGCAGCAGCAAAAGCGAACAGAACGCCCTGCG	778
Sbjct 384	CTGGCCCTGAGGGCTGAGAAGGGAGGGCTGCAGCAGCAAA-GCGAACAGAACGCCCTGCG	442
Query 779	CCGGGCAGCTGTGGGCCAGGGGCAGCTTCCACCTGCTGGATCACAGATGCCGGGCTCGC	838
Sbjct 443	CCAGGCAGCTGTGGGCCAGGG-CGACTTCCACCTGCTGGATCACAGAGGCC-GGGCTCGC	500
Query 839	TGCCAGGCTGACTTCCGGGCCAGTGCTGCTGATGTACTTTGGCTTCCCTCACTGCC	898
Sbjct 501	TGCAAGGCTGACTTCC-GGGGCAGTGGGTGCTGATGTACTTTGGCTTCACTC-ACTGCC	558
Query 899	CCT-ACATCTGCCAAAACAACATGGAAAAGCTTGGTGAAGGTGGTGGGCCAGCTGG	957
Sbjct 559	C-TGACATCTGCCAGA-CGAGCTGGAGAA-GCT-GGTGCA-GGTGGTGGG-CAGCTGG	612

PPCS-LOC100507214

GCACGAGGCCGCTCCCACCCAGACTTGGCTGTCCGCTCTGGGCCCTGGGCCAGCCCTTCGGGCTTGCTGAGCCTGGAGGCCAGGGAGAACATGCACTT(CGGGTTTGCTGAGGCTCTGAGGAGCTACCAAGGAGGCTGCGCTGCAGGCACCTTCTGGCAGTAGAGTTCACCACTTTGGCGACTATTGCACTGTGCGGGCTGAGGCTCTGAGATTTCTATGTCCTGTCTGAAATGCCCTGAAAC(AAGATCCAGTCATCTGGGGCCCAGTCAGGGAAAGTCAGTTAGAACATACTTCACCATCTGAAAAAGAACATCAATCCCCTGCTACTACAGAA(AACAACTCTGTTGGTGTATTCCAGCCAGCACAGTGAAGACAGGCTGAGGACTGCTACCAACAGATGTAGAACAGCTTATAGTGAAGCACATGGGTGAAAC(AAAGAACATGAGAACATAAGCATAGAAATTAAAGACACCTGTGATTGTTATTGCCCTCATTAACATATTAAAAACTAATGTTGGCTATCAGGTATGTTGGCTATCAGGTATGTTGAAAGC

5' partner: PPCS**Junction point****exon=2** 573..676

/gene="PPCS"

/gene_synonym="FLJ11838; MGC117357; MGC138220;

RP11-163G10.1"

BLAST vs mRNA


```
>ref|NM_024664.2| Homo sapiens phosphopantothenoylcysteine synthetase (PPCS), transcript variant 1, mRNA
Length=1489
GENE ID: 79717 PPCS| phosphopantothenoylcysteine synthetase [Homo sapiens]
Score = 612 bits (331), Expect = 4e-174
Identities = 331/331 (100%), Gaps = 0/331 (0%)
```

Strand=Plus/Plus

Query 9	CCGCTTCCCACCCAGACTTGGCTGTCCGCTCTGGGCCCTCGGGCCAGCCCTTCGGG	68
Sbjct 346	CCGCTTCCCACCCAGACTTGGCTGTCCGCTCTGGGCCCTCGGGCCAGCCCTTCGGG	405
Query 69	CTTGCTGAGCCTGGAGGCCAGGGAGAACATGCACTTCCGGTTTGCTGAGGCTCTGAGGAG	128
Sbjct 406	CTTGCTGAGCCTGGAGGCCAGGGAGAACATGCACTTCCGGTTTGCTGAGGCTCTGAGGAG	465
Query 129	CTACCAGGAGGCTGCCGCTGCAGGCACCTTCTGGCAGTAGAGTTCACCACTTGGCGGA	188
Sbjct 466	CTACCAGGAGGCTGCCGCTGCAGGCACCTTCTGGCAGTAGAGTTCACCACTTGGCGGA	525

Query	189	CTATTGCGATCTGGTGCAGGCCAGGCCTGCAGGCTCAATCCGCTAGGCCCTTCGCGAT	248
Sbjct	526	CTATTGCGATCTGGTGCAGGCCAGGCCTGCAGGCTCAATCCGCTAGGCCCTTCGCGAT	585
Query	249	GTTTACCTGGCTGGGCTGTGCAGATTCTATGTTCTGTCTGAAATGCCGAAACA	308
Sbjct	586	GTTTACCTGGCTGGGCTGTGCAGATTCTATGTTCTGTCTGAAATGCCGAAACA	645
Query	309	CAAGATCCAGTCATCTGGGGGCCACTGCAG	339
Sbjct	646	CAAGATCCAGTCATCTGGGGGCCACTGCAG	676

3' partner: LOC100507214




BLAST vs mRNA

```
>ref|XR_113349.1| PREDICTED: Homo sapiens hypothetical LOC100507214 (LOC100507214), partial miscRNA  
Length=668  
GENE ID: 100507214 LOC100507214| hypothetical LOC100507214 [Homo sapiens]  
Score = 544 bits (294), Expect = 1e-153  
Identities = 296/297 (99%), Gaps = 0/297 (0%)  
Strand=Plus/Plus
```

RMND5A-ANAPC1

TTGGCGTGAACAAAACAATCGGCCGCGCCGTGCAGGCACCGAACGTCGAGCGGGGCTGGGACGGGGCAGTCAGCGAGCGAACGGGACCGCGACTCGCCAGGGCTAGGGCGCATGGGCAGGGGGCTCCGGCTGCGCGGGCTCCCCCGCGCCGCGCTAGTCGCCCCCGCCTCGGCCGCC' CAGCCTCCCGCGCCGCCGCTGGGAACGAGGAGCAGGACGCGGCCCTCGCGGGGCCGAGCAGGCTGCGACACCTGGGCGCGAGGAGCGAGCGCGCGCTCCGGCATGGTCACTAGTGCGTACGGAGAAGGTGCTGACAAGTTCTCGGGCTACGGGAGCTGTGCGAGCGGCCGTGGA(GAGCTCACTCGACTACACCGGGCTCAAGCACCGACATCTGCAAGGCCACGGGAAAGATGCTGAATTTACAGGGACACTTCACTTGTGTTGACACAGTGC' GTAAAAAGAATAAAGGAGTACTGTTCAAAAATTGGCCTCCGACCACAAAGACATCCACAGCAGTGTGTTCTCGGGTTGAAAAGCCATTGATAAGGATTCACTTTAGAGATTGGAAACTCTCCCTTGGATTGCTCTTCCCCTAGAGATGCAATTATCACTGTCGTGAAACAGCCTGCTCAGACTGGGAGAGCTGTCTGT(TCTGGATTGGACGTCAAGGATCTTCCAAGCAGGGCTGCGAAGGAAACTTAAGGAGTCTATGTTCTTCAGAACAGAAACTGAGAGGAAGATGACGCC' TGAATGACATGAATCACGAGTCATGCTTAAATATGGAGTGGAGATTATGTCAGGGTGTGCGAAGGCTTCTCAGAGTGCACATCTGTCGTGTCATGAGTCAGTACCCGAGCTCATGACCACGAGTCACTCGAAGGAAAGGAATCGATGCTCAATGGGTCAACAGTATGTTCTCGTAGACAGGAGTTACTGATGTCATC' GTTCACGAGCATGCATCTAATTGAACTGACTGCACTGAGTCAGTCCTCCGGAACCAAGTGACTAATGAACTCGAAGTCTCCAATGGAACCCGTGCACTTCAAG

5' partner: RMND5A



Junction point
exon=2 520..662
/gene="RMND5A"

/gene_synonym="CTLH; FLJ12753; FLJ13910; FLJ21795; MGC78451; p44CTLH; RMD5"

BLAST vs mRNA

>ref|NM_022780.3| UniGene info linked to NM_022780.3GEO profiles info linked to NM_022780.3Gene info linked to NM_022780.3Genome view with mapviewer linked to NM_022780.3 Homo sapiens required for meiotic nuclear division 5 homolog A (*S. cerevisiae*) (RMND5A), mRNA

Length=6201

GENE ID: 64795 RMND5A | re
cerevisiae) [Homo sapiens]


Score = 1083 bits (586). Expect = 0.

Score = 1083 bits (580), Expect = 0.0
Identities = 600/607 (99%). Gaps = 0/607 (0%)

Strand=Plus/Plus

↑

3' partner: ANAPC1



Junction point

exon=25 3060..3238

/gene="ANAPC1 "

/gene_synonym="APC1; MCPR; TSG24"

BLAST vs mRNA

>ref|NM_022662.2| UniGene info linked to NM_022662.2GEO profiles info linked to NM_022662.2Gene info linked to NM_022662.2Genome view with mapviewer linked to NM_022662.2 Homo sapiens anaphase promoting complex subunit 1 (ANAPC1), mRNA

Length=6329

GENE ID: 64682 ANAPC1 | anaphase promoting complex subunit 1 [Homo sapiens]

Score = 510 bits (276), Expect = 2e-143

Identities = 359/393 (92%), Gaps = 30/393 (7%)

Strand=Plus/Plus



Query 606	AGGATTCACTTTAAGAGATTGGAAACTCTCCCTTGGAAATTGCTCTTCCCACAGAGA	665
Sbjct 3058	AGGATTCACTTTAAGAGATTGGAAACTCTCCCTTGGAAATTGCTCTTCCCACAGAGA	3117
Query 666	TGCAATTATCACTGTGTCAGCAGCTGCCTCAGACTGGCCAGAAGCTGCTGTCTCTT	725
Sbjct 3118	TGCAATTATCACTGTGTCAGCAGCTGCCTCAGACTGGCCAGAAGCTGCTGTCTCTT	3177
Query 726	GATTGGACGTCAGGATTTCCAAGCAGGCCGCGAAGGAAACTTACTCAAAGG-A-GTC	783
Sbjct 3178	GATTGGACGTCAGGATTTCCAAGCAGGCCGCGAAGGAAACTTACCCAAAGGGAAAGTC	3237
Query 784	T-----AT--G-T-T-CCTTCAG-AACAGAAACTGAG-AGGAAGATGACGGCATGAA	828
Sbjct 3238	TGTGCTCTCATCAGATGTTCTTCAGGAACAGAAACTGAGGAGGAAGATGACGGCATGAA	3297
Query 829	TGACATGAATCACGAG-TCATGTCAATTAAATGGAGTGA-GATTATG-TGCAGG-TGT	883
Sbjct 3298	TGACATGAATCACGAGGTATGTCATTAAATGGAGTGAAGATTAAAGGGTGCAGGATGT	3357
Query 884	GCGAAGGCTTCTTCAGAGTGCATC-TGTCCGTGTCAT-GTAGTGCAGTACCC-GAGCT	940
Sbjct 3358	GCGAAGGCTTCTTCAGAGTGCATCCTGTCGTCAACGTAGTGCAGTACCCAGAGCT	3417
Query 941	CA-TGACCACGAGT-CACTCGAAGGAA-GGAA 970	
Sbjct 3418	CAGTGACCACGAGTTCA-TCGA-GGAAAAGGAA 3448	

Supplemental References

- [1] Wilming LG, Gilbert JG, Howe K, Trevanion S, Hubbard T, and Harrow JL. The vertebrate genome annotation (Vega) database. *Nucleic Acids Res.* 2008; 36:D753-60.
- [2] Pruitt KD, Tatusova T, Klimke W, and Maglott DR. NCBI Reference Sequences: current status, policy and new initiatives. *Nucleic Acids Res.* 2009; 37:D32-6.
- [3] Karolchik D, Kuhn RM, Baertsch R, Barber GP, Clawson H, Diekhans M, Giardine B, Harte RA, Hinrichs AS, Hsu F et al. The UCSC Genome Browser Database: 2008 update. *Nucleic Acids Res.* 2008; 36:D773-9.
- [4] Romani A, Guerra M, Trerotola M, and Alberti S. Detection and analysis of spliced chimeric mRNAs in sequence databanks. *Nucleic Acids Res.* 2003; 31:1-8.
- [5] Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci U S A.* 2004; 101:2999-3004.
- [6] Guerra E, Trerotola M, Dell' Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C et al. A bi-cistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. *Cancer Res.* 2008; 68:8113-8121.
- [7] Li H, Wang J, Mor G, and Sklar J. A neoplastic gene fusion mimics trans-splicing of RNAs in normal human cells. *Science.* 2008; 321:1357-61.
- [8] Terrinoni A, Dell'Arciprete R, Fornaro M, Stella M, and Alberti S. The Cyclin D1 gene contains a cryptic promoter that is functional in human cancer cells. *Genes Chromosomes Cancer.* 2001; 31:209-20.
- [9] Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, and Chinnaiyan AM. Transcriptome sequencing to detect gene fusions in cancer. *Nature.* 2009; 458:97-101.
- [10] Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F et al. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. *Cancer Res.* 2009; 69:2734-8.
- [11] Communi D, Suarez-Huerta N, Dussossoy D, Savi P, and Boeynaems J-M. Cotranscription and Intergenic Splicing of Human P2Y11 and SSF1 Genes. *J. Biol. Chem.* 2001; 276:16561-16566.